<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Interventions for managing skeletal muscle spasticity following traumatic brain injury - Synnot, A - 2017 | Cochrane Library</title> <meta content="Interventions for managing skeletal muscle spasticity following traumatic brain injury - Synnot, A - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008929.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Interventions for managing skeletal muscle spasticity following traumatic brain injury - Synnot, A - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008929.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008929.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Interventions for managing skeletal muscle spasticity following traumatic brain injury" name="citation_title"/> <meta content="Anneliese Synnot" name="citation_author"/> <meta content="a.synnot@latrobe.edu.au" name="citation_author_email"/> <meta content="Marisa Chau" name="citation_author"/> <meta content="National Trauma Research Institute, Alfred Hospital, Monash University" name="citation_author_institution"/> <meta content="Veronica Pitt" name="citation_author"/> <meta content="Australian &amp; New Zealand Intensive Care Research Centre (ANZIC‐RC), Monash University" name="citation_author_institution"/> <meta content="Denise O'Connor" name="citation_author"/> <meta content="Monash University" name="citation_author_institution"/> <meta content="Russell L Gruen" name="citation_author"/> <meta content="Nanyang Technological University" name="citation_author_institution"/> <meta content="Jason Wasiak" name="citation_author"/> <meta content="University of Melbourne" name="citation_author_institution"/> <meta content="Ornella Clavisi" name="citation_author"/> <meta content="MOVE muscle, bone &amp; joint health" name="citation_author_institution"/> <meta content="Loyal Pattuwage" name="citation_author"/> <meta content="Centre for Evidence and Implementation" name="citation_author_institution"/> <meta content="Kate Phillips" name="citation_author"/> <meta content="Monash University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD008929.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/11/22" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008929.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008929.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008929.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Baclofen [therapeutic use]; Botulinum Toxins, Type A [therapeutic use]; Brain Injuries, Traumatic [*complications]; Casts, Surgical; Electric Stimulation Therapy; Head‐Down Tilt; Muscle Relaxants, Central [therapeutic use]; Muscle Spasticity [etiology, *therapy]; Neuromuscular Agents [therapeutic use]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008929.pub2&amp;doi=10.1002/14651858.CD008929.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008929.pub2&amp;doi=10.1002/14651858.CD008929.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008929.pub2&amp;doi=10.1002/14651858.CD008929.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008929.pub2&amp;doi=10.1002/14651858.CD008929.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008929.pub2&amp;doi=10.1002/14651858.CD008929.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008929.pub2&amp;doi=10.1002/14651858.CD008929.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008929.pub2&amp;doi=10.1002/14651858.CD008929.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008929.pub2&amp;doi=10.1002/14651858.CD008929.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008929.pub2&amp;doi=10.1002/14651858.CD008929.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008929.pub2&amp;doi=10.1002/14651858.CD008929.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008929.pub2&amp;doi=10.1002/14651858.CD008929.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008929.pub2&amp;doi=10.1002/14651858.CD008929.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008929.pub2&amp;doi=10.1002/14651858.CD008929.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008929.pub2&amp;doi=10.1002/14651858.CD008929.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008929.pub2&amp;doi=10.1002/14651858.CD008929.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008929.pub2&amp;doi=10.1002/14651858.CD008929.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008929.pub2&amp;doi=10.1002/14651858.CD008929.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008929.pub2&amp;doi=10.1002/14651858.CD008929.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008929.pub2&amp;doi=10.1002/14651858.CD008929.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008929.pub2&amp;doi=10.1002/14651858.CD008929.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008929.pub2&amp;doi=10.1002/14651858.CD008929.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008929.pub2&amp;doi=10.1002/14651858.CD008929.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008929.pub2&amp;doi=10.1002/14651858.CD008929.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="tIsQXAzh";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008929\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008929\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008929\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008929\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ms","zh_HANS","fa","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008929.pub2",title:"Interventions for managing skeletal muscle spasticity following traumatic brain injury",firstPublishedDate:"Nov 22, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Injuries Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tIsQXAzh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008929.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008929.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008929.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008929.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008929.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008929.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008929.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008929.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008929.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008929.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>14352 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008929.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008929.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008929.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008929.pub2/full#CD008929-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008929.pub2/full#CD008929-sec-0127"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008929.pub2/full#CD008929-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008929.pub2/full#CD008929-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008929.pub2/full#CD008929-sec-0036"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008929.pub2/full#CD008929-sec-0037"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008929.pub2/full#CD008929-sec-0062"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008929.pub2/full#CD008929-sec-0121"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008929.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008929.pub2/appendices#CD008929-sec-0132"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008929.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008929.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008929.pub2/media/CDSR/CD008929/table_n/CD008929StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008929.pub2/media/CDSR/CD008929/table_n/CD008929StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008929.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008929.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008929.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008929.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008929.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008929.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Interventions for managing skeletal muscle spasticity following traumatic brain injury</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008929.pub2/information#CD008929-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Anneliese Synnot</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008929.pub2/information#CD008929-cr-0003">Marisa Chau</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008929.pub2/information#CD008929-cr-0004">Veronica Pitt</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008929.pub2/information#CD008929-cr-0005">Denise O'Connor</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008929.pub2/information#CD008929-cr-0006">Russell L Gruen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008929.pub2/information#CD008929-cr-0007">Jason Wasiak</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008929.pub2/information#CD008929-cr-0008">Ornella Clavisi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008929.pub2/information#CD008929-cr-0009">Loyal Pattuwage</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008929.pub2/information#CD008929-cr-0010">Kate Phillips</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/information/en#CD008929-sec-0136">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 22 November 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008929.pub2">https://doi.org/10.1002/14651858.CD008929.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008929-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008929-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008929-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008929-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008929-abs-0007">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008929-abs-0001" lang="en"> <section id="CD008929-sec-0001"> <h3 class="title" id="CD008929-sec-0001">Background</h3> <p>Skeletal muscle spasticity is a major physical complication resulting from traumatic brain injury (TBI), which can lead to muscle contracture, joint stiffness, reduced range of movement, broken skin and pain. Treatments for spasticity include a range of pharmacological and non‐pharmacological interventions, often used in combination. Management of spasticity following TBI varies from other clinical populations because of the added complexity of behavioural and cognitive issues associated with TBI. </p> </section> <section id="CD008929-sec-0002"> <h3 class="title" id="CD008929-sec-0002">Objectives</h3> <p>To assess the effects of interventions for managing skeletal muscle spasticity in people with TBI. </p> </section> <section id="CD008929-sec-0003"> <h3 class="title" id="CD008929-sec-0003">Search methods</h3> <p>In June 2017, we searched key databases including the Cochrane Injuries Group Specialised Register, CENTRAL, MEDLINE (Ovid), Embase (Ovid) and others, in addition to clinical trials registries and the reference lists of included studies. </p> </section> <section id="CD008929-sec-0004"> <h3 class="title" id="CD008929-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) and cross‐over RCTs evaluating any intervention for the management of spasticity in TBI. Only studies where at least 50% of participants had a TBI (or for whom separate data for participants with TBI were available) were included. The primary outcomes were spasticity and adverse effects. Secondary outcome measures were classified according to the World Health Organization International Classification of Functioning, Disability and Health including body functions (sensory, pain, neuromusculoskeletal and movement‐related functions) and activities and participation (general tasks and demands; mobility; self‐care; domestic life; major life areas; community, social and civic life). </p> </section> <section id="CD008929-sec-0005"> <h3 class="title" id="CD008929-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane. Data were synthesised narratively; meta‐analysis was precluded due to the paucity and heterogeneity of data. </p> </section> <section id="CD008929-sec-0006"> <h3 class="title" id="CD008929-sec-0006">Main results</h3> <p>We included nine studies in this review which involved 134 participants with TBI. Only five studies reported between‐group differences, yielding outcome data for 105 participants with TBI. These five studies assessed the effects of a range of pharmacological (baclofen, botulinum toxin A) and non‐pharmacological (casting, physiotherapy, splints, tilt table standing and electrical stimulation) interventions, often in combination. The studies which tested the effect of baclofen and tizanidine did not report their results adequately. Where outcome data were available, spasticity and adverse events were reported, in addition to some secondary outcome measures. </p> <p>Of the five studies with results, three were funded by governments, charities or health services and two were funded by a pharmaceutical or medical technology company. The four studies without useable results were funded by pharmaceutical or medical technology companies. </p> <p>It was difficult to draw conclusions about the effectiveness of these interventions due to poor reporting, small study size and the fact that participants with TBI were usually only a proportion of the overall total. Meta‐analysis was not feasible due to the paucity of data and heterogeneity of interventions and comparator groups. Some studies concluded that the intervention they tested had beneficial effects on spasticity, and others found no difference between certain treatments. The most common adverse event was minor skin damage in people who received casting. We believe it would be misleading to provide any further description of study results given the quality of the evidence was very low for all outcomes. </p> </section> <section id="CD008929-sec-0007"> <h3 class="title" id="CD008929-sec-0007">Authors' conclusions</h3> <p>The very low quality and limited amount of evidence about the management of spasticity in people with TBI means that we are uncertain about the effectiveness or harms of these interventions. Well‐designed and adequately powered studies using functional outcome measures to test the interventions used in clinical practice are needed. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008929-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008929-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD008929-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD008929-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008929-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD008929-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD008929-abs-0011">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008929-abs-0008">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008929-abs-0003" lang="en"> <h3>Treatments for spasticity (overactive muscle contractions) following brain injury</h3> <p><b>Review question</b> </p> <p>We reviewed the evidence about the effect of treatments (drug and non‐drug) for spasticity following a brain injury caused by a blow to the head (traumatic brain injury (TBI)). </p> <p><b>Background</b> </p> <p>Many people with TBI experience muscle spasticity, when their muscles contract or tighten involuntarily. This can impact on a person's ability to carry out daily activities causing pain, stiffness and broken skin. There are many treatments used to manage spasticity, including medicines, casting, splints and stretches. Often, these treatments are used in combination. </p> <p><b>Study characteristics</b> </p> <p>We included nine studies in this review which involved 134 participants with TBI. Only five studies, including 105 people provided usable results. These studies tested the effects of a range of treatments, including medicines (baclofen or botulinum toxin A), casting, physiotherapy, splints, a table that moves people from the lying position to standing and electrical stimulation (where electrical impulses are delivered to the muscles). Studies inadequately reporting results had tested the effect of medicines (baclofen or tizanidine). </p> <p><b>Study funding sources</b> </p> <p>Of the five studies with results, three were funded by governments, charities or health services and two were funded by a drug manufacturer and medical technology company. The other four studies without useable results were funded by drug manufacturer or medical technology companies. </p> <p><b>Key results</b> </p> <p>This evidence is current to June 2017.</p> <p>Interpreting the results of the studies was difficult because of a lack of information and concerns about the quality of the evidence. For spasticity, some studies concluded that the treatment they tested made an improvement, and others found no difference between treatments. The most common side effect was minor skin damage in people who received casting. We believe it would be misleading to provide any further description of study results given the quality of the evidence was very low for all measurements. </p> <p><b>Quality of the evidence</b> </p> <p>The quality of this evidence was very low; we only had five studies with results and none of the studies were large or comparable with one another. We also had concerns about how they were conducted or analysed. Because of this, we cannot draw any firm conclusions about the benefits and harms of different treatments for spasticity in people with TBI. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008929-sec-0127" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008929-sec-0127"></div> <h3 class="title" id="CD008929-sec-0128">Implications for practice</h3> <section id="CD008929-sec-0128"> <p>This review identified a number of studies in which the authors evaluated the effectiveness of spasticity treatment in traumatic brain injury (TBI); however, there is insufficient evidence from clinical trials to guide clinical practice. </p> </section> <h3 class="title" id="CD008929-sec-0129">Implications for research</h3> <section id="CD008929-sec-0129"> <p>There is an urgent need for more high quality, adequately powered trials in this area; the lack of TBI participants in studies is of great concern. In addition, there is a need for further evaluation of the assessment tools to ensure that the outcomes for people with TBI and spasticity are reliable. Any future studies should include specific functional measures which focus on goal attainment for individual patients. </p> <p>Data need to be made available from studies which remain unpublished.</p> <p>Outcome assessment of spasticity treatment is complicated. Two assessment scales measuring the impairment caused by spasticity are generally used; the Modified Ashworth Scale (<a href="./references#CD008929-bbs2-0121" title="PandyanAD , JohnsonGR , PriceCI , CurlessRH , BarnesMP , RodgersH . A review of the properties and limitations of the Ashworth and modified Ashworth Scales as measures of spasticity. Clinical Rehabilitation1999; Vol. 13, issue 5:373‐83. ">Pandyan 1999</a>) and the Modified Tardieu Scale (<a href="./references#CD008929-bbs2-0097" title="HaughAB , PandyanAD , JohnsonGR . A systematic review of the Tardieu Scale for the measurement of spasticity. Disability and Rehabilitation2006; Vol. 28, issue 15:899‐907. ">Haugh 2006</a>). Four studies included within this review used the (Modified) Ashworth Scale. This scale is considered to measure resistance to passive movement not spasticity, as it does not evaluate a muscle's response to movement at speed (<a href="./references#CD008929-bbs2-0077" title="AllisonSC , AbrahamLD . Correlation of quantitative measures with the modified Ashworth Scale in the assessment of plantar flexor spasticity in patients with traumatic brain injury. Journal of Neurology1995; Vol. 242, issue 10:699‐706. ">Allison 1995</a>; <a href="./references#CD008929-bbs2-0122" title="PandyanA , GregoricM , BarnesM , WoodD , VanWijckF , BurridgeJ , et al. Spasticity: clinical perceptions, neurological realities and meaningful measurement. Disability and Rehabilitation2005; Vol. 27:2‐6. ">Pandyan 2005</a>). Spasticity is an indication of abnormal neural mechanisms causing a velocity‐dependent increase in tonic stretch reflexes (<a href="./references#CD008929-bbs2-0106" title="LanceJ . Pathophysiology of spasticity and clinical experience with baclofen. In: LanceJWFR , YoungRR , KoellaWP editor(s). Spasticity: Disordered Motor Control. Chicago (IL): Year Book Medical Publishers, 1980. ">Lance 1980</a>). Therefore, by this definition, it will only be seen when a muscle is moved at speed. Where spasticity may be present in a muscle, the muscle may have altered mechanical properties that have developed over time causing a resistance to passive movement. It is these properties which can affect the quantification of spasticity by the Modified Ashworth Scale (<a href="./references#CD008929-bbs2-0116" title="MorrisS . Ashworth and Tardieu Scales: their Clinical Relevance for Measuring Spasticity in Adult and Paediatric Neurological Populations. Physical Therapy Reviews2002; Vol. 7, issue 1:53‐62. ">Morris 2002</a>). In comparison, the Modified Tardieu Scale (<a href="./references#CD008929-bbs2-0097" title="HaughAB , PandyanAD , JohnsonGR . A systematic review of the Tardieu Scale for the measurement of spasticity. Disability and Rehabilitation2006; Vol. 28, issue 15:899‐907. ">Haugh 2006</a>; <a href="./references#CD008929-bbs2-0114" title="MehrholzJ , MajorY , MeissnerD , Sandi‐GahunS , KochR , PohlM . The influence of contractures and variation in measurement stretching velocity on the reliability of the Modified Ashworth Scale in patients with severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 1:63‐72. ">Mehrholz 2005</a>), used by two studies included within this review (<a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a>; <a href="./references#CD008929-bbs2-0002" title="LeungJ , HarveyLA , MoseleyAM , WhitesideB , SimpsonM , StroudK . Standing with electrical stimulation and splinting is no better than standing alone for management of ankle plantarflexion contractures in people with traumatic brain injury: a randomised trial. Journal of Physiotherapy2014;60:201‐8. ">Leung 2014</a>), is considered by many to be more appropriate measure with similar characteristics as the Modified Ashworth Scale; however, the scale requires that movement be carried out at two different speeds recording a 'catch angle.' It is this component of the scale that is more appropriate for measuring spasticity (<a href="./references#CD008929-bbs2-0097" title="HaughAB , PandyanAD , JohnsonGR . A systematic review of the Tardieu Scale for the measurement of spasticity. Disability and Rehabilitation2006; Vol. 28, issue 15:899‐907. ">Haugh 2006</a>; <a href="./references#CD008929-bbs2-0116" title="MorrisS . Ashworth and Tardieu Scales: their Clinical Relevance for Measuring Spasticity in Adult and Paediatric Neurological Populations. Physical Therapy Reviews2002; Vol. 7, issue 1:53‐62. ">Morris 2002</a>). However, it is also notable that there are reliability issues with both measures; the Modified Tardieu Scale has very good test‐retest reliability, but both have reduced inter‐rater reliability (<a href="./references#CD008929-bbs2-0092" title="FleurenJFM , VoermanGE , Erren‐WoltersCV , SnoekGJ , RietmanJS , HermensHJ , et al. Stop using the Ashworth Scale for the assessment of spasticity. Journal of Neurology, Neurosurgery and Psychiatry2010; Vol. 81, issue 1:46‐52. ">Fleuren 2010</a>; <a href="./references#CD008929-bbs2-0097" title="HaughAB , PandyanAD , JohnsonGR . A systematic review of the Tardieu Scale for the measurement of spasticity. Disability and Rehabilitation2006; Vol. 28, issue 15:899‐907. ">Haugh 2006</a>; <a href="./references#CD008929-bbs2-0114" title="MehrholzJ , MajorY , MeissnerD , Sandi‐GahunS , KochR , PohlM . The influence of contractures and variation in measurement stretching velocity on the reliability of the Modified Ashworth Scale in patients with severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 1:63‐72. ">Mehrholz 2005</a>; <a href="./references#CD008929-bbs2-0116" title="MorrisS . Ashworth and Tardieu Scales: their Clinical Relevance for Measuring Spasticity in Adult and Paediatric Neurological Populations. Physical Therapy Reviews2002; Vol. 7, issue 1:53‐62. ">Morris 2002</a>). </p> <p>Any spasticity intervention needs to address specific functional limitations for a person such as drinking from a glass or fastening a button (<a href="./references#CD008929-bbs2-0093" title="FrancisHP , WadeDT , Turner‐StokesL , KingswellRS , DottCS , CoxonEA . Does reducing spasticity translate into functional benefit? An exploratory meta‐analysis. Journal of Neurology, Neurosurgery and Psychiatry2004; Vol. 75, issue 11:1547‐51. ">Francis 2004</a>; <a href="./references#CD008929-bbs2-0045" title="MayerNH , WhyteJ , WannstedtG , EllisCA . Comparative impact of 2 botulinum toxin injection techniques for elbow flexor hypertonia. Archives of Physical Medicine and Rehabilitation2008; Vol. 89, issue 5:982‐7. ">Mayer 2008</a>; <a href="./references#CD008929-bbs2-0123" title="ParkeB , PennRD , SavoySM , CorcosD . Functional outcome after delivery of intrathecal baclofen. Archives of Physical Medicine and Rehabilitation1989; Vol. 70, issue 1:30‐2. ">Parke 1989</a>; <a href="./references#CD008929-bbs2-0125" title="PiersonSH , KatzDI , TarsyD . Botulinum toxin A in the treatment of spasticity: functional implications and patient selection. Archives of Physical Medicine and Rehabilitation1996; Vol. 77, issue 7:717‐21. ">Pierson 1996</a>). An individualised goal directed functional assessment combined with an impairment assessment is recommended to evaluate the effect of an intervention for people with a TBI. Global measures of function are only valid where global treatments such as baclofen are used. It is important that specific measures are identified for specific functional deficits so that any intervention can be assessed by the functional gains made by a person. Potential harms also need to be considered for treatments with proven effectiveness. Spasticity interventions can be costly and painful for a person. Spasticity can be blamed for weakness, contracture and loss of function, and if not clearly identified interventions for spasticity can be used inappropriately, causing further discomfort for no measurable benefit, and a waste of time and money. With respect to impairments such as pain and broken skin, impairment measures alone can indicate an effective outcome. </p> <p>It has been acknowledged that spasticity intervention should occur within the context of a rehabilitation team, and little evidence exists to demonstrate how or where this should occur (<a href="./references#CD008929-bbs2-0088" title="DemetriosM , KhanF , Turner‐StokesL , BrandC , McSweeneyS . Multidisciplinary rehabilitation following botulinum toxin and other focal intramuscular treatment for post‐stroke spasticity. Cochrane Database of Systematic Reviews2013, Issue 6. [DOI: 10.1002/14651858.CD009689.pub2] ">Demetrios 2013</a>; <a href="./references#CD008929-bbs2-0094" title="GiovannelliM , BorrielloG , CastriP , ProsperiniL , PozzilliC . Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis. Clinical Rehabilitation. London: SAGE PUBLICATIONS, INC., 2007; Vol. 21, issue 4:331‐7. [02692155] ">Giovannelli 2007</a>; <a href="./references#CD008929-bbs2-0120" title="OlverJ , EsquenaziA , FungVSC , SingerBJ , WardAB . Botulinum toxin assessment, intervention and aftercare for lower limb disorders of movement and muscle tone in adults: international consensus statement. European Journal of Neurology2010;17:57‐73. ">Olver 2010</a>; <a href="./references#CD008929-bbs2-0126" title="Royal College of Physicians. Spasticity in Adults: Management using Botulinum Toxin: National Guidelines. London (UK): Royal College of Physicians, 2009. ">RCP 2009</a>). It is recommended that "botox injection must be part of a rehabilitation program involving post‐injection exercise, muscle stretch and/or splinting to achieve an optimal clinical effect" (<a href="./references#CD008929-bbs2-0126" title="Royal College of Physicians. Spasticity in Adults: Management using Botulinum Toxin: National Guidelines. London (UK): Royal College of Physicians, 2009. ">RCP 2009</a>, p.vii). The implementation of 'botox' clinics which have a multidisciplinary approach to allow for assessment, treatment and review can mirror some of the rehabilitation processes that occur in a rehabilitation programme. However, when people have returned to living in the community these processes may not occur so effectively due to lack of access or funding. It is not only the complexity of TBI with its associated behaviours and cognitive issues that complicate managing this population, but also where a person lives, their access to services and the type of support they have available to live their life. </p> <p>A moderate to severe TBI can lead to long‐term disability impacting on ADL and quality of life. Impairments such as spasticity can reduce independence, and cause pain and dysfunction in a person's life. It is important to identify interventions for this population which will maximise the functional gains required for a person with TBI to achieve their goals. We need to assess these outcomes utilising reliable and valid assessment scales and this needs to occur within management programmes which have structure and support for clinicians and people with TBI alike. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008929-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008929-sec-0029"></div> <div class="table" id="CD008929-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Baclofen compared with placebo for spasticity in people with traumatic brain injury</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Baclofen compared with placebo for spasticity in people with traumatic brain injury</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with traumatic brain injury with spasticity in their arms and legs </p> <p><b>Settings:</b> outpatient rehabilitation clinic (US) </p> <p><b>Intervention:</b> intrathecal baclofen 50 μg (injected into the lumbar spine) </p> <p><b>Comparison:</b> saline placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Results and conclusions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Spasticity at up to 6 hours after treatment</b> </p> <p>(measured by the Ashworth Scale, 0‐, with a higher score indicating greater spasticity)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>We are uncertain about the effect of baclofen on spasticity compared with placebo.<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11<br/> (1)<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>V ery low</b><sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>We are uncertain about the effect of baclofen on adverse events compared with placebo.<sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>11<br/> (1)<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>V ery low</b><sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sensory functions and pain</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>No study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Neuromusculoskeletal and movement‐related functions up to 6 hours after treatment</b> </p> <p>(Measured by spasm and deep tendon reflex scores, 0‐5, with 0 being no reflexes and 5 being clonus, or repeated involuntary muscle contractions) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>We are uncertain about the effect of baclofen on neuromusculoskeletal and movement‐related functions compared with placebo.<sup>6</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>11</p> <p>(1)<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>V ery low</b><sup>7</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>General tasks and demands</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>No study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mobility</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>No study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Self‐care</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>No study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>1</sup>One study of baclofen reported an improvement in spasticity in the upper and lower limbs, compared to placebo, several hours after the injections but it was unclear how meaningful this improvement was due to reporting of P values only (<a href="./references#CD008929-bbs2-0003" title="MeythalerJM , DeVivoMJ , HadleyM . Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Archives of Physical Medicine and Rehabilitation1996; Vol. 77, issue 5:461‐6. ">Meythaler 1996</a>). </p> <p><sup>2</sup>Three additional studies, with 35 participants, measured this outcome but had no useable results (<a href="./references#CD008929-bbs2-0004" title="MeythalerJM , McCaryA , HadleyMN . Prospective assessment of continuous intrathecal infusion of baclofen for spasticity caused by acquired brain injury: a preliminary report. Journal of Neurosurgery1997; Vol. 87, issue 3:415‐9. ">Meythaler 1997</a>; <a href="./references#CD008929-bbs2-0005" title="MeythalerJM , Guin‐RenfroeS , HadleyMN . Continuously infused intrathecal baclofen for spastic/dystonic hemiplegia: a preliminary report. American Journal of Physical Medicine &amp; Rehabilitation1999; Vol. 78, issue 3:247‐54. ">Meythaler 1999a</a>; <a href="./references#CD008929-bbs2-0006" title="MeythalerJM , Guin‐RenfroeS , GrabbP , HadleyMN . Long‐term continuously infused intrathecal baclofen for spastic‐dystonic hypertonia in traumatic brain injury: 1‐year experience. Archives of Physical Medicine and Rehabilitation1999; Vol. 80, issue 1:13‐9. ">Meythaler 1999b</a>). </p> <p><sup>3</sup>Downgraded four times due to risk of bias limitations (this study provided insufficient information about random sequence generation or allocation concealment), our concerns about indirectness of the Ashworth Score, an inability to assess imprecision relating to an absence of confidence intervals and a further downgrade for there only being one study for this outcome and the likelihood of publication bias in this area. </p> <p><sup>4</sup>No adverse events or changes in alertness level were observed in the baclofen or placebo group. </p> <p><sup>5</sup>Downgraded three times due to risk of bias limitations (no study provided sufficient information about random sequence generation or allocation concealment), the fact that there was only one study for this outcome and the likelihood of publication bias in this area. </p> <p><sup>6</sup>One study reported improvement in upper and lower limb spasm and reflexes compared to placebo several hours after treatment but it was unclear how meaningful this improvement was due to reporting of P values only (<a href="./references#CD008929-bbs2-0003" title="MeythalerJM , DeVivoMJ , HadleyM . Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Archives of Physical Medicine and Rehabilitation1996; Vol. 77, issue 5:461‐6. ">Meythaler 1996</a>). </p> <p><sup>7</sup>Downgraded four times due to risk of bias limitations (no study provided sufficient information about random sequence generation or allocation concealment), an inability to assess imprecision relating to an absence of confidence intervals, the fact that there was only one study for this outcome and the likelihood of publication bias in this area. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008929-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Botulinum toxin A (with and without casting) compared with placebo (with and without casting) for spasticity in people with traumatic brain injury</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Botulinum toxin A (with and without casting) compared with placebo (with and without casting) for spasticity in people with traumatic brain injury</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with traumatic brain injury with spasticity in their arms (1 study) or calves (1 study) </p> <p><b>Settings:</b> rehabilitation/neurology clinics or acute general hospital, in Europe or the UK </p> <p><b>Intervention:</b> botulinum toxin A × 1 dose (500/1000 U) or botulinum toxin A × 1 dose of 200 U + serial casting </p> <p><b>Comparison:</b> placebo (± casting) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Results and conclusions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Spasticity at 4‐12 weeks</b> (measured by both Modified Ashworth Scale, 0‐5, at 12 weeks and Tardieu Scale, 0‐5, at 4 weeks) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>We are uncertain about the effect of botulinum toxin A (± casting) vs placebo (± casting) on spasticity.<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>47</p> <p>(2)<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>We are uncertain about the effect of botulinum toxin A (± casting) vs placebo (± casting) on adverse events.<sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>47</p> <p>(2)<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sensory functions and pain</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>No study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Neuromusculoskeletal and movement‐related functions at 12 weeks</b> (measured by ankle dorsiflexion) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>We are uncertain about the effect of botulinum toxin A (± casting) vs placebo (± casting) on adverse events.<sup>6</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>47</p> <p>(2)<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>7</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>General tasks and demands</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>No study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mobility</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>No study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Self‐care</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>No study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a> reported that "with abobotulinumtoxinA, the angle of catch (XV3 of the Tardieu Scale) improved in finger (+35 degree), elbow (+22 degree) and wrist (+12 degree) flexors" but no further outcome data were provided. For <a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a>, we calculated the between‐group difference in spasticity (as measured by the Modified Ashworth Scale) as mean difference 0.30 (95% confidence interval ‐0.87 to 1.47). </p> <p><sup>2</sup>Included studies: <a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a>; <a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a>. </p> <p><sup>3</sup>Downgraded four times due to: risk of bias concerns for both studies (downgraded twice, because either insufficient information about random sequence generation and allocation concealment, in one study, and potential selective outcome reporting in both studies), indirectness (one study included mixed traumatic brain injury and stroke populations, and measured spasticity using the Modified Ashworth Scale) and a high likelihood of publication bias in this area. </p> <p><sup>4</sup>In the main trial of <a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a> (in which the traumatic brain injury population was a part (9.5%)) the most common botulinum toxin A‐related adverse event was 'mild muscle weakness' and investigators reported that all adverse events were mild or moderate only. In <a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a>, botulinum toxin A was reported to be well tolerated, with only one participant with 'flu‐like' symptoms (i.e. shivering, sweating and fever). In groups who received casting (either alone, or in addition to botulinum toxin A), 41% to 50% developed 'minor' skin damage. Overall, 90.9% of those resolved spontaneously or with therapeutic dressing. </p> <p><sup>5</sup>Downgraded three times due to: risk of bias concerns for both studies (downgraded twice, because in one study there was insufficient information about random sequence generation and allocation concealment, and in both studies the adverse events data was reporting in percentages only) and a high likelihood of publication bias in this area. </p> <p><sup>6</sup><a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a> reported between‐group differences in ankle dorsiflexion, finding no differences between groups in a one‐way ANOVA (casting + placebo versus casting + botulinum toxin A: P = 0.11). However, they did not report any summary statistics for this, or any baseline scores. </p> <p><sup>7</sup>Downgraded four times due to: risk of bias concerns for both studies (downgraded twice, because either insufficient information about random sequence generation and allocation concealment, in one study, and potential selective outcome reporting in both studies), indirectness (one study included mixed traumatic brain injury and stroke populations) and a high likelihood of publication bias in this area. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008929-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Pseudoelastic orthosis versus traditional (static) splint for spasticity in people with traumatic brain injury</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Pseudoelastic orthosis versus traditional (static) splint for spasticity in people with traumatic brain injury</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Patient or population:</b> children/young people aged 4‐18 years with traumatic brain injury and with 'mild to severe spastic tetraparesis' (weakness) in all limbs </p> <p><b>Settings:</b> Istituro Eugenio Media (Italy) </p> <p><b>Intervention:</b> repositioning splints equipped with participant‐specific pseudoelastic hinges </p> <p><b>Comparison:</b> traditional splints with fixed angle braces </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Results and conclusions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Spasticity at up to 6 hours after treatment</b> </p> <p>(measured by the Modified Ashworth Scale, 0‐4, with a higher score indicating greater spasticity) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>We are uncertain about the effect of pseudoelastic splints compared with traditional splints on spasticity.<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>2</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>We are uncertain about the effect of pseudoelastic splints compared with traditional splints on adverse events.<sup>3</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>25<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>4</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sensory functions and pain</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>The included study did not report this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Neuromusculoskeletal and movement‐related functions post treatment</b> </p> <p>(measured by range of movement)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>We are uncertain about the effect of pseudoelastic splints compared with traditional splints on range of movement.<sup>5</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>25</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>6</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>General tasks and demands</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>The included study did not report this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mobility</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>The included study did not report this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Self‐care</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>The included study did not report this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>1</sup>One study comparing novel pseudoelastic orthoses to traditional fixed angle splints reported no improvement in spasticity in the upper and lower limbs, over a period of one month of intervention. and that results of the two steps were not significantly different (<a href="./references#CD008929-bbs2-0008" title="PittaccioS , GaravagliaL , ViscusoS , BerettaE , StrazzerS . Implementation, testing and pilot clinical evaluation of superelastic splints that decrease joint stiffness. Annals of Biomedical Engineering2013;41:2003‐17. ">Pittaccio 2013</a>). </p> <p><sup>2</sup>Downgraded four times due to risk of bias limitations (study provided no information about sequence generation and allocation concealment; blinding was impossible for participants or personnel and not reported for outcome assessors; selective outcome reporting bias was high); our concerns about indirectness of the Ashworth Score and indirectness due to 36% of participants not having traumatic brain injury and one participant was of dubious eligibility; an inability to assess imprecision relating to an absence of meaningful outcome data (no numerical data were provided for spasticity; investigators reported only that there were no significant differences), and there was only one study for this comparison/outcome and that publication bias was possible in this area. </p> <p><sup>3</sup>No adverse events were reported for pseudoelastic orthoses neither did any require adjustments after fitting. Adjustments were required for 30% of traditional splints to reduce skin rash, haematomas and oedema. </p> <p><sup>4</sup>Downgraded four times due to risk of bias limitations (study provided insufficient information about sequence generation and allocation concealment, blinding was impossible for participants and personnel and not reported for outcome assessors, and selective reporting bias was high). We had concerns about indirectness given that 36% of participants did not have traumatic brain injury and one participant was of dubious eligibility. Furthermore, there was only one study for this comparison/outcome and publication bias was possible in this area. </p> <p><sup>5</sup>One study reported no improvement in range of movement in the upper and lower limbs, over a period of one month of intervention (<a href="./references#CD008929-bbs2-0008" title="PittaccioS , GaravagliaL , ViscusoS , BerettaE , StrazzerS . Implementation, testing and pilot clinical evaluation of superelastic splints that decrease joint stiffness. Annals of Biomedical Engineering2013;41:2003‐17. ">Pittaccio 2013</a>). </p> <p><sup>6</sup>Downgraded five times due to risk of bias limitations (this study provided insufficient information about sequence generation and allocation concealment, blinding was impossible for participants and personnel and not reported for outcome assessors, and selective reporting bias was high). We had concerns about indirectness due to 36% of participants not having traumatic brain injury and one participant was of dubious eligibility; our inability to assess imprecision given that means and standard deviations were only presented within a small box and whiskers plot, and a further downgrade for there only being one study for this comparison/outcome and the likelihood of publication bias in this area. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008929-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008929-sec-0030"></div> <p>Traumatic brain injury (TBI) is the result of an external force to the head, that can lead to permanent damage to the brain. There are many causes of TBI including motor vehicle accidents, falls, violent assaults or blast injuries (<a href="./references#CD008929-bbs2-0109" title="MaasAI , StocchettiN , BullockR . Moderate and severe traumatic brain injury in adults. Lancet Neurology. 2008/07/19 2008; Vol. 7, issue 8:728‐41. ">Maas 2008</a>). In 2005, The US Centre for Disease Control and Prevention estimated at least 3.17 million Americans, approximately 1.1% of the US population, are living with long‐term disability as a result of TBI (<a href="./references#CD008929-bbs2-0132" title="SummersCR , IvinsB , SchwabKA . Traumatic brain injury in the United States: an epidemiologic overview. Mount Sinai Journal of Medicine2009; Vol. 76, issue 2:105‐10. ">Summers 2009</a>). In Europe, the incidence of TBI in studies published between 1983 and 2013 has been estimated to be between 47.3 to 849 per 100,000 population per year (<a href="./references#CD008929-bbs2-0086" title="BrazinovaA , RehorcikovaV , TaylorMS , BuckovaV , MajdanM , PsotaM , et al. Epidemiology of Traumatic Brain Injury in Europe: A Living Systematic Review. Journal of Neurotrauma2016:Epub ahead of print. [DOI: 10.1089/neu.2015.4126] ">Brazinova 2016</a>). There are limited data available for low‐ to middle‐income countries. The impact of TBI to a person can be far‐reaching and may result in ongoing physical, cognitive and behavioural issues (<a href="./references#CD008929-bbs2-0103" title="KhanF , BaguleyIJ , CameronID . Rehabilitation after traumatic brain injury. Medical Journal of Australia. 2003/03/14 2003; Vol. 178, issue 6:290‐5. ">Khan 2003</a>). Skeletal muscle spasticity is one of the major physical complications following TBI (<a href="./references#CD008929-bbs2-0085" title="BrashearA , ElovicE . Why is spasticity important?. Spasticity: Diagnosis and Management. New York (NY): Demos Medical Publishing, 2016:3‐4. ">Brashear 2016</a>). </p> <section id="CD008929-sec-0031"> <h3 class="title" id="CD008929-sec-0031">Description of the condition</h3> <p>Spasticity is defined as an ongoing contraction of a muscle caused by an increase in muscle tone and deep tendon reflexes that is partly due to a reduction of the skeletal stretch reflex threshold (<a href="./references#CD008929-bbs2-0106" title="LanceJ . Pathophysiology of spasticity and clinical experience with baclofen. In: LanceJWFR , YoungRR , KoellaWP editor(s). Spasticity: Disordered Motor Control. Chicago (IL): Year Book Medical Publishers, 1980. ">Lance 1980</a>). It is often described as muscle overactivity. Spasticity occurs due to damage of upper motor neurons (UMN) of the corticoreticular pathways in the brain cortex or internal capsule, or damage to the UMNs in the reticulospinal or vestibulospinal tracts in the spinal cord (<a href="./references#CD008929-bbs2-0122" title="PandyanA , GregoricM , BarnesM , WoodD , VanWijckF , BurridgeJ , et al. Spasticity: clinical perceptions, neurological realities and meaningful measurement. Disability and Rehabilitation2005; Vol. 27:2‐6. ">Pandyan 2005</a>). Spasticity may occur sporadically or continuously, for periods of short and long duration. </p> <p>Spasticity tends to affect the antigravity muscle groups in the upper and lower limbs (<a href="./references#CD008929-bbs2-0118" title="NairKPS , MarsdenJ . The management of spasticity in adults. BMJ2014;349:g4737. ">Nair 2014</a>). In the upper limbs, this can commonly include the shoulder adductors, elbow, wrist and finger flexors, forearm pronators and thumb adductors. In the lower limbs, spasticity often affects the hip adductors, knee flexors, ankle plantarflexors and invertors, and big toe extensors (<a href="./references#CD008929-bbs2-0118" title="NairKPS , MarsdenJ . The management of spasticity in adults. BMJ2014;349:g4737. ">Nair 2014</a>). Spasticity can also affect muscles in the neck. </p> <p>There are limited epidemiological data regarding the prevalence of spasticity following TBI (<a href="./references#CD008929-bbs2-0044" title="MartinA , AbogunrinS , KurthH , DinetJ . Epidemiological, humanistic, and economic burden of illness of lower limb spasticity in adults: a systematic review. Neuropsychiatric Disease and Treatment2014;10:111‐22. ">Martin 2014</a>; <a href="./references#CD008929-bbs2-0113" title="McGuireJ . Epidemiology of spasticity in the adult and child. In: BrashearA editor(s). Spasticity: Diagnosis and Management. 2nd Edition. New York (NY): Demos Medical Publishing, 2016. ">McGuire 2016</a>). In one systematic review of the epidemiology of lower limb spasticity, <a href="./references#CD008929-bbs2-0044" title="MartinA , AbogunrinS , KurthH , DinetJ . Epidemiological, humanistic, and economic burden of illness of lower limb spasticity in adults: a systematic review. Neuropsychiatric Disease and Treatment2014;10:111‐22. ">Martin 2014</a> identified only one study (<a href="./references#CD008929-bbs2-0131" title="SingerBJ , JegasothyGM , SingerKP , AllisonGT , DunneJW . Incidence of ankle contracture after moderate to severe acquired brain injury. Archives of Physical Medicine and Rehabilitation. 2004/09/18 2004; Vol. 85, issue 9:1465‐9. ">Singer 2004</a>), conducted in 105 people with TBI that found the prevalence of ankle spasticity was 13%. Similarly, <a href="./references#CD008929-bbs2-0113" title="McGuireJ . Epidemiology of spasticity in the adult and child. In: BrashearA editor(s). Spasticity: Diagnosis and Management. 2nd Edition. New York (NY): Demos Medical Publishing, 2016. ">McGuire 2016</a> was only able to find one study of spasticity prevalence following TBI (<a href="./references#CD008929-bbs2-0135" title="WedekindC , Lippert‐GrünerM . Long‐term outcome in severe traumatic brain injury is significantly influenced by brainstem involvement. Brain Injuries2005;19:681‐4. ">Wedekind 2005</a>), which was a study of 32 people with TBI, in which the prevalence of spasticity (location unclear) was 32%. While both the definition and measurement of spasticity is inconsistent, and often poorly defined (<a href="./references#CD008929-bbs2-0111" title="MalhotraS , PandyanAD , DayCR , JonesPW , HermensH . Spasticity, an impairment that is poorly defined and poorly measured. Clinical Rehabilitation2009;23:651‐8. ">Malhotra 2009</a>), <a href="./references#CD008929-bbs2-0113" title="McGuireJ . Epidemiology of spasticity in the adult and child. In: BrashearA editor(s). Spasticity: Diagnosis and Management. 2nd Edition. New York (NY): Demos Medical Publishing, 2016. ">McGuire 2016</a> suggests that by extrapolating data from studies in other populations (including people with stroke, spinal cord injury and multiple sclerosis), 'problematic' spasticity may occur in between 30% and 50% of people with TBI. </p> <p>Spasticity can lead to a range of musculoskeletal issues such as muscle contracture, involuntary and uncontrollable shaking, joint stiffness, reduced range of movement, broken skin and pain (<a href="./references#CD008929-bbs2-0074" title="AdaL , O'DwyerN , O'NeillE . Relation between spasticity, weakness and contracture of the elbow flexors and upper limb activity after stroke: an observational study. Disability and Rehabilitation2006; Vol. 28, issue 13‐14:891‐7. ">Ada 2006a</a>; <a href="./references#CD008929-bbs2-0075" title="AdaL , DorschS , CanningCG . Strengthening interventions increase strength and improve activity after stroke: a systematic review. Australian Journal of Physiotherapy2006; Vol. 52, issue 4:241‐8. ">Ada 2006b</a>). The debilitating nature of the condition can directly impact a person's ability to carry out normal activities of daily living (ADL), such as self‐care and household tasks, and is likely to lead to dependency on carers or family members for assistance. Participation in daily life and opportunities for community integration can prove difficult and may ultimately impact the person's quality of life (<a href="./references#CD008929-bbs2-0105" title="KwakkelG , WagenaarR , TwiskJ , LankhorstG , KoetsierJ . Intensity of leg and arm training after primary middle‐cerebral‐artery stroke: a randomised trial. Lancet1999; Vol. 354:191‐6. ">Kwakkel 1999</a>). Management of spasticity in people with TBI varies from other clinical populations primarily due to behavioural and cognitive issues that affect their ability to participate in, or tolerate, treatment (e.g. their ability to follow instructions, monitor use of a spastic limb or tolerate a cast). These factors are likely to impact on whether or not a treatment is effective in this population and limit the applicability of findings from other populations where behavioural and cognitive issues are not a primary concern (<a href="./references#CD008929-bbs2-0112" title="ManchesterD , HodgkinsonA , CaseyT . Prolonged, severe behavioural disturbance following traumatic brain injury: what can be done?. Brain Injury1997;11:605‐17. ">Manchester 1997</a>; <a href="./references#CD008929-bbs2-0139" title="WoodRL , McCreaJD , WoodLM , MerrimanRN . Clinical and cost effectiveness of post‐acute neurobehavioural rehabilitation. Brain Injury1999;13:69‐88. ">Wood 1999</a>). Furthermore, some studies have shown that mobility limitations can be improved over time and that the presence, distribution and severity of spasticity may not necessarily be the best determinant in recovery and mobility outcomes (<a href="./references#CD008929-bbs2-0137" title="WilliamsG , BankyM , OlverJ . Severity and distribution of spasticity does not limit mobility or influence compensatory strategies following traumatic brain injury. Brain Injury2015;29(10):1232‐8. ">Williams 2015a</a>; <a href="./references#CD008929-bbs2-0138" title="WilliamsG , BankyM , OlverJ . Distribution of lower limb spasticity does not influence mobility outcome following traumatic brain injury: an observational study. Journal of Head Trauma Rehabilitation2015;30(5):E49‐57. ">Williams 2015b</a>). </p> <p>The measurement of spasticity in clinical practice, and in research, is challenging (<a href="./references#CD008929-bbs2-0111" title="MalhotraS , PandyanAD , DayCR , JonesPW , HermensH . Spasticity, an impairment that is poorly defined and poorly measured. Clinical Rehabilitation2009;23:651‐8. ">Malhotra 2009</a>). The most common scales to measure spasticity are the (Modified) Ashworth Scale (<a href="./references#CD008929-bbs2-0121" title="PandyanAD , JohnsonGR , PriceCI , CurlessRH , BarnesMP , RodgersH . A review of the properties and limitations of the Ashworth and modified Ashworth Scales as measures of spasticity. Clinical Rehabilitation1999; Vol. 13, issue 5:373‐83. ">Pandyan 1999</a>) and the (Modified) Tardieu Scale (<a href="./references#CD008929-bbs2-0097" title="HaughAB , PandyanAD , JohnsonGR . A systematic review of the Tardieu Scale for the measurement of spasticity. Disability and Rehabilitation2006; Vol. 28, issue 15:899‐907. ">Haugh 2006</a>). The (Modified) Ashworth Scale is commonly used by clinicians as it is the easier scale to complete (<a href="./references#CD008929-bbs2-0121" title="PandyanAD , JohnsonGR , PriceCI , CurlessRH , BarnesMP , RodgersH . A review of the properties and limitations of the Ashworth and modified Ashworth Scales as measures of spasticity. Clinical Rehabilitation1999; Vol. 13, issue 5:373‐83. ">Pandyan 1999</a>), however it only measures the resistance in a muscle, which may or may not be caused by spasticity (<a href="./references#CD008929-bbs2-0124" title="PatrickE , AdaL . The Tardieu Scale differentiates contracture from spasticity whereas the Ashworth Scale is confounded by it. Clinical Rehabilitation2006;20:173‐82. ">Patrick 2006</a>). This is in contrast to the (Modified) Tardieu Scale which measures spasticity by the spasticity catch angle as well as resistance in the muscle (<a href="./references#CD008929-bbs2-0097" title="HaughAB , PandyanAD , JohnsonGR . A systematic review of the Tardieu Scale for the measurement of spasticity. Disability and Rehabilitation2006; Vol. 28, issue 15:899‐907. ">Haugh 2006</a>). The Tardieu has also demonstrated greater test‐retest and inter‐rater reliability compared with the Modified Ashworth Scale (<a href="./references#CD008929-bbs2-0114" title="MehrholzJ , MajorY , MeissnerD , Sandi‐GahunS , KochR , PohlM . The influence of contractures and variation in measurement stretching velocity on the reliability of the Modified Ashworth Scale in patients with severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 1:63‐72. ">Mehrholz 2005</a>). The (Modified) Tardieu includes a continuous and nominal (or sometimes considered ordinal (<a href="./references#CD008929-bbs2-0097" title="HaughAB , PandyanAD , JohnsonGR . A systematic review of the Tardieu Scale for the measurement of spasticity. Disability and Rehabilitation2006; Vol. 28, issue 15:899‐907. ">Haugh 2006</a>)) component, and the (Modified) Ashworth is ordinal, but both are commonly treated as continuous scales by trialists. While there does not appear to be a clear consensus about the most appropriate way to analyse these scales, we note that for another five‐point ordinal scale used in TBI (the Glasgow Outcome Scale (<a href="./references#CD008929-bbs2-0101" title="JennettB , BondM . Assessment of outcome after severe brain damage. Lancet1975;1:480‐4. ">Jennett 1975</a>)), a sliding dichotomy or proportional odds methodology is recommended for analysis (<a href="./references#CD008929-bbs2-0110" title="MaasAIR , SteyerbergEW , MarmarouA , McHughGS , LingsmaHF , ButcherI , et al. IMPACT recommendations for improving the design and analysis of clinical trials in moderate to severe traumatic brain injury. Neurotherapeutics2010;7:127‐34. ">Maas 2010</a>). </p> </section> <section id="CD008929-sec-0032"> <h3 class="title" id="CD008929-sec-0032">Description of the intervention</h3> <p>Interventions for managing skeletal muscle spasticity can be broadly categorised as either pharmacological or non‐pharmacological. Examples of pharmacological interventions include baclofen (<a href="./references#CD008929-bbs2-0082" title="BeckerR , AlbertiO , BauerBL . Continuous intrathecal baclofen infusion in severe spasticity after traumatic or hypoxic brain injury. Journal of Neurology1997; Vol. 244, issue 3:160‐6. ">Becker 1997</a>), botulinum toxin A, clonidine, dantrolene sodium, tizanidine and phenol injection (<a href="./references#CD008929-bbs2-0115" title="MeythalerJM , Guin‐RenfroeS , JohnsonA , BrunnerRM . Prospective assessment of tizanidine for spasticity due to acquired brain injury. Archives of Physical Medicine and Rehabilitation2001; Vol. 82, issue 9:1155‐63. ">Meythaler 2001a</a>; <a href="./references#CD008929-bbs2-0141" title="YelnikAP , SimonO , BensmailD , Chaleat‐ValayerE , DecqP , DehailP , et al. Drug treatments for spasticity. Annals of Physical &amp; Rehabilitation Medicine2009; Vol. 52, issue 10:746‐56. ">Yelnik 2009</a>). Examples of non‐pharmacological interventions include casting, splinting, stretching, strengthening, transcutaneous electric nerve stimulation (TENS) (<a href="./references#CD008929-bbs2-0080" title="AydinG , TomrukS , KeleşI , DemirS , OrkunS . Transcutaneous electrical nerve stimulation versus baclofen in spasticity: clinical and electrophysiologic comparison. American Journal of Physical Medicine &amp; Rehabilitation2005; Vol. 84, issue 8:584‐92. [0894‐9115] ">Aydin 2005</a>), Bobath treatment, weight bearing gait training and seating. In practice, a combination of both pharmacological and non‐pharmacological interventions is used to manage spasticity. Interventions can be either focal or systemic in their action. Focal interventions involve treatment of one or two muscle groups whereas systemic interventions are used to treat generalised spasticity. </p> </section> <section id="CD008929-sec-0033"> <h3 class="title" id="CD008929-sec-0033">How the intervention might work</h3> <p>Interventions used to manage spasticity all aim to reduce overactivity within the muscle so that it can be lengthened (<a href="./references#CD008929-bbs2-0091" title="EsquenaziA . Improvements in healthcare and cost benefits associated with botulinum toxin treatment of spasticity and muscle overactivity. European Journal of Neurology2006; Vol. 13 (Suppl 4):27‐34. ">Esquenazi 2006</a>). </p> <p>Pharmacological interventions can act locally at the muscle or systemically through the central nervous system. For example, botulinum toxin A and phenol are both injected locally at the site of the spastic muscle whereas other interventions such as tizanidine and clonidine are administered orally. Oral medications act systemically and can induce unwanted adverse effects, such as drowsiness. For those with severe spasticity in multiple areas, adverse effects associated with oral medications can sometimes outweigh the potential benefits of reduced spasticity. An alternative approach, as seen with baclofen, is to administer the treatment through a pump into the space around the spinal cord, thus reducing the impact of adverse effects whilst maintaining improved outcomes for spasticity (<a href="./references#CD008929-bbs2-0082" title="BeckerR , AlbertiO , BauerBL . Continuous intrathecal baclofen infusion in severe spasticity after traumatic or hypoxic brain injury. Journal of Neurology1997; Vol. 244, issue 3:160‐6. ">Becker 1997</a>). </p> <p>Non‐pharmacological interventions involve the use of physical modalities such as stretching and strengthening to promote elongation and control of spastic muscles, or external devices such as casting or splinting to modify and maintain correct positioning of a spastic muscle. Table 1 provides a summary of the range of different interventions and their mode of action. </p> <section id="CD008929-sec-0034"> <h4 class="title">Table 1: Examples of the range of interventions to manage spasticity</h4> <p> <div class="table" id="CD008929-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Pharmacological intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Mode of action</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Non‐pharmacological intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Mode of action</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baclofen</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Administered orally or via intrathecal pump to limit the release of excitatory neurotransmitters in the spinal cord. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Casting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Applied directly to the limb to maintain the muscle in an extended position.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Botulinum toxin A</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A neurotoxin injected directly into the muscle to block the release of the neurotransmitter acetylcholine. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Splinting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thermoplastic or fabric material that is customised to provide support to a person's limb and maintain the limb in the corrected position. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clonidine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Administered orally or by transdermal patch to act on the central nervous system by reducing the excitability of alpha motor neurons. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seating</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Custom made seating for people to provide maximal support and reduce the impact of spasticity. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dantrolene sodium</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Administered orally to reduce the excitation‐contraction coupling within the skeletal muscle and decrease the strength of muscle contraction. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stretching</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Promotes elongation of a muscle for varying lengths of time causing viscous deformation changes. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Phenol</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Injected into specific nerves to induce neurolysis to permanently block nerve transmission.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Transcutaneous electric nerve stimulation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Portable electric stimulator placed on the skin over a spastic muscle to reduce pain.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tizanidine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Administered orally to act on the central nervous system and reduce the excitability of alpha motor neurons. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Surgery </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Surgical techniques primarily aim to alter the structure of a muscle or nerve or relocate a tendon to change its function. </p> </td> </tr> </tbody> </table> </div> </p> </section> </section> <section id="CD008929-sec-0035"> <h3 class="title" id="CD008929-sec-0035">Why it is important to do this review</h3> <p>A range of interventions are currently used to manage skeletal muscle spasticity for people with TBI. Clinical management often involves a combination of pharmacological and non‐pharmacological interventions. Management of spasticity following TBI varies from other clinical populations because of the added complexity of behavioural and cognitive issues associated with TBI. Furthermore, the current management for spasticity in other conditions may not be applicable to TBI as a result of global UMN damage that can occur such as axonal shearing, haemorrhage and hypoxia. A comprehensive systematic review of interventions assessed in the TBI population is needed to identify those likely to have the greatest impact for managing spasticity as well as determining whether the severity of TBI or the timing of an intervention is relevant to the outcome. </p> <p>Reviews of interventions for spasticity in people with TBI are focused solely on the effect of one intervention (botulinum toxin A), and include people with spasticity due to other conditions, predominantly stroke (<a href="./references#CD008929-bbs2-0081" title="BakerJA , PereiraG . The efficacy of botulinum toxin A on improving ease of care in the upper and lower limbs: a systematic review and meta‐analysis using the Grades of Recommendation, Assessment, Development and Evaluation approach. Clinical Rehabilitation2015;29:731‐40. ">Baker 2015</a>; <a href="./references#CD008929-bbs2-0087" title="DashtipourK , ChenJJ , WalkerHW , LeeMY . Systematic literature review of abobotulinumtoxinA in clinical trials for lower limb spasticity. Medicine2016;95:e2468. ">Dashtipour 2016</a>; <a href="./references#CD008929-bbs2-0089" title="DongY , WuT , HuX , WangT . Efficacy and safety of botulinum toxin type A for upper limb spasticity after stroke or traumatic brain injury: a systematic review with meta‐analysis and trial sequential analysis. European Journal of Physical Rehabilitation Medicine2017;53:256‐67. ">Dong 2017</a>). None of these reviews allow conclusions to be drawn specific to people with TBI. Systematic reviews that consider the effects of a broader range of interventions for managing spasticity have done so in populations other than TBI such as stroke (<a href="./references#CD008929-bbs2-0133" title="TariccoM , AdoneR , PagliacciC , TelaroE . Pharmacological interventions for spasticity following spinal cord injury. Cochrane Database of Systematic Reviews2000, Issue 2. [DOI: 10.1002/14651858.CD001131] ">Taricco 2000</a>) and spinal cord injury (<a href="./references#CD008929-bbs2-0088" title="DemetriosM , KhanF , Turner‐StokesL , BrandC , McSweeneyS . Multidisciplinary rehabilitation following botulinum toxin and other focal intramuscular treatment for post‐stroke spasticity. Cochrane Database of Systematic Reviews2013, Issue 6. [DOI: 10.1002/14651858.CD009689.pub2] ">Demetrios 2013</a>; <a href="./references#CD008929-bbs2-0100" title="HsiehJTC , WolfeDL , McIntyreA , JanzenS , TownsonAF , ShortC , et al. Spasticity following spinal cord injury. In: EngJJ , TeasellRW , MillerWC , WolfeDL , TownsonAF , HsiehJTC , et al. editor(s). Spinal Cord Injury Rehabilitation Evidence, Version 4.0. Vancouver (BC): SCIRE Project, 2012. ">Hsieh 2012</a>). To our knowledge, there are no systematic reviews that consider all potential interventions used to manage skeletal muscle spasticity specifically for people with TBI. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008929-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008929-sec-0036"></div> <p>To assess the effects of interventions for managing skeletal muscle spasticity in people with TBI. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008929-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008929-sec-0037"></div> <section id="CD008929-sec-0038"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008929-sec-0039"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCT). Cross‐over trials were included as long as the sequence of treatments was randomly allocated. </p> </section> <section id="CD008929-sec-0040"> <h4 class="title">Types of participants</h4> <p>We included people with TBI of any age (i.e. children and adults), who had skeletal muscle spasticity experienced at any time after injury. We made a post‐hoc decision to include only studies that either: </p> <p> <ul id="CD008929-list-0001"> <li> <p>included at least 50% of people with TBI amongst their participants;</p> </li> <li> <p>provided disaggregated data for participants with TBI if the proportion of participants within the trial was less than 50%. </p> </li> </ul> </p> <p>This decision was made in response to the identification of a large number of studies with mixed populations (e.g. stroke and TBI) that were found during screening to ensure the evidence would be applicable to people with TBI. </p> </section> <section id="CD008929-sec-0041"> <h4 class="title">Types of interventions</h4> <p>We included studies that compared any of the following: pharmacological or non‐pharmacological intervention (or a combination of both) or placebo/no treatment. </p> </section> <section id="CD008929-sec-0042"> <h4 class="title">Types of outcome measures</h4> <section id="CD008929-sec-0043"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD008929-list-0002"> <li> <p>Spasticity, measured using common tools such as the Tardieu or Modified Tardieu Scale (<a href="./references#CD008929-bbs2-0097" title="HaughAB , PandyanAD , JohnsonGR . A systematic review of the Tardieu Scale for the measurement of spasticity. Disability and Rehabilitation2006; Vol. 28, issue 15:899‐907. ">Haugh 2006</a>), or the Ashworth Scale or Modified Ashworth (<a href="./references#CD008929-bbs2-0121" title="PandyanAD , JohnsonGR , PriceCI , CurlessRH , BarnesMP , RodgersH . A review of the properties and limitations of the Ashworth and modified Ashworth Scales as measures of spasticity. Clinical Rehabilitation1999; Vol. 13, issue 5:373‐83. ">Pandyan 1999</a>). </p> </li> <li> <p>Adverse events.</p> </li> </ul> </p> <p>As a post‐hoc decision, we took Tardieu or Modified Tardieu, in preference to the (Modified) Ashworth Scale, in the instance that an included study used both these measures. This decision was made given the (Modified) Ashworth poorly differentiates between spasticity and contracture (<a href="./references#CD008929-bbs2-0124" title="PatrickE , AdaL . The Tardieu Scale differentiates contracture from spasticity whereas the Ashworth Scale is confounded by it. Clinical Rehabilitation2006;20:173‐82. ">Patrick 2006</a>), and as the Tardieu is considered to have greater test‐retest and inter‐rater reliability compared with the Modified Ashworth Scale (<a href="./references#CD008929-bbs2-0114" title="MehrholzJ , MajorY , MeissnerD , Sandi‐GahunS , KochR , PohlM . The influence of contractures and variation in measurement stretching velocity on the reliability of the Modified Ashworth Scale in patients with severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 1:63‐72. ">Mehrholz 2005</a>). </p> </section> <section id="CD008929-sec-0044"> <h5 class="title">Secondary outcomes</h5> <p>A range of secondary outcomes were included, classified according to the World Health Organization International Classification of Functioning, Disability and Health (<a href="./references#CD008929-bbs2-0136" title="World Health Organization. International Classification of Functioning, Disability &amp; Health. apps.who.int/classifications/icfbrowser/ (accessed 2 July 2010). ">WHO 2010</a>) using the following domains. </p> <p>Body functions</p> <p> <ul id="CD008929-list-0003"> <li> <p>Sensory functions and pain (e.g. pain intensity).</p> </li> <li> <p>Neuromusculoskeletal and movement‐related functions (e.g. goniometric measurement).</p> </li> </ul> </p> <p>Activities and participation</p> <p> <ul id="CD008929-list-0004"> <li> <p>General tasks and demands (e.g. Canadian Occupational Performance Measure (<a href="./references#CD008929-bbs2-0107" title="LawM , BaptisteS , CarswellA , McCollMA , PolatajkoH , PollockN . Canadian Occupational Performance Measure. Canada: CAOT Publications, 2000. ">Law 2000</a>)). </p> </li> <li> <p>Mobility (e.g. gait and balance measures).</p> </li> <li> <p>Self‐care (e.g. Functional Independence Measure (<a href="./references#CD008929-bbs2-0102" title="KeithRA , GrangerCV , HamiltonBB , SherwinFS . The functional independence measure: a new tool for rehabilitation. Advances in Clinical Rehabilitation1987;1:6‐18. ">Keith 1987</a>)). </p> </li> <li> <p>Domestic life (e.g. Goal Attainment Scale (<a href="./references#CD008929-bbs2-0104" title="KiresukTJ , SmithA , CardilloJE . Goal Attainment Scaling: Applications, Theory, and Measurement. Hillsdale (NJ): Lawrence Erlbaum Associates, 1994. ">Kiresuk 1994</a>)). </p> </li> <li> <p>Major life areas (e.g. Functional Assessment Measure (<a href="./references#CD008929-bbs2-0096" title="HallKM , HamiltonBB , GordonWA , ZaslerND . Characteristics and comparisons of functional assessment indices: disability rating scale, functional independence measure, and functional assessment measure. Journal of Head Trauma Rehabilitation1993;8:60‐74. ">Hall 1993</a>)). </p> </li> <li> <p>Community, social and civic life (e.g. quality of life measures).</p> </li> </ul> </p> <section id="CD008929-sec-0045"> <h6 class="title">Information size calculation</h6> <p>In line with Cochrane Injuries policy, we undertook a post‐hoc information size calculation, to determine the sample size required in a meta‐analysis for the primary outcome, spasticity. Determining the parameters for this calculation was difficult, as the most commonly used measure of spasticity (the Ashworth or Modified Ashworth Scale) was not necessarily the most clinically meaningful, or appropriate (<a href="./references#CD008929-bbs2-0097" title="HaughAB , PandyanAD , JohnsonGR . A systematic review of the Tardieu Scale for the measurement of spasticity. Disability and Rehabilitation2006; Vol. 28, issue 15:899‐907. ">Haugh 2006</a>), and it is also an ordinal scale that is frequently treated as continuous. Considering we could be combining more than one spasticity scale, we applied the 'rule of thumb' for determining a 'small' difference between two groups as a standardised mean difference (SMD) of 0.2 standard deviations (<a href="./references#CD008929-bbs2-0095" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso‐CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence ‐ imprecision. Journal of Clinical Epidemiology2011;64:1283‐93. ">Guyatt 2011</a>). Assuming 90% power at the 5% significance level, this means that we require 526 participants in both the intervention and control groups within a meta‐analysis to be able to detect a difference between groups, if such a difference exists. </p> </section> </section> </section> </section> <section id="CD008929-sec-0046"> <h3 class="title">Search methods for identification of studies</h3> <p>To reduce publication and retrieval bias, we did not restrict our search by language, date or publication status. </p> <section id="CD008929-sec-0047"> <h4 class="title">Electronic searches</h4> <p>The information in this review is current to June 2017. Studies were identified through searches run in 2013, 2016 and 2017. </p> <p>In November 2013, we searched the following databases:</p> <p> <ul id="CD008929-list-0005"> <li> <p>Cochrane Injuries Group specialised register (1 November 2013);</p> </li> <li> <p>the Cochrane Library (2013, Issue 10);</p> </li> <li> <p>Ovid MEDLINE(R), Ovid MEDLINE(R) In‐Process &amp; Other Non‐Indexed Citations, Ovid MEDLINE(R) Daily and Ovid OLDMEDLINE(R) (1946 to 1 November 2013); </p> </li> <li> <p>Embase Classic + Embase (OvidSP) (1947 to 1 November 2013);</p> </li> <li> <p>PubMed (<a href="http://www.ncbi.nlm.nih.gov/pubmed/" target="_blank">www.ncbi.nlm.nih.gov/pubmed/</a>) (1 November 2013); </p> </li> <li> <p>ISI Web of Science: Science Citation Index Expanded (SCI‐EXPANDED) (1970 to 01 November 2013); </p> </li> <li> <p>ISI Web of Science: Conference Proceedings Citation Index‐Science (CPCI‐S) (1990 to 1 November 2013); </p> </li> <li> <p>CINAHL Plus (1939 to 1 November 2013);</p> </li> <li> <p>PsycINFO (1806 to November 2013);</p> </li> <li> <p>PEDro (Physiotherapy Evidence Database) (1929 to November 2013);</p> </li> <li> <p>OTSeeker (Occupational Therapy Systematic Evaluation of Evidence) www.otseeker.com (1955 to November 2013); </p> </li> <li> <p>Database of Abstracts of Reviews of Effects (DARE) (November 2013).</p> </li> </ul> </p> <p>In May 2016, the Cochrane Injuries Group Information Specialist developed and ran a new search. This was because of changes in the author team that meant we were unable to locate the exact search strategies used in the original search (beyond the MEDLINE strategy). The database list was reduced and included: </p> <p> <ul id="CD008929-list-0006"> <li> <p>Cochrane Injuries Group Specialised Register (16 May 2016);</p> </li> <li> <p>MEDLINE (OvidSP) (16 May 2016);</p> </li> <li> <p>Embase Classic and Embase (OvidSP) (16 May 2016).</p> </li> </ul> </p> <p>The search strategies for the 2016 search are listed in <a href="./appendices#CD008929-sec-0133">Appendix 1</a>. </p> <p>The Cochrane Injuries Information Specialist conducted a final prepublication search in June 2017. Given these searches were revised again by the Cochrane Injuries Information Specialist, we have listed the databases below. Some of the original databases were not searched in 2017 as the databases did not yield any unique studies in earlier searches. </p> <p>We searched the following databases in June 2017 (and deduplicated against earlier yields): </p> <p> <ul id="CD008929-list-0007"> <li> <p>Cochrane Injuries Group Specialised Register (SR‐INJ) (22 June 2017);</p> </li> <li> <p>the Cochrane Library (2017, Issue 6);</p> </li> <li> <p>Ovid MEDLINE(R), Ovid MEDLINE(R) In‐Process &amp; Other Non‐Indexed Citations, Ovid MEDLINE(R) Daily and Ovid OLDMEDLINE(R) (2013 to 22 June 2017); </p> </li> <li> <p>Ovid Embase (1974 to 22 June 2017);</p> </li> <li> <p>PubMed (not MEDLINE) (<a href="http://www.ncbi.nlm.nih.gov/pubmed/" target="_blank">www.ncbi.nlm.nih.gov/pubmed/</a>) (22 June 2017); </p> </li> <li> <p>ISI Web of Science: Science Citation Index Expanded (SCI‐EXPANDED) (1970 to 22 June 2017); </p> </li> <li> <p>ISI Web of Science: Conference Proceedings Citation Index‐Science (CPCI‐S) (1990 to 22 June 2017); </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>) (22 June 2017); </p> </li> <li> <p>WHO International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>) (22 June 2017). </p> </li> </ul> </p> <p>These search strategies are listed in <a href="./appendices#CD008929-sec-0134">Appendix 2</a> so they can be used in future updates. </p> </section> <section id="CD008929-sec-0048"> <h4 class="title">Searching other resources</h4> <p>We screened the reference lists of all included articles and relevant reviews to identify additional studies for inclusion in the review. </p> </section> </section> <section id="CD008929-sec-0049"> <h3 class="title" id="CD008929-sec-0049">Data collection and analysis</h3> <section id="CD008929-sec-0050"> <h4 class="title">Selection of studies</h4> <p>Two review authors (KP, MC or AS) independently screened citations on abstract and title against the selection criteria. We obtained potentially eligible citations in full text and repeated the process. The two review authors discussed disagreements regarding study eligibility until consensus was reached or consulted a third review author for a final decision. For trials with mixed populations, we contacted study authors to obtain data or clarification (or both) to inform inclusion and exclusion decisions. </p> </section> <section id="CD008929-sec-0051"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (KP, MC or AS) independently extracted the data from included studies using a standardised data collection form, that was first piloted by two authors. One review author (KP) made a final check. We contacted the primary authors of included studies to provide data and clarification where adequate data were not reported. </p> </section> <section id="CD008929-sec-0052"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (KP, MC or AS) independently assessed risk of bias of the included studies using the Cochrane 'Risk of bias' tool (<a href="./references#CD008929-bbs2-0098" title="HigginsJP , AltmanDG , GøtzschePC , JüniP , MoherD , OxmanAD , et al. Cochrane Bias Methods Group, Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ2011;343:d5928. ">Higgins 2011</a>). We assessed sequence generation; allocation concealment; blinding of participants, personnel and outcome assessors; incomplete outcome data; selective outcome reporting; baseline imbalances and other bias issues. Additional domains for cross‐over trials included appropriate study design and adequate washout period. Studies were rated as low, high or unclear risk of bias for each domain, according to the criteria used in the Cochrane 'Risk of bias' tool. </p> </section> <section id="CD008929-sec-0053"> <h4 class="title">Measures of treatment effect</h4> <p>We extracted raw data (means and standard deviations for continuous outcomes and number of events for binary outcomes) for the primary and secondary outcomes. Where these were not provided, we extracted additional data such as sum scores and P values. We extracted postintervention scores over change scores. </p> <p>Where possible, we calculated summary data as risk ratio (RR) with 95% confidence intervals (CI) (dichotomous outcomes) and mean difference (MD) with 95% CI (continuous data). Had we been able to pool continuous outcomes where the outcome was measured using different tools across studies, we would have used standardised mean difference (SMD) with 95% CI. We analysed data in Review Manager 5 (<a href="./references#CD008929-bbs2-0127" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011. ">RevMan 2011</a>). </p> </section> <section id="CD008929-sec-0054"> <h4 class="title">Unit of analysis issues</h4> <p>We sought to explore unit of analysis issues in the cross‐over trials, but were unable to do so due to insufficient reporting. </p> </section> <section id="CD008929-sec-0055"> <h4 class="title">Dealing with missing data</h4> <p>We contacted the primary authors of potentially eligible studies to provide data and clarification, where required. While several authors provided additional information to inform eligibility decisions, we did not receive any additional outcome data (some authors did not respond to our contact and others no longer had access to study data). We describe missing data and dropouts/attrition for each included study in the 'Risk of bias' table, and discussed the extent to which the missing data could have altered the results and conclusions of the review. </p> </section> <section id="CD008929-sec-0056"> <h4 class="title">Assessment of heterogeneity</h4> <p>We considered the clinical heterogeneity of studies, but statistical assessment of heterogeneity was not possible due to the absence of meta‐analysis. If meta‐analysis is possible in future updates, we will consider the magnitude and direction of effect and make a visual inspection of forest plots to assess the degree of overlap of CIs across separate studies and statistical heterogeneity quantified using the I<sup>2</sup> statistic (<a href="./references#CD008929-bbs2-0098" title="HigginsJP , AltmanDG , GøtzschePC , JüniP , MoherD , OxmanAD , et al. Cochrane Bias Methods Group, Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ2011;343:d5928. ">Higgins 2011</a>). </p> </section> <section id="CD008929-sec-0057"> <h4 class="title">Assessment of reporting biases</h4> <p>Due to insufficient studies, formal assessment of reporting bias (via funnel plots) could not be carried out. In future updates, if there are more than 10 studies assessing the same outcome(s), we will construct a funnel plot to investigate small study effects (<a href="./references#CD008929-bbs2-0098" title="HigginsJP , AltmanDG , GøtzschePC , JüniP , MoherD , OxmanAD , et al. Cochrane Bias Methods Group, Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ2011;343:d5928. ">Higgins 2011</a>). </p> </section> <section id="CD008929-sec-0058"> <h4 class="title">Data synthesis</h4> <p>We had planned to pool outcome data for studies that were considered sufficiently similar. The diversity of interventions and comparator groups as well as paucity of data available meant that a pooled analysis was not possible, therefore the results for each study are presented narratively. We grouped and assessed studies based on the type of intervention (pharmacological or non‐pharmacological or a combination of both) and the comparison group (no treatment, placebo studies or an alternative intervention). </p> <p>We assessed and reported the quality of the body of evidence contributing each outcome using the GRADE criteria (<a href="./references#CD008929-bbs2-0129" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011</a>). These five criteria are: risk of bias, inconsistency, imprecision, indirectness and publication bias. Two review authors (AS, MC) independently assessed the quality of the evidence using the GRADE approach (<a href="./references#CD008929-bbs2-0128" title="RyanR , HillS . How to GRADE the quality of the evidence. Cochrane Consumers and Communication Group, Version 3.0 December 2016. cccrg.cochrane.org/sites/cccrg.cochrane.org/files/public/uploads/how_to_grade_revising_1_december_2016.pdf (accessed prior to 25 October 2017). ">Ryan 2016</a>; <a href="./references#CD008929-bbs2-0129" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011</a>). </p> </section> <section id="CD008929-sec-0059"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We were unable to conduct planned subgroup analyses due to the lack of data. Should there be sufficient data in future updates, we will undertake subgroup analyses to investigate the effect of: </p> <p> <ul id="CD008929-list-0008"> <li> <p>timing of intervention post injury (i.e. early: within two years, versus late: at least two years' postinjury); </p> </li> <li> <p>severity of TBI defined by the Glasgow Coma Scale (<a href="./references#CD008929-bbs2-0134" title="TeasdaleG , JennettB . Assessment of coma and impaired consciousness. Lancet1974;304:814. ">Teasdale 1974</a>); </p> </li> <li> <p>severity of spasticity as defined by the Ashworth Scale for muscle spasticity;</p> </li> <li> <p>single intervention versus combined interventions;</p> </li> <li> <p>mixed population studies versus studies with TBI participants only;</p> </li> <li> <p>adults versus children.</p> </li> </ul> </p> </section> <section id="CD008929-sec-0060"> <h4 class="title">Sensitivity analysis</h4> <p>We were unable to conduct the planned sensitivity analysis due to the lack of available data. Should there be sufficient studies in future updates, we will investigate the effect of removing studies with inadequate or unclear allocation concealment from meta‐analyses. This domain was selected as the allocation sequence can be concealed in all RCTs (unlike some domains, e.g. like blinding), and there is empirical evidence demonstrating the increased risk of selection bias that can be introduced by unconcealed allocation in studies with more subjective outcomes (such as spasticity and others assessed in this review) (<a href="./references#CD008929-bbs2-0140" title="WoodL , EggerM , GluudLL , SchulzK , JüniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ2008;336:601‐5. ">Wood 2008</a>). </p> <section id="CD008929-sec-0061"> <h5 class="title">'Summary of findings' tables</h5> <p>We made a post‐hoc decision to prepare 'Summary of findings' tables to present the meta‐analysed or narrative results along with the GRADE ratings of our main outcomes. These outcomes were selected on the basis of their clinical importance, rather than the study results. The outcomes included in the 'Summary of findings' table are: spasticity, adverse events, sensory functions and pain, neuromusculoskeletal and movement‐related functions, general tasks and demands, mobility and self‐care. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008929-sec-0062" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008929-sec-0062"></div> <section id="CD008929-sec-0063"> <h3 class="title">Description of studies</h3> <section id="CD008929-sec-0064"> <h4 class="title">Results of the search</h4> <p>Combining the yields of all searches up to June 2017, we identified 1743 citations after deduplication, excluding 1527 of these on title and abstract (see <a href="#CD008929-fig-0001">Figure 1</a>). This left 216 citations assessed in full text, of which 201 were excluded (see <a href="#CD008929-fig-0001">Figure 1</a>; <a href="#CD008929-sec-0080">Excluded studies</a>; <a href="./references#CD008929-sec-0144" title="">Characteristics of excluded studies</a> table and <a href="#CD008929-tbl-0004">Table 1</a> for more information and reasons). </p> <div class="figure" id="CD008929-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram for searches up until June 2017. TBA: traumatic brain injury." data-id="CD008929-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008929.pub2/media/CDSR/CD008929/image_n/nCD008929-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram for searches up until June 2017. TBA: traumatic brain injury.</p> </div> </div> </div> <div class="table" id="CD008929-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Excluded studies with less than 50% of participants with traumatic brain injury</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Author (year)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n TBI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>% TBI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>%TBI Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>%TBI comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Botulinum toxin A vs placebo</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0053" title="NCT00900666 . Efficacy of botulinum toxin Injections in the rectus femoris to treat stiff knee gait following acquired brain injury. clinicaltrials.gov/ct2/show/NCT00900666 Date first received: 13 May 2009. ">NCT00900666</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Botulinum toxin A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0020" title="BurbaudP , WiartL , DubosJL , GaujardE , DebelleixX , JosephPA , et al. A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. Journal of Neurology, Neurosurgery, and Psychiatry. 1996/09/01 1996; Vol. 61, issue 3:265‐9. ">Burbaud 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Botulinum toxin A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0029" title="FietzekUM , KossmehlP , ScheloskyL , EbersbachG , WisselJ . Early botulinum toxin treatment for spastic pes equinovarus ‐ a randomized double‐blind placebo‐controlled study. European Journal of Neurology2014;21:1089‐95. ">Fietzek 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Botulinum toxin A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0032" title="GrazkoMA , PoloKB , JabbariB . Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology. 1995/04/01 1995; Vol. 45, issue 4:712‐7. [0028‐3878: (Print)] ">Grazko 1995</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Botulinum toxin A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cross‐over trial</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0060" title="SimpsonDM , GraciesJM , YablonSA , BarbanoR , BrashearA , BoNT/TZD Study Team. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo‐controlled study. Journal of Neurology, Neurosurgery, and Psychiatry2009; Vol. 80, issue 4:380‐5. ">Simpson 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Botulinum toxin A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tizanidine or placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 and 26 placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008929-bbs2-0061" title="SmithSJ , EllisE , WhiteS , MooreAP . A double‐blind placebo‐controlled study of botulinum toxin in upper limb spasticity after stroke or head injury. Clinical Rehabilitation2000; Vol. 14, issue 1:5‐13. ">Smith 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Botulinum toxin A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Botulinum toxin A vs therapy</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0033" title="GuoF , YueW , RenL , ZhangYM , YangJ . Botulinum toxin type A plus rehabilitative training for improving the motor function of the upper limbs and activities of daily life in patients with stroke and brain injury. Neural Regeneration Research2006; Vol. 1, issue 9:859‐61. ">Guo 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Botulinum toxin A with rehab</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rehab only</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Botulinum toxin A vs botulinum toxin A (dosage)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0031" title="GraciesJM , LugassyM , WeiszDJ , VecchioM , FlanaganS , SimpsonDM . Botulinum toxin dilution and endplate targeting in spasticity: a double‐blind controlled study. Archives of Physical Medicine and Rehabilitation2009; Vol. 90, issue 1:9‐16. GraciesJM , WeiszDJ , YangBY , FlanaganS , SimpsonDM . Impact of botulinum toxin type A (BTX‐A) dilution and endplate targeting technique in upper limb spasticity (abstract). Annals of Neurology2002;52(Suppl 3):S87. ">Gracies 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High dilution botulinum toxin A with endplate target</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low dilution botulinum toxin A with end plate target</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Botulinum toxin A vs botulinum toxin A (volume)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0030" title="FranciscoGE , BoakeC , VaughnA . Botulinum toxin in upper limb spasticity after acquired brain injury: a randomized trial comparing dilution techniques. American Journal of Physical Medicine &amp; Rehabilitation2002; Vol. 81, issue 5:355‐63. ">Francisco 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High volume botulinum toxin A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low volume botulinum toxin A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008929-bbs2-0013" title="BarnesM , SchnitzlerA , MedeirosL , AguilarM , Lehnert‐BatarA , MinnaschP . Efficacy and safety of NT 201 for upper limb spasticity of various etiologies ‐ a randomized parallel‐group study. Acta Neurologica Scandinavica2010; Vol. 122, issue 4:295‐302. ">Barnes 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High volume botulinum toxin A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low volume botulinum toxin A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Botulinum toxin A vs botulinum toxin A (location)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0023" title="ChildersMK , StacyM , CookeDL , StonningtonHH . Comparison of two injection techniques using botulinum toxin in spastic hemiplegia. American Journal of Physical Medicine &amp; Rehabilitation1996; Vol. 75, issue 6:462‐9. ">Childers 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Botulinum toxin A injections towards mid belly</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Botulinum toxin A injections away from mid belly</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0031" title="GraciesJM , LugassyM , WeiszDJ , VecchioM , FlanaganS , SimpsonDM . Botulinum toxin dilution and endplate targeting in spasticity: a double‐blind controlled study. Archives of Physical Medicine and Rehabilitation2009; Vol. 90, issue 1:9‐16. GraciesJM , WeiszDJ , YangBY , FlanaganS , SimpsonDM . Impact of botulinum toxin type A (BTX‐A) dilution and endplate targeting technique in upper limb spasticity (abstract). Annals of Neurology2002;52(Suppl 3):S87. ">Gracies 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High dilution botulinum toxin A with endplate target</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low dilution botulinum toxin A with end plate target</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Baclofen vs placebo</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0010" title="ArmstrongRW , SteinbokP , CochraneDD , KubeSD , FifeSE , FarrellK . Intrathecally administered baclofen for treatment of children with spasticity of cerebral origin. Journal of Neurosurgery1997;87(3):409‐14. ">Armstrong 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intrathecal dose of baclofen</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Saline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0065" title="VanSchaeybroeckP , NuttinB , LagaeL , SchrijversE , BorghgraefC , FeysP . Intrathecal baclofen for intractable cerebral spasticity: a prospective placebo‐controlled, double‐blind study. Neurosurgery2000; Vol. 46, issue 3:603‐9. ">Van Schaeybroeck 2000</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intrathecal baclofen</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Cyclobenzaprine vs placebo</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0011" title="AshbyP , BurkeD , RaoS , JonesRF . Assessment of cyclobenzaprine in the treatment of spasticity. Journal of Neurology, Neurosurgery, and Psychiatry1972; Vol. 35, issue 5:599‐605. ">Ashby 1972</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cyclobenzaprine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cross‐over trial</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Phenothiazine vs placebo</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0021" title="BurkeD , HammondC , SkuseN , JonesRF . A phenothiazine derivative in the treatment of spasticity. Journal of Neurology, Neurosurgery, and Psychiatry1975; Vol. 38, issue 5:469‐74. ">Burke 1975</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phenothiazine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cross‐over trial</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Tizanidine vs placebo</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0047" title="MeythalerJM , Guin‐RenfroeS , JohnsonA , BrunnerRM . Prospective assessment of tizanidine for spasticity due to acquired brain injury. Archives of Physical Medicine and Rehabilitation2001; Vol. 82, issue 9:1155‐63. ">Meythaler 2001b</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tizanidine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cross‐over trial</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Tizanidine vs botulinum toxin A</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0060" title="SimpsonDM , GraciesJM , YablonSA , BarbanoR , BrashearA , BoNT/TZD Study Team. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo‐controlled study. Journal of Neurology, Neurosurgery, and Psychiatry2009; Vol. 80, issue 4:380‐5. ">Simpson 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Botulinum toxin A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tizanidine or placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 and 26 placebo</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Tizanidine vs diazepam</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0017" title="BesA , EyssetteM , Pierrot‐DeseillignyE , RohmerF , WarterJM . A multi‐centre, double‐blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia. Current Medical Research and Opinion1988; Vol. 10, issue 10:709‐18. ">Bes 1988</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tizanidine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diazepam</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Casting vs control</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0035" title="HarveyL , deJongI , GoehlG , MardwedelS . Twelve weeks of nightly stretch does not reduce thumb web‐space contractures in people with a neurological condition: a randomised controlled trial. Australian Journal of Physiotherapy2006;52(4):251‐8. ">Harvey 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Splint</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No splint</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Casting vs therapy</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0035" title="HarveyL , deJongI , GoehlG , MardwedelS . Twelve weeks of nightly stretch does not reduce thumb web‐space contractures in people with a neurological condition: a randomised controlled trial. Australian Journal of Physiotherapy2006;52(4):251‐8. ">Harvey 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Splint</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No splint</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Splinting vs control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0026" title="CopleyJ , KuipersK , FlemingJ , RassafianiM . Individualised resting hand splints for adults with acquired brain injury: a randomized, single blinded, single case design. Neurorehabilitation2013;32:885‐98. ">Copley 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Individualised hand splint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No splint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0039" title="LanninNA , HorsleySA , HerbertR , McCuskeyA , CusiekA . Splinting the hand in the functional position after brain impairment: a randomized, controlled trial. Archives of Physical Medicine and Rehabilitation2003; Vol. 84, issue 2:297‐302. ">Lannin 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stretching and hand splint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stretching only</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0064" title="ThibautA , DeltombeT , WannezS , GosseriesO , ZieglerE , DieniC , et al. Impact of soft splints on upper limb spasticity in chronic patients with disorders of consciousness: a randomized, single‐blind, controlled trial. Brain Injury2015;29:830‐6. ">Thibaut 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Soft splints</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Splinting vs therapy</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0039" title="LanninNA , HorsleySA , HerbertR , McCuskeyA , CusiekA . Splinting the hand in the functional position after brain impairment: a randomized, controlled trial. Archives of Physical Medicine and Rehabilitation2003; Vol. 84, issue 2:297‐302. ">Lannin 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stretching and hand splint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stretching only</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0064" title="ThibautA , DeltombeT , WannezS , GosseriesO , ZieglerE , DieniC , et al. Impact of soft splints on upper limb spasticity in chronic patients with disorders of consciousness: a randomized, single‐blind, controlled trial. Brain Injury2015;29:830‐6. ">Thibaut 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Soft splints</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stretching</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Functional electrical stimulation vs control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0022" title="ChangCL , MuninMC , SkidmoreER , NiyonkuruC , HuberLM , WeberDJ . Effect of baseline spastic hemiparesis on recover of upper‐limb function following botulinum toxin type A injections and postinjection therapy. Archives of Physical Medicine and Rehabilitation2009;90:1462‐7. ">Chang 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Upper limb botulinum toxin A injections for higher hand function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Upper limb botulinum toxin A injections for lower hand function</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Electrical stimulation + splinting vs splinting</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0040" title="LeungJ , HarveyLA , MoseleyAM , TseC , BryantJ , WyndhamS , et al. Electrical stimulation and splinting were not clearly more effective than splinting alone for contracture management after acquired brain injury: a randomised trial. Journal of Physiotherapy2012;58:231‐40. ">Leung 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Electrical stimulation to the wrist and finger extensor muscles for 1 hour a day + wrist splint for 12 hours a day, over 4 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wrist splint for 12 hours a day, over 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Repetitive peripheral magnetic stimulation vs sham</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0038" title="KrewerC , HartlS , MüllerF , KoenigE . Effects of repetitive peripheral magnetic stimulation on upper‐limb spasticity and impairment in patients with spastic hemiparesis: a randomized, double‐blind, sham‐controlled study. Archives of Physical and Medical Rehabilitation2014;95:1039‐47. ">Krewer 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Repetitive peripheral magnetic stimulation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham stimulation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Transcutaneous electrical acupoint stimulation vs another dose</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0067" title="ZhaoW , WangC , LiZ , ChenL , LiJ , CuiW , et al. Efficacy and safety of transcutaneous electrical acupoint stimulation to treat muscle spasticity following brain injury: a double‐blinded, multicenter, randomized controlled trial. PLoS One2015;2:e0116976. ">Zhao 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transcutaneous electrical acupoint stimulation (100 Hz)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transcutaneous electrical acupoint stimulation (2 Hz)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Transcutaneous electrical acupoint stimulation vs sham</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0067" title="ZhaoW , WangC , LiZ , ChenL , LiJ , CuiW , et al. Efficacy and safety of transcutaneous electrical acupoint stimulation to treat muscle spasticity following brain injury: a double‐blinded, multicenter, randomized controlled trial. PLoS One2015;2:e0116976. ">Zhao 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transcutaneous electrical acupoint stimulation (100 Hz)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham stimulation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Ultrasound vs infrared</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0051" title="Nakhostin AnsariN , NaghdiS , HassonS , RastgooM . Efficacy of therapeutic ultrasound and infrared in the management of muscle spasticity. Brain Injury2009; Vol. 23, issue 7‐8:632‐8. ">Nakhostin 2009</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Infrared</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic ultrasound</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Robot vs bobath</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0028" title="FazekasG , HorvathM , TroznaiT , TothA . Robot‐mediated upper limb physiotherapy for patients with spastic hemiparesis: a preliminary study. Journal of Rehabilitation Medicine2007; Vol. 39, issue 7:580‐2. [1650‐1977] ">Fazekas 2007</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Robot‐mediated therapy with bobath therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bobath therapy</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>n: number of participants; NR: not reported; TBI: traumatic brain injury.</p> <p>Some studies are listed in the table twice, given their multiple comparisons.</p> </div> </div> <p>Of the remaining 15 studies that were considered for inclusion, we require further information about five studies (see the <a href="./references#CD008929-sec-0145" title="">Characteristics of studies awaiting classification</a> table) and one study is ongoing (see the <a href="./references#CD008929-sec-0146" title="">Characteristics of ongoing studies</a> table). The anticipated end date for the ongoing study investigating the combined effect of serial casting and botulinum toxin A on ankle contractures is September 2018 (<a href="./references#CD008929-bbs2-0073" title="ACTRN12615000821594 . Effectiveness of combining serial casting and botulinum toxin for the management of ankle contractures after traumatic brain injury: a randomised controlled study. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365685 Date first received: 10 August 2015. ">ACTRN12615000821594</a>). </p> <p>We therefore included nine completed trials (<a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a>; <a href="./references#CD008929-bbs2-0002" title="LeungJ , HarveyLA , MoseleyAM , WhitesideB , SimpsonM , StroudK . Standing with electrical stimulation and splinting is no better than standing alone for management of ankle plantarflexion contractures in people with traumatic brain injury: a randomised trial. Journal of Physiotherapy2014;60:201‐8. ">Leung 2014</a>; <a href="./references#CD008929-bbs2-0003" title="MeythalerJM , DeVivoMJ , HadleyM . Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Archives of Physical Medicine and Rehabilitation1996; Vol. 77, issue 5:461‐6. ">Meythaler 1996</a>; <a href="./references#CD008929-bbs2-0004" title="MeythalerJM , McCaryA , HadleyMN . Prospective assessment of continuous intrathecal infusion of baclofen for spasticity caused by acquired brain injury: a preliminary report. Journal of Neurosurgery1997; Vol. 87, issue 3:415‐9. ">Meythaler 1997</a>; <a href="./references#CD008929-bbs2-0005" title="MeythalerJM , Guin‐RenfroeS , HadleyMN . Continuously infused intrathecal baclofen for spastic/dystonic hemiplegia: a preliminary report. American Journal of Physical Medicine &amp; Rehabilitation1999; Vol. 78, issue 3:247‐54. ">Meythaler 1999a</a>; <a href="./references#CD008929-bbs2-0006" title="MeythalerJM , Guin‐RenfroeS , GrabbP , HadleyMN . Long‐term continuously infused intrathecal baclofen for spastic‐dystonic hypertonia in traumatic brain injury: 1‐year experience. Archives of Physical Medicine and Rehabilitation1999; Vol. 80, issue 1:13‐9. ">Meythaler 1999b</a>; <a href="./references#CD008929-bbs2-0007" title="NCT00287157 . Pilot, proof‐of‐concept study of sublingual tizanidine in children with chronic traumatic brain injury (TBI). clinicaltrials.gov/ct2/show/NCT00287157 Date first received: 6 February 2006. ">NCT00287157</a>; <a href="./references#CD008929-bbs2-0008" title="PittaccioS , GaravagliaL , ViscusoS , BerettaE , StrazzerS . Implementation, testing and pilot clinical evaluation of superelastic splints that decrease joint stiffness. Annals of Biomedical Engineering2013;41:2003‐17. ">Pittaccio 2013</a>; <a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a>). </p> </section> <section id="CD008929-sec-0065"> <h4 class="title">Included studies</h4> <section id="CD008929-sec-0066"> <h5 class="title">Design</h5> <p>We included nine studies involving data from 385 participants (134 with TBI) (<a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a>; <a href="./references#CD008929-bbs2-0002" title="LeungJ , HarveyLA , MoseleyAM , WhitesideB , SimpsonM , StroudK . Standing with electrical stimulation and splinting is no better than standing alone for management of ankle plantarflexion contractures in people with traumatic brain injury: a randomised trial. Journal of Physiotherapy2014;60:201‐8. ">Leung 2014</a>; <a href="./references#CD008929-bbs2-0003" title="MeythalerJM , DeVivoMJ , HadleyM . Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Archives of Physical Medicine and Rehabilitation1996; Vol. 77, issue 5:461‐6. ">Meythaler 1996</a>; <a href="./references#CD008929-bbs2-0004" title="MeythalerJM , McCaryA , HadleyMN . Prospective assessment of continuous intrathecal infusion of baclofen for spasticity caused by acquired brain injury: a preliminary report. Journal of Neurosurgery1997; Vol. 87, issue 3:415‐9. ">Meythaler 1997</a>; <a href="./references#CD008929-bbs2-0005" title="MeythalerJM , Guin‐RenfroeS , HadleyMN . Continuously infused intrathecal baclofen for spastic/dystonic hemiplegia: a preliminary report. American Journal of Physical Medicine &amp; Rehabilitation1999; Vol. 78, issue 3:247‐54. ">Meythaler 1999a</a>; <a href="./references#CD008929-bbs2-0006" title="MeythalerJM , Guin‐RenfroeS , GrabbP , HadleyMN . Long‐term continuously infused intrathecal baclofen for spastic‐dystonic hypertonia in traumatic brain injury: 1‐year experience. Archives of Physical Medicine and Rehabilitation1999; Vol. 80, issue 1:13‐9. ">Meythaler 1999b</a>; <a href="./references#CD008929-bbs2-0007" title="NCT00287157 . Pilot, proof‐of‐concept study of sublingual tizanidine in children with chronic traumatic brain injury (TBI). clinicaltrials.gov/ct2/show/NCT00287157 Date first received: 6 February 2006. ">NCT00287157</a>; <a href="./references#CD008929-bbs2-0008" title="PittaccioS , GaravagliaL , ViscusoS , BerettaE , StrazzerS . Implementation, testing and pilot clinical evaluation of superelastic splints that decrease joint stiffness. Annals of Biomedical Engineering2013;41:2003‐17. ">Pittaccio 2013</a>; <a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a>; see <a href="./references#CD008929-sec-0143" title="">Characteristics of included studies</a> table). Of these, three were parallel group RCTs, with two (<a href="./references#CD008929-bbs2-0002" title="LeungJ , HarveyLA , MoseleyAM , WhitesideB , SimpsonM , StroudK . Standing with electrical stimulation and splinting is no better than standing alone for management of ankle plantarflexion contractures in people with traumatic brain injury: a randomised trial. Journal of Physiotherapy2014;60:201‐8. ">Leung 2014</a>) or three comparator groups (<a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a>; <a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a>). Six were randomised cross‐over trials comparing treatment with placebo or standard care (<a href="./references#CD008929-bbs2-0003" title="MeythalerJM , DeVivoMJ , HadleyM . Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Archives of Physical Medicine and Rehabilitation1996; Vol. 77, issue 5:461‐6. ">Meythaler 1996</a>; <a href="./references#CD008929-bbs2-0004" title="MeythalerJM , McCaryA , HadleyMN . Prospective assessment of continuous intrathecal infusion of baclofen for spasticity caused by acquired brain injury: a preliminary report. Journal of Neurosurgery1997; Vol. 87, issue 3:415‐9. ">Meythaler 1997</a>; <a href="./references#CD008929-bbs2-0005" title="MeythalerJM , Guin‐RenfroeS , HadleyMN . Continuously infused intrathecal baclofen for spastic/dystonic hemiplegia: a preliminary report. American Journal of Physical Medicine &amp; Rehabilitation1999; Vol. 78, issue 3:247‐54. ">Meythaler 1999a</a>; <a href="./references#CD008929-bbs2-0006" title="MeythalerJM , Guin‐RenfroeS , GrabbP , HadleyMN . Long‐term continuously infused intrathecal baclofen for spastic‐dystonic hypertonia in traumatic brain injury: 1‐year experience. Archives of Physical Medicine and Rehabilitation1999; Vol. 80, issue 1:13‐9. ">Meythaler 1999b</a>; <a href="./references#CD008929-bbs2-0007" title="NCT00287157 . Pilot, proof‐of‐concept study of sublingual tizanidine in children with chronic traumatic brain injury (TBI). clinicaltrials.gov/ct2/show/NCT00287157 Date first received: 6 February 2006. ">NCT00287157</a>; <a href="./references#CD008929-bbs2-0008" title="PittaccioS , GaravagliaL , ViscusoS , BerettaE , StrazzerS . Implementation, testing and pilot clinical evaluation of superelastic splints that decrease joint stiffness. Annals of Biomedical Engineering2013;41:2003‐17. ">Pittaccio 2013</a>). </p> <p>Of the nine trials, three did not identify between‐group differences in outcome data, neither did they report sufficient information about the results to allow us to calculate these differences (<a href="./references#CD008929-bbs2-0004" title="MeythalerJM , McCaryA , HadleyMN . Prospective assessment of continuous intrathecal infusion of baclofen for spasticity caused by acquired brain injury: a preliminary report. Journal of Neurosurgery1997; Vol. 87, issue 3:415‐9. ">Meythaler 1997</a>; <a href="./references#CD008929-bbs2-0005" title="MeythalerJM , Guin‐RenfroeS , HadleyMN . Continuously infused intrathecal baclofen for spastic/dystonic hemiplegia: a preliminary report. American Journal of Physical Medicine &amp; Rehabilitation1999; Vol. 78, issue 3:247‐54. ">Meythaler 1999a</a>; <a href="./references#CD008929-bbs2-0006" title="MeythalerJM , Guin‐RenfroeS , GrabbP , HadleyMN . Long‐term continuously infused intrathecal baclofen for spastic‐dystonic hypertonia in traumatic brain injury: 1‐year experience. Archives of Physical Medicine and Rehabilitation1999; Vol. 80, issue 1:13‐9. ">Meythaler 1999b</a>). Results from one trial remain unpublished and unavailable (<a href="./references#CD008929-bbs2-0007" title="NCT00287157 . Pilot, proof‐of‐concept study of sublingual tizanidine in children with chronic traumatic brain injury (TBI). clinicaltrials.gov/ct2/show/NCT00287157 Date first received: 6 February 2006. ">NCT00287157</a>). As such, only the data from five studies (combined 350 participants, of whom 105 had TBI) contributed outcome data to the results of this review (<a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a>; <a href="./references#CD008929-bbs2-0002" title="LeungJ , HarveyLA , MoseleyAM , WhitesideB , SimpsonM , StroudK . Standing with electrical stimulation and splinting is no better than standing alone for management of ankle plantarflexion contractures in people with traumatic brain injury: a randomised trial. Journal of Physiotherapy2014;60:201‐8. ">Leung 2014</a>; <a href="./references#CD008929-bbs2-0003" title="MeythalerJM , DeVivoMJ , HadleyM . Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Archives of Physical Medicine and Rehabilitation1996; Vol. 77, issue 5:461‐6. ">Meythaler 1996</a>; <a href="./references#CD008929-bbs2-0008" title="PittaccioS , GaravagliaL , ViscusoS , BerettaE , StrazzerS . Implementation, testing and pilot clinical evaluation of superelastic splints that decrease joint stiffness. Annals of Biomedical Engineering2013;41:2003‐17. ">Pittaccio 2013</a>; <a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a>). </p> </section> <section id="CD008929-sec-0067"> <h5 class="title">Number of participants</h5> <p>Within each study, the number of participants (TBI and non‐TBI) ranged from six (<a href="./references#CD008929-bbs2-0005" title="MeythalerJM , Guin‐RenfroeS , HadleyMN . Continuously infused intrathecal baclofen for spastic/dystonic hemiplegia: a preliminary report. American Journal of Physical Medicine &amp; Rehabilitation1999; Vol. 78, issue 3:247‐54. ">Meythaler 1999a</a>) to 243 (<a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a>). Most of these trials included mixed populations (TBI and non‐TBI). Two studies solely recruited people with TBI (51 combined participants) (<a href="./references#CD008929-bbs2-0006" title="MeythalerJM , Guin‐RenfroeS , GrabbP , HadleyMN . Long‐term continuously infused intrathecal baclofen for spastic‐dystonic hypertonia in traumatic brain injury: 1‐year experience. Archives of Physical Medicine and Rehabilitation1999; Vol. 80, issue 1:13‐9. ">Meythaler 1999b</a>; <a href="./references#CD008929-bbs2-0002" title="LeungJ , HarveyLA , MoseleyAM , WhitesideB , SimpsonM , StroudK . Standing with electrical stimulation and splinting is no better than standing alone for management of ankle plantarflexion contractures in people with traumatic brain injury: a randomised trial. Journal of Physiotherapy2014;60:201‐8. ">Leung 2014</a>), while <a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a> provided disaggregated data for their subgroup of 23 participants with TBI (in the form of a conference abstract; <a href="./references#CD008929-bbs2-0119" title="O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">O'Dell 2015</a>). In the remaining six studies with mixed populations, the number of participants with TBI ranged from three (<a href="./references#CD008929-bbs2-0005" title="MeythalerJM , Guin‐RenfroeS , HadleyMN . Continuously infused intrathecal baclofen for spastic/dystonic hemiplegia: a preliminary report. American Journal of Physical Medicine &amp; Rehabilitation1999; Vol. 78, issue 3:247‐54. ">Meythaler 1999a</a>) to 20 (<a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a>), and the proportions of participants with TBI ranged from 50% (<a href="./references#CD008929-bbs2-0005" title="MeythalerJM , Guin‐RenfroeS , HadleyMN . Continuously infused intrathecal baclofen for spastic/dystonic hemiplegia: a preliminary report. American Journal of Physical Medicine &amp; Rehabilitation1999; Vol. 78, issue 3:247‐54. ">Meythaler 1999a</a>) to 91% (<a href="./references#CD008929-bbs2-0003" title="MeythalerJM , DeVivoMJ , HadleyM . Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Archives of Physical Medicine and Rehabilitation1996; Vol. 77, issue 5:461‐6. ">Meythaler 1996</a>). </p> </section> <section id="CD008929-sec-0068"> <h5 class="title">Setting</h5> <p>All the trials were conducted in high‐income settings, including the US (four trials), Australia (one trial), the UK (one trial), Italy (one trial) and Israel (one trial). One trial drew data from sites in nine high‐income countries (Belgium, Czech Republic, France, Hungary, Italy, Poland, Russia, Slovakia, USA) (<a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a>). Participants were recruited from either tertiary care (outpatient or inpatient, or both) rehabilitation clinics or acute general hospitals. </p> <p>Of the five studies with results, three were funded by governments, charities or health services (<a href="./references#CD008929-bbs2-0003" title="MeythalerJM , DeVivoMJ , HadleyM . Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Archives of Physical Medicine and Rehabilitation1996; Vol. 77, issue 5:461‐6. ">Meythaler 1996</a>; <a href="./references#CD008929-bbs2-0002" title="LeungJ , HarveyLA , MoseleyAM , WhitesideB , SimpsonM , StroudK . Standing with electrical stimulation and splinting is no better than standing alone for management of ankle plantarflexion contractures in people with traumatic brain injury: a randomised trial. Journal of Physiotherapy2014;60:201‐8. ">Leung 2014</a>; <a href="./references#CD008929-bbs2-0008" title="PittaccioS , GaravagliaL , ViscusoS , BerettaE , StrazzerS . Implementation, testing and pilot clinical evaluation of superelastic splints that decrease joint stiffness. Annals of Biomedical Engineering2013;41:2003‐17. ">Pittaccio 2013</a>), and two were funded by pharmaceutical/medical technology companies (<a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a>; <a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a>). The four studies without useable results were funded by pharmaceutical/medical technology companies (<a href="./references#CD008929-bbs2-0004" title="MeythalerJM , McCaryA , HadleyMN . Prospective assessment of continuous intrathecal infusion of baclofen for spasticity caused by acquired brain injury: a preliminary report. Journal of Neurosurgery1997; Vol. 87, issue 3:415‐9. ">Meythaler 1997</a>; <a href="./references#CD008929-bbs2-0005" title="MeythalerJM , Guin‐RenfroeS , HadleyMN . Continuously infused intrathecal baclofen for spastic/dystonic hemiplegia: a preliminary report. American Journal of Physical Medicine &amp; Rehabilitation1999; Vol. 78, issue 3:247‐54. ">Meythaler 1999a</a>; <a href="./references#CD008929-bbs2-0006" title="MeythalerJM , Guin‐RenfroeS , GrabbP , HadleyMN . Long‐term continuously infused intrathecal baclofen for spastic‐dystonic hypertonia in traumatic brain injury: 1‐year experience. Archives of Physical Medicine and Rehabilitation1999; Vol. 80, issue 1:13‐9. ">Meythaler 1999b</a>; <a href="./references#CD008929-bbs2-0007" title="NCT00287157 . Pilot, proof‐of‐concept study of sublingual tizanidine in children with chronic traumatic brain injury (TBI). clinicaltrials.gov/ct2/show/NCT00287157 Date first received: 6 February 2006. ">NCT00287157</a>). </p> </section> <section id="CD008929-sec-0069"> <h5 class="title">Participants</h5> <section id="CD008929-sec-0070"> <h6 class="title">Age and sex</h6> <p>With the exception of <a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a>, data for age and gender were not reported separately for TBI participants when they formed a proportion of 'mixed' populations. For this reason, the following information relates to the whole sample (including non‐TBI participants) within trials except for <a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a>, along with <a href="./references#CD008929-bbs2-0002" title="LeungJ , HarveyLA , MoseleyAM , WhitesideB , SimpsonM , StroudK . Standing with electrical stimulation and splinting is no better than standing alone for management of ankle plantarflexion contractures in people with traumatic brain injury: a randomised trial. Journal of Physiotherapy2014;60:201‐8. ">Leung 2014</a> and <a href="./references#CD008929-bbs2-0006" title="MeythalerJM , Guin‐RenfroeS , GrabbP , HadleyMN . Long‐term continuously infused intrathecal baclofen for spastic‐dystonic hypertonia in traumatic brain injury: 1‐year experience. Archives of Physical Medicine and Rehabilitation1999; Vol. 80, issue 1:13‐9. ">Meythaler 1999b</a>, which were the only trials in which all participants had a diagnosis of TBI. </p> <p>Seven studies included adults, with a mean (or median) age of participants between 24 years (<a href="./references#CD008929-bbs2-0003" title="MeythalerJM , DeVivoMJ , HadleyM . Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Archives of Physical Medicine and Rehabilitation1996; Vol. 77, issue 5:461‐6. ">Meythaler 1996</a>) and 41.5 years (<a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a>). Two studies included children (<a href="./references#CD008929-bbs2-0007" title="NCT00287157 . Pilot, proof‐of‐concept study of sublingual tizanidine in children with chronic traumatic brain injury (TBI). clinicaltrials.gov/ct2/show/NCT00287157 Date first received: 6 February 2006. ">NCT00287157</a>; <a href="./references#CD008929-bbs2-0008" title="PittaccioS , GaravagliaL , ViscusoS , BerettaE , StrazzerS . Implementation, testing and pilot clinical evaluation of superelastic splints that decrease joint stiffness. Annals of Biomedical Engineering2013;41:2003‐17. ">Pittaccio 2013</a>); only <a href="./references#CD008929-bbs2-0008" title="PittaccioS , GaravagliaL , ViscusoS , BerettaE , StrazzerS . Implementation, testing and pilot clinical evaluation of superelastic splints that decrease joint stiffness. Annals of Biomedical Engineering2013;41:2003‐17. ">Pittaccio 2013</a> reported the mean age of participants, being 7.75 years. Where reported, all studies include more males than females, ranging from 60% (<a href="./references#CD008929-bbs2-0005" title="MeythalerJM , Guin‐RenfroeS , HadleyMN . Continuously infused intrathecal baclofen for spastic/dystonic hemiplegia: a preliminary report. American Journal of Physical Medicine &amp; Rehabilitation1999; Vol. 78, issue 3:247‐54. ">Meythaler 1999a</a>) to 92% (<a href="./references#CD008929-bbs2-0004" title="MeythalerJM , McCaryA , HadleyMN . Prospective assessment of continuous intrathecal infusion of baclofen for spasticity caused by acquired brain injury: a preliminary report. Journal of Neurosurgery1997; Vol. 87, issue 3:415‐9. ">Meythaler 1997</a>). </p> </section> <section id="CD008929-sec-0071"> <h6 class="title">Body part treated</h6> <p>Four studies treated spasticity anywhere in the lower limbs, but also treated upper limb spasticity, if present (<a href="./references#CD008929-bbs2-0003" title="MeythalerJM , DeVivoMJ , HadleyM . Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Archives of Physical Medicine and Rehabilitation1996; Vol. 77, issue 5:461‐6. ">Meythaler 1996</a>; <a href="./references#CD008929-bbs2-0004" title="MeythalerJM , McCaryA , HadleyMN . Prospective assessment of continuous intrathecal infusion of baclofen for spasticity caused by acquired brain injury: a preliminary report. Journal of Neurosurgery1997; Vol. 87, issue 3:415‐9. ">Meythaler 1997</a>; <a href="./references#CD008929-bbs2-0005" title="MeythalerJM , Guin‐RenfroeS , HadleyMN . Continuously infused intrathecal baclofen for spastic/dystonic hemiplegia: a preliminary report. American Journal of Physical Medicine &amp; Rehabilitation1999; Vol. 78, issue 3:247‐54. ">Meythaler 1999a</a>; <a href="./references#CD008929-bbs2-0006" title="MeythalerJM , Guin‐RenfroeS , GrabbP , HadleyMN . Long‐term continuously infused intrathecal baclofen for spastic‐dystonic hypertonia in traumatic brain injury: 1‐year experience. Archives of Physical Medicine and Rehabilitation1999; Vol. 80, issue 1:13‐9. ">Meythaler 1999b</a>). Two studies treated spasticity in the calf muscles (gastrocnemius, or gastrocnemius and soleus) (<a href="./references#CD008929-bbs2-0002" title="LeungJ , HarveyLA , MoseleyAM , WhitesideB , SimpsonM , StroudK . Standing with electrical stimulation and splinting is no better than standing alone for management of ankle plantarflexion contractures in people with traumatic brain injury: a randomised trial. Journal of Physiotherapy2014;60:201‐8. ">Leung 2014</a>; <a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a>), while <a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a> treated spasticity in the upper limbs only (specifically elbow flexors, wrist flexors or finger flexors) and <a href="./references#CD008929-bbs2-0008" title="PittaccioS , GaravagliaL , ViscusoS , BerettaE , StrazzerS . Implementation, testing and pilot clinical evaluation of superelastic splints that decrease joint stiffness. Annals of Biomedical Engineering2013;41:2003‐17. ">Pittaccio 2013</a> treated spasticity in the ankle or elbow. One study did not report the location of the spasticity (<a href="./references#CD008929-bbs2-0007" title="NCT00287157 . Pilot, proof‐of‐concept study of sublingual tizanidine in children with chronic traumatic brain injury (TBI). clinicaltrials.gov/ct2/show/NCT00287157 Date first received: 6 February 2006. ">NCT00287157</a>). </p> </section> </section> <section id="CD008929-sec-0072"> <h5 class="title">Interventions and comparators</h5> <p>The nine studies tested a varied range of pharmacological and non‐pharmacological interventions. Pharmacological interventions that were tested against saline/placebo included intrathecal baclofen (<a href="./references#CD008929-bbs2-0003" title="MeythalerJM , DeVivoMJ , HadleyM . Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Archives of Physical Medicine and Rehabilitation1996; Vol. 77, issue 5:461‐6. ">Meythaler 1996</a>; <a href="./references#CD008929-bbs2-0004" title="MeythalerJM , McCaryA , HadleyMN . Prospective assessment of continuous intrathecal infusion of baclofen for spasticity caused by acquired brain injury: a preliminary report. Journal of Neurosurgery1997; Vol. 87, issue 3:415‐9. ">Meythaler 1997</a>; <a href="./references#CD008929-bbs2-0005" title="MeythalerJM , Guin‐RenfroeS , HadleyMN . Continuously infused intrathecal baclofen for spastic/dystonic hemiplegia: a preliminary report. American Journal of Physical Medicine &amp; Rehabilitation1999; Vol. 78, issue 3:247‐54. ">Meythaler 1999a</a>; <a href="./references#CD008929-bbs2-0006" title="MeythalerJM , Guin‐RenfroeS , GrabbP , HadleyMN . Long‐term continuously infused intrathecal baclofen for spastic‐dystonic hypertonia in traumatic brain injury: 1‐year experience. Archives of Physical Medicine and Rehabilitation1999; Vol. 80, issue 1:13‐9. ">Meythaler 1999b</a>) and tizanidine (<a href="./references#CD008929-bbs2-0007" title="NCT00287157 . Pilot, proof‐of‐concept study of sublingual tizanidine in children with chronic traumatic brain injury (TBI). clinicaltrials.gov/ct2/show/NCT00287157 Date first received: 6 February 2006. ">NCT00287157</a>). Two additional, three‐armed trials tested botulinum toxin A; <a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a> tested two different doses of botulinum toxin A against placebo, and <a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a> assessed botulinum toxin A plus casting against placebo plus casting and against physiotherapy. </p> <p>Non‐pharmacological interventions and comparisons tested include casting and physiotherapy (<a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a>), pseudoelastic orthosis versus a traditional splint (<a href="./references#CD008929-bbs2-0008" title="PittaccioS , GaravagliaL , ViscusoS , BerettaE , StrazzerS . Implementation, testing and pilot clinical evaluation of superelastic splints that decrease joint stiffness. Annals of Biomedical Engineering2013;41:2003‐17. ">Pittaccio 2013</a>), and a combination of tilt table standing, electrical stimulation and ankle splinting versus tilt table standing alone (<a href="./references#CD008929-bbs2-0002" title="LeungJ , HarveyLA , MoseleyAM , WhitesideB , SimpsonM , StroudK . Standing with electrical stimulation and splinting is no better than standing alone for management of ankle plantarflexion contractures in people with traumatic brain injury: a randomised trial. Journal of Physiotherapy2014;60:201‐8. ">Leung 2014</a>). </p> <p>More details are provided about the interventions tested, grouped under different comparisons. </p> <section id="CD008929-sec-0073"> <h6 class="title">Baclofen versus placebo</h6> <p><a href="./references#CD008929-bbs2-0003" title="MeythalerJM , DeVivoMJ , HadleyM . Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Archives of Physical Medicine and Rehabilitation1996; Vol. 77, issue 5:461‐6. ">Meythaler 1996</a> examined the effect of intrathecal baclofen for spastic hypertonia in the lower limbs. Eleven participants were allocated to receive a bolus intrathecal injection of either normal saline or baclofen 50 μg. Cross‐over of participants occurred 48 hours after the initial administration. This study was in two parts: use of a bolus dose and then those participants with an adequate response were progressed to implantation of an intrathecal baclofen pump. This would be considered the usual method for evaluation for implantation of a baclofen pump. </p> <p>The three other baclofen studies (<a href="./references#CD008929-bbs2-0004" title="MeythalerJM , McCaryA , HadleyMN . Prospective assessment of continuous intrathecal infusion of baclofen for spasticity caused by acquired brain injury: a preliminary report. Journal of Neurosurgery1997; Vol. 87, issue 3:415‐9. ">Meythaler 1997</a>; <a href="./references#CD008929-bbs2-0005" title="MeythalerJM , Guin‐RenfroeS , HadleyMN . Continuously infused intrathecal baclofen for spastic/dystonic hemiplegia: a preliminary report. American Journal of Physical Medicine &amp; Rehabilitation1999; Vol. 78, issue 3:247‐54. ">Meythaler 1999a</a>; <a href="./references#CD008929-bbs2-0006" title="MeythalerJM , Guin‐RenfroeS , GrabbP , HadleyMN . Long‐term continuously infused intrathecal baclofen for spastic‐dystonic hypertonia in traumatic brain injury: 1‐year experience. Archives of Physical Medicine and Rehabilitation1999; Vol. 80, issue 1:13‐9. ">Meythaler 1999b</a>) also assessed intrathecal baclofen infusion at the same dosage (50 μg), but provided no useable results. </p> </section> <section id="CD008929-sec-0074"> <h6 class="title">Botulinum toxin A (with or without casting) versus placebo (with or without casting)</h6> <p><a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a> assessed the effect of botulinum toxin A versus placebo for upper limb spasticity in 23 participants with TBI. In the initial treatment cycle, 14 participants received either abobotulinumtoxinA (500 U or 1000 U) and nine received placebo. The mode of administration was intramuscular injection. However, for participants with TBI, results were given in a binary method (only intervention versus placebo, without regard to dosage of abobotulinumtoxinA). </p> <p><a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a> compared the effects of three different interventions in 25 adults with lower limb spasticity, which we split into three, two‐arm comparisons. The comparison included here is botulinum toxin A injections plus casting (12 participants) (200 U/leg) versus placebo plus casting (12 participants) (total of 4 mL saline injections). </p> </section> <section id="CD008929-sec-0075"> <h6 class="title">Physiotherapy versus placebo plus casting or botulinum toxin A plus casting</h6> <p>The remaining comparisons for <a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a> were physiotherapy alone (11 participants) compared with casting plus botulinum toxin A injections (12 participants) (200 U/leg) or casting with placebo (12 participants) (total of 4 mL saline injections) in adults with lower limb spasticity. </p> </section> <section id="CD008929-sec-0076"> <h6 class="title">Tizanidine versus placebo</h6> <p><a href="./references#CD008929-bbs2-0007" title="NCT00287157 . Pilot, proof‐of‐concept study of sublingual tizanidine in children with chronic traumatic brain injury (TBI). clinicaltrials.gov/ct2/show/NCT00287157 Date first received: 6 February 2006. ">NCT00287157</a> assessed the effect of tizanidine versus placebo on spasticity, cognition and daily function. The results were unpublished and no data were available. </p> </section> <section id="CD008929-sec-0077"> <h6 class="title">Pseudoelastic orthosis versus traditional splint</h6> <p>In <a href="./references#CD008929-bbs2-0008" title="PittaccioS , GaravagliaL , ViscusoS , BerettaE , StrazzerS . Implementation, testing and pilot clinical evaluation of superelastic splints that decrease joint stiffness. Annals of Biomedical Engineering2013;41:2003‐17. ">Pittaccio 2013</a>, 25 children with elbow or ankle spasticity wore a spring‐loaded orthosis comprised of two parts that could rotate relative to one another around a common axis that was individually customised and worn for one month. A traditional static splint was fitted and worn for one month. These treatments were delivered in a randomised cross‐over manner. </p> </section> <section id="CD008929-sec-0078"> <h6 class="title">Tilt table standing, electrical stimulation and ankle splinting versus tilt table standing alone </h6> <p><a href="./references#CD008929-bbs2-0002" title="LeungJ , HarveyLA , MoseleyAM , WhitesideB , SimpsonM , StroudK . Standing with electrical stimulation and splinting is no better than standing alone for management of ankle plantarflexion contractures in people with traumatic brain injury: a randomised trial. Journal of Physiotherapy2014;60:201‐8. ">Leung 2014</a> (36 participants) evaluated a multi‐modal treatment including 30 minutes of tilt table standing with electrical stimulation to the ankle dorsiflexors five times a week, with 12 hours per day of ankle splinting, at least five days a week. This was compared to the control group, who received 30 minutes of tilt table standing, three times a week. The total programme duration for intervention and control groups was six weeks. </p> </section> </section> <section id="CD008929-sec-0079"> <h5 class="title">Outcomes</h5> <p>For the five studies in which outcome data were provided, results were available for the primary outcomes of spasticity (assessed using the Tardieu Scale (<a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a>; <a href="./references#CD008929-bbs2-0002" title="LeungJ , HarveyLA , MoseleyAM , WhitesideB , SimpsonM , StroudK . Standing with electrical stimulation and splinting is no better than standing alone for management of ankle plantarflexion contractures in people with traumatic brain injury: a randomised trial. Journal of Physiotherapy2014;60:201‐8. ">Leung 2014</a>), the Ashworth Scale (<a href="./references#CD008929-bbs2-0003" title="MeythalerJM , DeVivoMJ , HadleyM . Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Archives of Physical Medicine and Rehabilitation1996; Vol. 77, issue 5:461‐6. ">Meythaler 1996</a>), or the Modified Ashworth Scale (<a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a>; <a href="./references#CD008929-bbs2-0008" title="PittaccioS , GaravagliaL , ViscusoS , BerettaE , StrazzerS . Implementation, testing and pilot clinical evaluation of superelastic splints that decrease joint stiffness. Annals of Biomedical Engineering2013;41:2003‐17. ">Pittaccio 2013</a>; <a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a>)) and adverse events. All authors treated their measures of spasticity as continuous and numerical data provided were often sparse. Secondary outcomes measured included neuromusculoskeletal and movement‐related functions (i.e. deep tendon reflexes, ankle range of movement), mobility, major life areas and community, social and civic life. The remaining secondary outcomes of interest to this review (sensory function and pain, general tasks and demands, self‐care and domestic life) were not measured. Detailed information about the domains and scores used for these outcomes and the timing of their measurement in the studies is described in <a href="#CD008929-tbl-0005">Table 2</a> and <a href="#CD008929-tbl-0006">Table 3</a>. </p> <div class="table" id="CD008929-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Primary outcome measures</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Outcome measure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Domains with score</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Studies referring to this outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Time point analysis</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Ashworth Scale (0‐4, lower score = better; <a href="./references#CD008929-bbs2-0121" title="PandyanAD , JohnsonGR , PriceCI , CurlessRH , BarnesMP , RodgersH . A review of the properties and limitations of the Ashworth and modified Ashworth Scales as measures of spasticity. Clinical Rehabilitation1999; Vol. 13, issue 5:373‐83. ">Pandyan 1999</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0: no increase in muscle tone.</p> <p>1: slight increase in muscle tone, manifested by a catch and release or by minimum resistance through remainder of range of motion </p> <p>2: more marked increase in muscle tone through most of the range of motion; limb easily moved. </p> <p>3: considerable increase in muscle tone; passive movement is difficult.</p> <p>4: rigid limb.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0003" title="MeythalerJM , DeVivoMJ , HadleyM . Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Archives of Physical Medicine and Rehabilitation1996; Vol. 77, issue 5:461‐6. ">Meythaler 1996</a>; </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline, and 1, 2, 4, 6 hours</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0008" title="PittaccioS , GaravagliaL , ViscusoS , BerettaE , StrazzerS . Implementation, testing and pilot clinical evaluation of superelastic splints that decrease joint stiffness. Annals of Biomedical Engineering2013;41:2003‐17. ">Pittaccio 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline, and 4, 8 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Modified Ashworth Scale (0‐5, lower score = better; <a href="./references#CD008929-bbs2-0121" title="PandyanAD , JohnsonGR , PriceCI , CurlessRH , BarnesMP , RodgersH . A review of the properties and limitations of the Ashworth and modified Ashworth Scales as measures of spasticity. Clinical Rehabilitation1999; Vol. 13, issue 5:373‐83. ">Pandyan 1999</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0: no increase in muscle tone.</p> <p>1: slight increase in muscle tone, manifested by a catch and release or is moved in flexion, extension/abduction, adduction, etc. </p> <p>1+: slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the range of motion. </p> <p>2: More marked increase in muscle tone through most of the range of motion, but the affected part is easily moved. </p> <p>3: considerable increase in muscle tone, passive movement is difficult.</p> <p>4: affected part is rigid flexion or extension/abduction or adduction.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline, 12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline, 4 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tardieu Scale (TS; 2 measurements: Quality of Muscle Reaction 0‐4, lower score better, and Angle of muscle reaction, R2 ‐ R1; <a href="./references#CD008929-bbs2-0097" title="HaughAB , PandyanAD , JohnsonGR . A systematic review of the Tardieu Scale for the measurement of spasticity. Disability and Rehabilitation2006; Vol. 28, issue 15:899‐907. ">Haugh 2006</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Quality of muscle reaction </p> <p>0: no resistance throughout the course of the passive movement.</p> <p>1: slight resistance throughout the course of the passive movement, with no clear catch at precise angle. </p> <p>2: clear catch at precise angle, interrupting the passive movement, followed by release.</p> <p>3: fatigable clonus (&lt; 10 seconds when maintaining pressure) occurring at precise angle. </p> <p>4: infatigable clonus (&gt; 10 seconds when maintaining pressure) occurring at precise angle. </p> <p>Angle of muscle reaction (also referred to as R2 ‐ R1)</p> <p>Measured relative to the position of minimal stretch of the muscle (corresponding to angle) where it is relative to the resting anatomic position. </p> <p>R2: first measure (the maximum passive range of movement of the muscle group).</p> <p>R1: second measure (the angle at which the initial 'catch' or muscle resistance is felt when the muscle is moved from its shortest to longest position using a 'rapid velocity stretch'). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline, 4 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0002" title="LeungJ , HarveyLA , MoseleyAM , WhitesideB , SimpsonM , StroudK . Standing with electrical stimulation and splinting is no better than standing alone for management of ankle plantarflexion contractures in people with traumatic brain injury: a randomised trial. Journal of Physiotherapy2014;60:201‐8. ">Leung 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline, and 6 and 10 weeks</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD008929-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Secondary outcome measures</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Outcome measure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Domains with score</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Studies referring to this outcome</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> ICF classification</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Glasgow Coma Scale (<a href="./references#CD008929-bbs2-0134" title="TeasdaleG , JennettB . Assessment of coma and impaired consciousness. Lancet1974;304:814. ">Teasdale 1974</a>) </p> <p>(3‐15, higher score = better)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eye opening (E)</p> <p>4: spontaneous</p> <p>3: to voice</p> <p>2: to pain</p> <p>1: none</p> <p>Verbal response (V)</p> <p>5: normal conversation</p> <p>4: disoriented conversation</p> <p>3: words, but not coherent</p> <p>2: no words, only sounds</p> <p>1: none</p> <p>Motor response (M)</p> <p>6: normal</p> <p>5: localised to pain</p> <p>4: withdraws to pain</p> <p>3: decorticate posture (an abnormal posture that can include rigidity, clenched fists, legs held straight out, and arms bent inward towards the body with the wrists and fingers bend and held on the chest) </p> <p>2: decerebrate (an abnormal posture that can include rigidity, arms and legs held straight out, toes pointed downward, head and neck arched backwards) </p> <p>1: none</p> <p>The final GCS score or grade is the sum of these numbers.</p> <p>Severe: GCS 3‐8 (minimum possible score is 3)</p> <p>Moderate: GCS 9‐12</p> <p>Mild: GCS 13‐15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>b. Body functions</p> <p>b1‐b8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Glasgow Outcome Scale (<a href="./references#CD008929-bbs2-0101" title="JennettB , BondM . Assessment of outcome after severe brain damage. Lancet1975;1:480‐4. ">Jennett 1975</a>) </p> <p>(1‐5, higher score = better)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To generalise and categorise the outcomes of people with TBI.</p> <p>1: dead</p> <p>2: vegetative state (meaning the person is unresponsive, but alive; a "vegetable" in lay language) </p> <p>3: severely disabled (conscious but the person requires others for daily support due to disability) </p> <p>4: moderately disabled (the person is independent but disabled)</p> <p>5: good recovery (the person has resumed most normal activities but may have minor residual problems) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Body function</p> <p>b1‐b8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range of movement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The joint is taken through the total arc of movement from flexion to extension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a> (ankle) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Body function</p> <p>b7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Deep tendon reflexes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: reflexes absent</p> <p>1: hyporeflexia</p> <p>2: normal</p> <p>3: mild hyperreflexia</p> <p>4: 3 or 4 beats clonus only</p> <p>5: clonus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0003" title="MeythalerJM , DeVivoMJ , HadleyM . Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Archives of Physical Medicine and Rehabilitation1996; Vol. 77, issue 5:461‐6. ">Meythaler 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Body function</p> <p>b750</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disability Assessment Scale (DAS; <a href="./references#CD008929-bbs2-0084" title="BrashearA , ZafonteR , CorcoranM , Galvez‐JimenezN , GraciesJM , GordonMF , et al. Inter‐ and intrarater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper‐limb poststroke spasticity. Archives of Physical and Medical Rehabilitation2002;83:1349‐54. ">Brashear 2002</a>; 0‐3, lower score better) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>People are interviewed to determine the extent of functional impairment in: hygiene, dressing, limb position and pain, according to the following scale: </p> <p>0: no disability</p> <p>1: mild disability (noticeable but does not interfere significantly with normal activities)</p> <p>2: moderate disability (normal activities require increased effort or assistance, or both) </p> <p>3: severe disability (normal activities limited)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Activities and participation</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ICF: International Classification of Functioning.</p> </div> </div> </section> </section> <section id="CD008929-sec-0080"> <h4 class="title">Excluded studies</h4> <p>In total, we excluded 169 studies on reading the full text, for reasons including no TBI participants (96 studies), less than 50% of participants had TBI and results not presented separately (27 studies), no evaluation of treatments for spasticity (28 studies) or ineligible study design (e.g. review article; 18 references; see <a href="./references#CD008929-sec-0144" title="">Characteristics of excluded studies</a> for a list of 58 key studies excluded on full text). </p> <p>Given the relatively large number of studies (27) that were excluded as less than 50% of study participants had a TBI (and the data for these participants were not presented separately), we provided more information in <a href="#CD008929-tbl-0004">Table 1</a>. Across these studies, there were 1000 participants, of whom 142 (14%) had TBI. The percentage of people within each study who had TBI ranged from 2% to 47%. </p> </section> </section> <section id="CD008929-sec-0081"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias for all included studies varied as detailed in the <a href="./references#CD008929-sec-0143" title="">Characteristics of included studies</a> table, and presented in <a href="#CD008929-fig-0002">Figure 2</a> and <a href="#CD008929-fig-0003">Figure 3</a>. Many items were scored as 'unclear' due to poor reporting. </p> <div class="figure" id="CD008929-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. Nine studies are included in this review." data-id="CD008929-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008929.pub2/media/CDSR/CD008929/image_n/nCD008929-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. Nine studies are included in this review. </p> </div> </div> </div> <div class="figure" id="CD008929-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study (note: only Meythaler 1996 and Verplancke 2005 contributed outcome data to the review)." data-id="CD008929-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008929.pub2/media/CDSR/CD008929/image_n/nCD008929-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study (note: only <a href="./references#CD008929-bbs2-0003" title="MeythalerJM , DeVivoMJ , HadleyM . Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Archives of Physical Medicine and Rehabilitation1996; Vol. 77, issue 5:461‐6. ">Meythaler 1996</a> and <a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a> contributed outcome data to the review). </p> </div> </div> </div> <section id="CD008929-sec-0082"> <h4 class="title">Allocation</h4> <p>Of the nine included studies, investigators involved in only two studies clearly reported the methods of both randomisation and allocation concealment, and these were assessed at low risk of bias for these domains (<a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a>; <a href="./references#CD008929-bbs2-0002" title="LeungJ , HarveyLA , MoseleyAM , WhitesideB , SimpsonM , StroudK . Standing with electrical stimulation and splinting is no better than standing alone for management of ankle plantarflexion contractures in people with traumatic brain injury: a randomised trial. Journal of Physiotherapy2014;60:201‐8. ">Leung 2014</a>). None of the other study authors provided details of either randomisation or allocation concealment methods, making it difficult to determine any associated risks of bias. Seven studies were thus rated at 'unclear' risk of bias for both these domains. </p> </section> <section id="CD008929-sec-0083"> <h4 class="title">Blinding</h4> <p>Five studies reported adequate blinding of participants and personnel (<a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a>; <a href="./references#CD008929-bbs2-0003" title="MeythalerJM , DeVivoMJ , HadleyM . Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Archives of Physical Medicine and Rehabilitation1996; Vol. 77, issue 5:461‐6. ">Meythaler 1996</a>; <a href="./references#CD008929-bbs2-0004" title="MeythalerJM , McCaryA , HadleyMN . Prospective assessment of continuous intrathecal infusion of baclofen for spasticity caused by acquired brain injury: a preliminary report. Journal of Neurosurgery1997; Vol. 87, issue 3:415‐9. ">Meythaler 1997</a>; <a href="./references#CD008929-bbs2-0005" title="MeythalerJM , Guin‐RenfroeS , HadleyMN . Continuously infused intrathecal baclofen for spastic/dystonic hemiplegia: a preliminary report. American Journal of Physical Medicine &amp; Rehabilitation1999; Vol. 78, issue 3:247‐54. ">Meythaler 1999a</a>; <a href="./references#CD008929-bbs2-0006" title="MeythalerJM , Guin‐RenfroeS , GrabbP , HadleyMN . Long‐term continuously infused intrathecal baclofen for spastic‐dystonic hypertonia in traumatic brain injury: 1‐year experience. Archives of Physical Medicine and Rehabilitation1999; Vol. 80, issue 1:13‐9. ">Meythaler 1999b</a>). In three studies neither participants nor personnel could be blinded due to the obvious differences between interventions and controls (e.g. serial casting, different orthoses/splints), leading to ratings of high risk (<a href="./references#CD008929-bbs2-0002" title="LeungJ , HarveyLA , MoseleyAM , WhitesideB , SimpsonM , StroudK . Standing with electrical stimulation and splinting is no better than standing alone for management of ankle plantarflexion contractures in people with traumatic brain injury: a randomised trial. Journal of Physiotherapy2014;60:201‐8. ">Leung 2014</a>; <a href="./references#CD008929-bbs2-0008" title="PittaccioS , GaravagliaL , ViscusoS , BerettaE , StrazzerS . Implementation, testing and pilot clinical evaluation of superelastic splints that decrease joint stiffness. Annals of Biomedical Engineering2013;41:2003‐17. ">Pittaccio 2013</a>; <a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a>). The registry entry for <a href="./references#CD008929-bbs2-0007" title="NCT00287157 . Pilot, proof‐of‐concept study of sublingual tizanidine in children with chronic traumatic brain injury (TBI). clinicaltrials.gov/ct2/show/NCT00287157 Date first received: 6 February 2006. ">NCT00287157</a> provided insufficient information and as such this study was rated as unclear. </p> <p>Four studies explicitly reported that outcome assessors were blinded (<a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a>; <a href="./references#CD008929-bbs2-0002" title="LeungJ , HarveyLA , MoseleyAM , WhitesideB , SimpsonM , StroudK . Standing with electrical stimulation and splinting is no better than standing alone for management of ankle plantarflexion contractures in people with traumatic brain injury: a randomised trial. Journal of Physiotherapy2014;60:201‐8. ">Leung 2014</a>; <a href="./references#CD008929-bbs2-0003" title="MeythalerJM , DeVivoMJ , HadleyM . Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Archives of Physical Medicine and Rehabilitation1996; Vol. 77, issue 5:461‐6. ">Meythaler 1996</a>; <a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a>). It is noteworthy that these were amongst the only studies with outcome data included in the review. In four studies, it was unclear if outcome assessors were blinded (<a href="./references#CD008929-bbs2-0004" title="MeythalerJM , McCaryA , HadleyMN . Prospective assessment of continuous intrathecal infusion of baclofen for spasticity caused by acquired brain injury: a preliminary report. Journal of Neurosurgery1997; Vol. 87, issue 3:415‐9. ">Meythaler 1997</a>; <a href="./references#CD008929-bbs2-0005" title="MeythalerJM , Guin‐RenfroeS , HadleyMN . Continuously infused intrathecal baclofen for spastic/dystonic hemiplegia: a preliminary report. American Journal of Physical Medicine &amp; Rehabilitation1999; Vol. 78, issue 3:247‐54. ">Meythaler 1999a</a>; <a href="./references#CD008929-bbs2-0006" title="MeythalerJM , Guin‐RenfroeS , GrabbP , HadleyMN . Long‐term continuously infused intrathecal baclofen for spastic‐dystonic hypertonia in traumatic brain injury: 1‐year experience. Archives of Physical Medicine and Rehabilitation1999; Vol. 80, issue 1:13‐9. ">Meythaler 1999b</a>; <a href="./references#CD008929-bbs2-0007" title="NCT00287157 . Pilot, proof‐of‐concept study of sublingual tizanidine in children with chronic traumatic brain injury (TBI). clinicaltrials.gov/ct2/show/NCT00287157 Date first received: 6 February 2006. ">NCT00287157</a>), and in one study outcome assessors could not be blinded, hence it was rated at high risk (<a href="./references#CD008929-bbs2-0008" title="PittaccioS , GaravagliaL , ViscusoS , BerettaE , StrazzerS . Implementation, testing and pilot clinical evaluation of superelastic splints that decrease joint stiffness. Annals of Biomedical Engineering2013;41:2003‐17. ">Pittaccio 2013</a>). </p> </section> <section id="CD008929-sec-0084"> <h4 class="title">Incomplete outcome data</h4> <p>Six studies reported no losses to follow‐up and were at low risk of attrition bias (<a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a>; <a href="./references#CD008929-bbs2-0003" title="MeythalerJM , DeVivoMJ , HadleyM . Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Archives of Physical Medicine and Rehabilitation1996; Vol. 77, issue 5:461‐6. ">Meythaler 1996</a>; <a href="./references#CD008929-bbs2-0004" title="MeythalerJM , McCaryA , HadleyMN . Prospective assessment of continuous intrathecal infusion of baclofen for spasticity caused by acquired brain injury: a preliminary report. Journal of Neurosurgery1997; Vol. 87, issue 3:415‐9. ">Meythaler 1997</a>; <a href="./references#CD008929-bbs2-0005" title="MeythalerJM , Guin‐RenfroeS , HadleyMN . Continuously infused intrathecal baclofen for spastic/dystonic hemiplegia: a preliminary report. American Journal of Physical Medicine &amp; Rehabilitation1999; Vol. 78, issue 3:247‐54. ">Meythaler 1999a</a>; <a href="./references#CD008929-bbs2-0006" title="MeythalerJM , Guin‐RenfroeS , GrabbP , HadleyMN . Long‐term continuously infused intrathecal baclofen for spastic‐dystonic hypertonia in traumatic brain injury: 1‐year experience. Archives of Physical Medicine and Rehabilitation1999; Vol. 80, issue 1:13‐9. ">Meythaler 1999b</a>; <a href="./references#CD008929-bbs2-0008" title="PittaccioS , GaravagliaL , ViscusoS , BerettaE , StrazzerS . Implementation, testing and pilot clinical evaluation of superelastic splints that decrease joint stiffness. Annals of Biomedical Engineering2013;41:2003‐17. ">Pittaccio 2013</a>). <a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a> reported four withdrawals and three deaths; however, their final measurements for these participants were those taken before withdrawal from the study (rated as unclear as they did not report which group they were randomised to). <a href="./references#CD008929-bbs2-0002" title="LeungJ , HarveyLA , MoseleyAM , WhitesideB , SimpsonM , StroudK . Standing with electrical stimulation and splinting is no better than standing alone for management of ankle plantarflexion contractures in people with traumatic brain injury: a randomised trial. Journal of Physiotherapy2014;60:201‐8. ">Leung 2014</a> reported four losses to follow‐up, with reasons that were unrelated to the trial; however, they were not balanced between groups. Both studies were rated as unclear risk of bias. The rating for <a href="./references#CD008929-bbs2-0007" title="NCT00287157 . Pilot, proof‐of‐concept study of sublingual tizanidine in children with chronic traumatic brain injury (TBI). clinicaltrials.gov/ct2/show/NCT00287157 Date first received: 6 February 2006. ">NCT00287157</a> was 'unclear' due to lack of information. </p> </section> <section id="CD008929-sec-0085"> <h4 class="title">Selective reporting</h4> <p>One study was at low risk of bias given the availability of a published protocol, which aligned with the subsequently published trial (<a href="./references#CD008929-bbs2-0002" title="LeungJ , HarveyLA , MoseleyAM , WhitesideB , SimpsonM , StroudK . Standing with electrical stimulation and splinting is no better than standing alone for management of ankle plantarflexion contractures in people with traumatic brain injury: a randomised trial. Journal of Physiotherapy2014;60:201‐8. ">Leung 2014</a>). Three studies were at unclear risk of bias for selective reporting, as there were no published protocols (<a href="./references#CD008929-bbs2-0003" title="MeythalerJM , DeVivoMJ , HadleyM . Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Archives of Physical Medicine and Rehabilitation1996; Vol. 77, issue 5:461‐6. ">Meythaler 1996</a>; <a href="./references#CD008929-bbs2-0004" title="MeythalerJM , McCaryA , HadleyMN . Prospective assessment of continuous intrathecal infusion of baclofen for spasticity caused by acquired brain injury: a preliminary report. Journal of Neurosurgery1997; Vol. 87, issue 3:415‐9. ">Meythaler 1997</a>; <a href="./references#CD008929-bbs2-0006" title="MeythalerJM , Guin‐RenfroeS , GrabbP , HadleyMN . Long‐term continuously infused intrathecal baclofen for spastic‐dystonic hypertonia in traumatic brain injury: 1‐year experience. Archives of Physical Medicine and Rehabilitation1999; Vol. 80, issue 1:13‐9. ">Meythaler 1999b</a>). One study was also rated at unclear risk of bias as, while it did have a published protocol for the main study, the TBI subset outcome data for different doses of the active intervention were conflated and results were given in the form of percentages only (<a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a>). Three studies did not reference published protocols (neither could we identify any) and were at high risk due to additional incomplete reporting of their results (<a href="./references#CD008929-bbs2-0005" title="MeythalerJM , Guin‐RenfroeS , HadleyMN . Continuously infused intrathecal baclofen for spastic/dystonic hemiplegia: a preliminary report. American Journal of Physical Medicine &amp; Rehabilitation1999; Vol. 78, issue 3:247‐54. ">Meythaler 1999a</a>; <a href="./references#CD008929-bbs2-0008" title="PittaccioS , GaravagliaL , ViscusoS , BerettaE , StrazzerS . Implementation, testing and pilot clinical evaluation of superelastic splints that decrease joint stiffness. Annals of Biomedical Engineering2013;41:2003‐17. ">Pittaccio 2013</a>; <a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a>). <a href="./references#CD008929-bbs2-0007" title="NCT00287157 . Pilot, proof‐of‐concept study of sublingual tizanidine in children with chronic traumatic brain injury (TBI). clinicaltrials.gov/ct2/show/NCT00287157 Date first received: 6 February 2006. ">NCT00287157</a> was at high risk of bias as the authors advised that the trial data were "negative," and was subsequently not published. </p> </section> <section id="CD008929-sec-0086"> <h4 class="title">Other potential sources of bias</h4> <section id="CD008929-sec-0087"> <h5 class="title">Baseline imbalances</h5> <p>With regards to baseline imbalances, five studies were at low risk of bias (<a href="./references#CD008929-bbs2-0003" title="MeythalerJM , DeVivoMJ , HadleyM . Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Archives of Physical Medicine and Rehabilitation1996; Vol. 77, issue 5:461‐6. ">Meythaler 1996</a>; <a href="./references#CD008929-bbs2-0004" title="MeythalerJM , McCaryA , HadleyMN . Prospective assessment of continuous intrathecal infusion of baclofen for spasticity caused by acquired brain injury: a preliminary report. Journal of Neurosurgery1997; Vol. 87, issue 3:415‐9. ">Meythaler 1997</a>; <a href="./references#CD008929-bbs2-0005" title="MeythalerJM , Guin‐RenfroeS , HadleyMN . Continuously infused intrathecal baclofen for spastic/dystonic hemiplegia: a preliminary report. American Journal of Physical Medicine &amp; Rehabilitation1999; Vol. 78, issue 3:247‐54. ">Meythaler 1999a</a>; <a href="./references#CD008929-bbs2-0006" title="MeythalerJM , Guin‐RenfroeS , GrabbP , HadleyMN . Long‐term continuously infused intrathecal baclofen for spastic‐dystonic hypertonia in traumatic brain injury: 1‐year experience. Archives of Physical Medicine and Rehabilitation1999; Vol. 80, issue 1:13‐9. ">Meythaler 1999b</a>; <a href="./references#CD008929-bbs2-0008" title="PittaccioS , GaravagliaL , ViscusoS , BerettaE , StrazzerS . Implementation, testing and pilot clinical evaluation of superelastic splints that decrease joint stiffness. Annals of Biomedical Engineering2013;41:2003‐17. ">Pittaccio 2013</a>). Four studies were judged as unclear for this domain (<a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a>; <a href="./references#CD008929-bbs2-0002" title="LeungJ , HarveyLA , MoseleyAM , WhitesideB , SimpsonM , StroudK . Standing with electrical stimulation and splinting is no better than standing alone for management of ankle plantarflexion contractures in people with traumatic brain injury: a randomised trial. Journal of Physiotherapy2014;60:201‐8. ">Leung 2014</a>; <a href="./references#CD008929-bbs2-0007" title="NCT00287157 . Pilot, proof‐of‐concept study of sublingual tizanidine in children with chronic traumatic brain injury (TBI). clinicaltrials.gov/ct2/show/NCT00287157 Date first received: 6 February 2006. ">NCT00287157</a>; <a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a>). <a href="./references#CD008929-bbs2-0007" title="NCT00287157 . Pilot, proof‐of‐concept study of sublingual tizanidine in children with chronic traumatic brain injury (TBI). clinicaltrials.gov/ct2/show/NCT00287157 Date first received: 6 February 2006. ">NCT00287157</a> was judged as unclear due to lack of information, whereas the other two studies described their groups as being 'similar' at baseline, but subsequently outlined some differences between the groups. </p> </section> <section id="CD008929-sec-0088"> <h5 class="title">Appropriate study design</h5> <p>For the six cross‐over trials, five used an appropriate study design (<a href="./references#CD008929-bbs2-0003" title="MeythalerJM , DeVivoMJ , HadleyM . Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Archives of Physical Medicine and Rehabilitation1996; Vol. 77, issue 5:461‐6. ">Meythaler 1996</a>; <a href="./references#CD008929-bbs2-0004" title="MeythalerJM , McCaryA , HadleyMN . Prospective assessment of continuous intrathecal infusion of baclofen for spasticity caused by acquired brain injury: a preliminary report. Journal of Neurosurgery1997; Vol. 87, issue 3:415‐9. ">Meythaler 1997</a>; <a href="./references#CD008929-bbs2-0005" title="MeythalerJM , Guin‐RenfroeS , HadleyMN . Continuously infused intrathecal baclofen for spastic/dystonic hemiplegia: a preliminary report. American Journal of Physical Medicine &amp; Rehabilitation1999; Vol. 78, issue 3:247‐54. ">Meythaler 1999a</a>; <a href="./references#CD008929-bbs2-0006" title="MeythalerJM , Guin‐RenfroeS , GrabbP , HadleyMN . Long‐term continuously infused intrathecal baclofen for spastic‐dystonic hypertonia in traumatic brain injury: 1‐year experience. Archives of Physical Medicine and Rehabilitation1999; Vol. 80, issue 1:13‐9. ">Meythaler 1999b</a>; <a href="./references#CD008929-bbs2-0008" title="PittaccioS , GaravagliaL , ViscusoS , BerettaE , StrazzerS . Implementation, testing and pilot clinical evaluation of superelastic splints that decrease joint stiffness. Annals of Biomedical Engineering2013;41:2003‐17. ">Pittaccio 2013</a>). The remaining trial was at unclear risk of bias. </p> </section> <section id="CD008929-sec-0089"> <h5 class="title">Adequate washout period</h5> <p>Three cross‐over trials provided enough information to be judged as having an adequate washout period (low risk of bias) (<a href="./references#CD008929-bbs2-0003" title="MeythalerJM , DeVivoMJ , HadleyM . Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Archives of Physical Medicine and Rehabilitation1996; Vol. 77, issue 5:461‐6. ">Meythaler 1996</a>; <a href="./references#CD008929-bbs2-0004" title="MeythalerJM , McCaryA , HadleyMN . Prospective assessment of continuous intrathecal infusion of baclofen for spasticity caused by acquired brain injury: a preliminary report. Journal of Neurosurgery1997; Vol. 87, issue 3:415‐9. ">Meythaler 1997</a>; <a href="./references#CD008929-bbs2-0005" title="MeythalerJM , Guin‐RenfroeS , HadleyMN . Continuously infused intrathecal baclofen for spastic/dystonic hemiplegia: a preliminary report. American Journal of Physical Medicine &amp; Rehabilitation1999; Vol. 78, issue 3:247‐54. ">Meythaler 1999a</a>). Investigators in one trial judged it unethical to have a washout period (<a href="./references#CD008929-bbs2-0008" title="PittaccioS , GaravagliaL , ViscusoS , BerettaE , StrazzerS . Implementation, testing and pilot clinical evaluation of superelastic splints that decrease joint stiffness. Annals of Biomedical Engineering2013;41:2003‐17. ">Pittaccio 2013</a>). Statistical tests were conducted and presented demonstrating that sequential order did not affect treatment response, so this trial was also assessed as having a low risk of bias. The remaining two cross‐over trials were at unclear risk of bias for this domain (<a href="./references#CD008929-bbs2-0006" title="MeythalerJM , Guin‐RenfroeS , GrabbP , HadleyMN . Long‐term continuously infused intrathecal baclofen for spastic‐dystonic hypertonia in traumatic brain injury: 1‐year experience. Archives of Physical Medicine and Rehabilitation1999; Vol. 80, issue 1:13‐9. ">Meythaler 1999b</a>; <a href="./references#CD008929-bbs2-0007" title="NCT00287157 . Pilot, proof‐of‐concept study of sublingual tizanidine in children with chronic traumatic brain injury (TBI). clinicaltrials.gov/ct2/show/NCT00287157 Date first received: 6 February 2006. ">NCT00287157</a>). </p> </section> <section id="CD008929-sec-0090"> <h5 class="title">Other bias</h5> <p>With regards to 'other bias', three studies (<a href="./references#CD008929-bbs2-0004" title="MeythalerJM , McCaryA , HadleyMN . Prospective assessment of continuous intrathecal infusion of baclofen for spasticity caused by acquired brain injury: a preliminary report. Journal of Neurosurgery1997; Vol. 87, issue 3:415‐9. ">Meythaler 1997</a>; <a href="./references#CD008929-bbs2-0005" title="MeythalerJM , Guin‐RenfroeS , HadleyMN . Continuously infused intrathecal baclofen for spastic/dystonic hemiplegia: a preliminary report. American Journal of Physical Medicine &amp; Rehabilitation1999; Vol. 78, issue 3:247‐54. ">Meythaler 1999a</a>; <a href="./references#CD008929-bbs2-0006" title="MeythalerJM , Guin‐RenfroeS , GrabbP , HadleyMN . Long‐term continuously infused intrathecal baclofen for spastic‐dystonic hypertonia in traumatic brain injury: 1‐year experience. Archives of Physical Medicine and Rehabilitation1999; Vol. 80, issue 1:13‐9. ">Meythaler 1999b</a>) were at high risk of bias due to unit of analysis issues (outcomes were analysed by looking at upper versus lower extremities, rather than considering each muscle separately; scores for muscle tone, spasms and reflexes were averaged for the upper or lower extremities in each participant). Four studies were at unclear risk of bias due to insufficient information (<a href="./references#CD008929-bbs2-0007" title="NCT00287157 . Pilot, proof‐of‐concept study of sublingual tizanidine in children with chronic traumatic brain injury (TBI). clinicaltrials.gov/ct2/show/NCT00287157 Date first received: 6 February 2006. ">NCT00287157</a>); the close role of the funder (a pharmaceutical company) in the study design, conduct and analysis (<a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a>); the inclusion of a participant who did not meet the study inclusion criteria (<a href="./references#CD008929-bbs2-0008" title="PittaccioS , GaravagliaL , ViscusoS , BerettaE , StrazzerS . Implementation, testing and pilot clinical evaluation of superelastic splints that decrease joint stiffness. Annals of Biomedical Engineering2013;41:2003‐17. ">Pittaccio 2013</a>); and marked differences in the number of tilt table sessions between the intevention and control groups (<a href="./references#CD008929-bbs2-0002" title="LeungJ , HarveyLA , MoseleyAM , WhitesideB , SimpsonM , StroudK . Standing with electrical stimulation and splinting is no better than standing alone for management of ankle plantarflexion contractures in people with traumatic brain injury: a randomised trial. Journal of Physiotherapy2014;60:201‐8. ">Leung 2014</a>). We did not identify any other bias concerns with the remaining two studies (<a href="./references#CD008929-bbs2-0003" title="MeythalerJM , DeVivoMJ , HadleyM . Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Archives of Physical Medicine and Rehabilitation1996; Vol. 77, issue 5:461‐6. ">Meythaler 1996</a>; <a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a>). </p> </section> </section> </section> <section id="CD008929-sec-0091"> <h3 class="title" id="CD008929-sec-0091">Effects of interventions</h3> <p>See: <a href="./full#CD008929-tbl-0001"><b>Summary of findings for the main comparison</b> Baclofen compared with placebo for spasticity in people with traumatic brain injury</a>; <a href="./full#CD008929-tbl-0002"><b>Summary of findings 2</b> Botulinum toxin A (with and without casting) compared with placebo (with and without casting) for spasticity in people with traumatic brain injury</a>; <a href="./full#CD008929-tbl-0003"><b>Summary of findings 3</b> Pseudoelastic orthosis versus traditional (static) splint for spasticity in people with traumatic brain injury</a> </p> <section id="CD008929-sec-0092"> <h4 class="title">Baclofen versus placebo</h4> <p>One study with usable results compared baclofen versus placebo (<a href="./references#CD008929-bbs2-0003" title="MeythalerJM , DeVivoMJ , HadleyM . Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Archives of Physical Medicine and Rehabilitation1996; Vol. 77, issue 5:461‐6. ">Meythaler 1996</a>). (Three other studies compared baclofen to placebo but had no useable results; <a href="./references#CD008929-bbs2-0004" title="MeythalerJM , McCaryA , HadleyMN . Prospective assessment of continuous intrathecal infusion of baclofen for spasticity caused by acquired brain injury: a preliminary report. Journal of Neurosurgery1997; Vol. 87, issue 3:415‐9. ">Meythaler 1997</a>; <a href="./references#CD008929-bbs2-0005" title="MeythalerJM , Guin‐RenfroeS , HadleyMN . Continuously infused intrathecal baclofen for spastic/dystonic hemiplegia: a preliminary report. American Journal of Physical Medicine &amp; Rehabilitation1999; Vol. 78, issue 3:247‐54. ">Meythaler 1999a</a>; <a href="./references#CD008929-bbs2-0006" title="MeythalerJM , Guin‐RenfroeS , GrabbP , HadleyMN . Long‐term continuously infused intrathecal baclofen for spastic‐dystonic hypertonia in traumatic brain injury: 1‐year experience. Archives of Physical Medicine and Rehabilitation1999; Vol. 80, issue 1:13‐9. ">Meythaler 1999b</a>.) A summary of the results of the main outcomes for this comparison is provided in <a href="./full#CD008929-tbl-0001">summary of findings Table for the main comparison</a>. </p> <section id="CD008929-sec-0093"> <h5 class="title">Spasticity</h5> <p><a href="./references#CD008929-bbs2-0003" title="MeythalerJM , DeVivoMJ , HadleyM . Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Archives of Physical Medicine and Rehabilitation1996; Vol. 77, issue 5:461‐6. ">Meythaler 1996</a> (11 participants, all included in the analysis) reported between‐group differences in both the lower and upper extremity Ashworth scores using P values, but with no effect sizes or CIs. It was unclear which statistical tests were used. As the study authors did not report any raw data for the placebo group results, we could do no further analysis. The authors reported a 'significant' improvement with baclofen compared to placebo at four hours (P = 0.0084) and six hours (P = 0.0163) after administration. Baclofen was also associated with 'significant' improvements compared to placebo for upper extremity Ashworth score (P = 0.0097) at four hours after administration, however this effect was not sustained at six hours (P value not reported). </p> <p>The quality of the evidence on the effect of baclofen versus placebo for spasticity was very low (downgraded four times). This was due to risk of bias limitations (no study provided sufficient information about the random sequence generation or allocation concealment), our concerns about indirectness of the Ashworth score, an inability to assess imprecision relating to an absence of CIs and a further downgrade for there only being a single study for this outcome and the likelihood of publication bias in this area. Considered together with the fact that we could not judge how clinically relevant the improvements were in this study, we were very uncertain about the effect of baclofen on spasticity and unable to draw any conclusions. </p> </section> <section id="CD008929-sec-0094"> <h5 class="title">Adverse events</h5> <p>There were no adverse events or changes in alertness level in the baclofen or placebo groups (see <a href="#CD008929-tbl-0007">Table 4</a>). </p> <div class="table" id="CD008929-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Adverse effects</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Adverse effect</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Number of participants affected</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Studies</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Deep vein thrombosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 participants withdrawn from physiotherapy group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Contracture at subtalar joint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 participants withdrawn from the casting + placebo group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No adverse events or changes in alertness level were observed in the baclofen group or placebo arm </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0003" title="MeythalerJM , DeVivoMJ , HadleyM . Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Archives of Physical Medicine and Rehabilitation1996; Vol. 77, issue 5:461‐6. ">Meythaler 1996</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unspecified "treatment emergent AE [adverse effects]": "none were unexpected"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/23 participants, no other information given.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a> (<a href="./references#CD008929-bbs2-0119" title="O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">O'Dell 2015</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skin rashes/oedema/tolerability issues</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No pseudoelastic device required adjustment for comfort; 30% of traditional devices did. Families reported novel treatment tolerated for 40% longer than traditional (<a href="./references#CD008929-bbs2-0008" title="PittaccioS , GaravagliaL , ViscusoS , BerettaE , StrazzerS . Implementation, testing and pilot clinical evaluation of superelastic splints that decrease joint stiffness. Annals of Biomedical Engineering2013;41:2003‐17. ">Pittaccio 2013</a>). </p> <p>2 participants adherence to splinting was affected by 'skin problems' and 'poor tolerance' (<a href="./references#CD008929-bbs2-0002" title="LeungJ , HarveyLA , MoseleyAM , WhitesideB , SimpsonM , StroudK . Standing with electrical stimulation and splinting is no better than standing alone for management of ankle plantarflexion contractures in people with traumatic brain injury: a randomised trial. Journal of Physiotherapy2014;60:201‐8. ">Leung 2014</a>). </p> <p>50% of participants in casting group and 41.7% of participants in casting + botulinum toxin A group developed 'minor skin damage'. Overall, 90% of those resolved spontaneously or with therapeutic dressing (<a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0002" title="LeungJ , HarveyLA , MoseleyAM , WhitesideB , SimpsonM , StroudK . Standing with electrical stimulation and splinting is no better than standing alone for management of ankle plantarflexion contractures in people with traumatic brain injury: a randomised trial. Journal of Physiotherapy2014;60:201‐8. ">Leung 2014</a>; <a href="./references#CD008929-bbs2-0008" title="PittaccioS , GaravagliaL , ViscusoS , BerettaE , StrazzerS . Implementation, testing and pilot clinical evaluation of superelastic splints that decrease joint stiffness. Annals of Biomedical Engineering2013;41:2003‐17. ">Pittaccio 2013</a>; <a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fainting, fatigue, storming<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Several participants' adherence to the tilt table was affected due to fainting, fatigue and storming. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0002" title="LeungJ , HarveyLA , MoseleyAM , WhitesideB , SimpsonM , StroudK . Standing with electrical stimulation and splinting is no better than standing alone for management of ankle plantarflexion contractures in people with traumatic brain injury: a randomised trial. Journal of Physiotherapy2014;60:201‐8. ">Leung 2014</a> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>When someone with a head injury responds to a sensation with a tonic posture or sympathetic response. </p> </div> </div> <p>The quality of the evidence on the effect of baclofen versus placebo for spasticity was very low (downgraded three times). This was due to the same risk of bias concerns as for spasticity and that there was only one study for this outcome and the likelihood of publication bias in this area. As such, we were very uncertain about the effect of baclofen on adverse events compared to placebo and were unable to draw any conclusions. </p> </section> <section id="CD008929-sec-0095"> <h5 class="title">Neuromusculoskeletal and movement‐related functions</h5> <p><a href="./references#CD008929-bbs2-0003" title="MeythalerJM , DeVivoMJ , HadleyM . Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Archives of Physical Medicine and Rehabilitation1996; Vol. 77, issue 5:461‐6. ">Meythaler 1996</a> (11 participants, all included in the analysis) reported that lower extremity spasm scores were significantly improved for baclofen versus placebo at four hours (P = 0.0073) and six hours (P = 0.0049) as were lower extremity reflex scores (P = 0.0086 at four hours and P = 0.0085 at six hours). This effect was also observed for the upper extremity spasm scores (P = 0.0117) and reflex scores (P = 0.0272) at four hours after administration when baclofen was compared to placebo. This effect was not sustained at six hours (P value not reported). </p> <p>The quality of this evidence was very low (downgraded four times, for all the reasons outlined for spasticity) and we are very uncertain about the effect of baclofen on neuromusculoskeletal and movement‐related functions. </p> </section> <section id="CD008929-sec-0096"> <h5 class="title">Outcomes not measured</h5> <p>The study did not report: sensory functions and pain; general tasks and demands; mobility; self‐care; domestic life; major life areas; and community, social and civic life. </p> </section> </section> <section id="CD008929-sec-0097"> <h4 class="title">Botulinum toxin A (with and without casting) versus placebo (with and without casting)</h4> <p>Two studies compared botulinum toxin A (with and without casting) versus placebo (with and without casting) (<a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a>; <a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a>). A summary of the results of the main outcomes for this comparison is provided in <a href="./full#CD008929-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD008929-sec-0098"> <h5 class="title">Spasticity</h5> <p><a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a> (23 participants) report that four weeks after injection, "with abobotulinumtoxinA, the angle of catch (XV3 of the TS) improved in finger (+35 degree), elbow (+22 degree) and wrist (+12 degree) flexors, resulting in a gain in active muscle extension of at least 5 degrees active range of movement." No further outcome data were provided, and they did not comment on the 'statistical significance' of this result. We note that the dosage that produced this result (500 U or 1000 U) was unclear as data from both groups (total 14 participants) were pooled against placebo (nine participants). </p> <p><a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a> (35 participants) compared three different interventions, which we report as three two‐arm comparisons (the authors analysed pre‐ and post‐treatment differences in the Modified Ashworth Scale within groups, but not between groups). As such, we calculated the between‐group difference in spasticity (as measured by the Modified Ashworth Scale at 12 weeks) for botulinum toxin A plus casting versus placebo plus casting as MD 0.30 points (95% CI ‐0.87 to 1.47; <a href="./references#CD008929-fig-0004" title="">Analysis 1.1</a>). </p> <p>The quality of the evidence for this outcome was very low (downgraded four times). This was due to risk of bias concerns for both studies (downgraded twice, because either insufficient information about random sequence generation and allocation concealment, in one study, and potential selective outcome reporting in both studies), indirectness (one study measured spasticity using the Modified Ashworth Scale) and a high likelihood of publication bias in this area. As such, we were very uncertain about the effect of botulinum toxin A with and without casting versus placebo with and without casting on spasticity and were unable to draw any conclusions. </p> </section> <section id="CD008929-sec-0099"> <h5 class="title">Adverse events</h5> <p>In <a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a>, the authors reported that "7 of 23 patients experienced a treatment emergent AE [adverse event]" and that of these, "none were unexpected." There was no further detail given in the short conference proceeding reporting results for the TBI population. In the main trial publication (of which people with TBI only made up 9%), the most common treatment‐related adverse event was 'mild muscle weakness' and investigators reported that all adverse events were mild or moderate only (see <a href="#CD008929-tbl-0007">Table 4</a>). </p> <p>In <a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a>, botulinum toxin A was to be well tolerated, with only one participant with 'flu‐like' symptoms (i.e. shivering, sweating and fever). For the casting group, 50% developed minor skin damage (66.6% of those was partial thickness skin loss involving epidermis). Finally, in the botulinum toxin A plus casting group, 41.7% of participants developed skin damage (60% of those was discolouration, but skin still intact). Overall, 90.9% of those resolved spontaneously or with therapeutic dressing (see <a href="#CD008929-tbl-0007">Table 4</a>). </p> <p>The quality of the evidence for adverse events was very low (downgraded three times). This was due to risk of bias concerns for both studies (downgraded twice, because in one study there was insufficient information about random sequence generation and allocation concealment, and in both studies the adverse events data were reporting in percentages only) and a high likelihood of publication bias in this area. As such, we were very uncertain about the effect of botulinum toxin A with and without casting versus placebo with and without casting on adverse events and were unable to draw any conclusions. </p> </section> <section id="CD008929-sec-0100"> <h5 class="title">Neuromusculoskeletal and movement‐related functions</h5> <p><a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a> reported between‐group differences in ankle dorsiflexion, and found no differences between groups in a one‐way ANOVA (placebo plus casting versus botulinum toxin A plus casting: P = 0.11). However, they did not report any summary statistics for this, or any baseline scores. </p> <p>The quality of the evidence for neuromusculoskeletal and movement‐related functions was very low for the reasons outlined for spasticity (downgraded four times). As such, we were very uncertain about the effect of botulinum toxin A with and without casting versus placebo with and without casting on neuromusculoskeletal and movement‐related functions and were unable to draw any conclusions. </p> </section> <section id="CD008929-sec-0101"> <h5 class="title">Major life areas</h5> <p>Both <a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a> and <a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a> measured outcomes we classified under major life area outcomes. <a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a> reported an "improvement in subjective function for the treated group (&gt;1 grade decrease from baseline for the principal target of treatment on the Disability Assessment Scale (DAS)): 71% versus 22% for placebo." They did not provide this in absolute numbers, or comment on the 'statistical significance' of the result. <a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a> reported Glasgow Outcome Scale (GOS) and Glasgow Coma Scale scores at follow‐up in each of the three groups, but reported mean values and did not report between‐group differences. </p> <p>The quality of the evidence for major life areas was very low (downgraded three times). This was due to risk of bias concerns for both studies (downgraded twice, because in one study there was insufficient information about random sequence generation and allocation concealment, and in both studies the outcome data were inappropriately analysed or reported in percentages only) and a high likelihood of publication bias in this area. As such, we were uncertain about the effect of botulinum toxin A with and without casting versus placebo with and without casting on major life areas and were unable to draw any conclusions. </p> </section> <section id="CD008929-sec-0102"> <h5 class="title">Community, social and civic life</h5> <p>In <a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a>, the authors reported two quality of life measures (subscores of the 36‐item Short Form Health (SF‐36) and the EuroQol (EQ‐5D); however, these outcomes were not reported separately for the subset of participants with TBI. </p> </section> <section id="CD008929-sec-0103"> <h5 class="title">Outcomes not measured</h5> <p>The studies did not report: sensory functions and pain, general tasks and demands, mobility, self‐care and domestic life. </p> </section> </section> <section id="CD008929-sec-0104"> <h4 class="title">Physiotherapy versus placebo plus casting or botulinum toxin A plus casting</h4> <p>One study compared physiotherapy versus placebo plus casting or botulinum toxin A plus casting (<a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a>). </p> <section id="CD008929-sec-0105"> <h5 class="title">Spasticity</h5> <p><a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a> compared three treatment groups: physiotherapy, placebo plus casting and botulinum toxin A plus casting. The authors analysed pre‐ and post‐treatment differences in the Modified Ashworth Scale within but not between groups. As such, we calculated the following between‐group differences in spasticity (as measured by the Modified Ashworth Scale at 12 weeks): botulinum toxin A plus casting versus physiotherapy (MD ‐0.50 points, 95% CI ‐1.82 to 0.82; <a href="./references#CD008929-fig-0005" title="">Analysis 2.1</a>) and placebo plus casting versus physiotherapy (MD ‐0.80 points, 95% CI ‐2.00 to 0.40; <a href="./references#CD008929-fig-0006" title="">Analysis 3.1</a>). </p> <p>The quality of the evidence for physiotherapy compared to casting or botulinum toxin A plus casting on spasticity was very low. This was due to concerns about risk of bias related to insufficient information provided about allocation concealment and blinding, concerns about indirectness of the Modified Ashworth Scale, an inability to assess imprecision relating to an absence of CIs and a further downgrade for there only being one study for this outcome and the likelihood of publication bias in this area. As such, we are very uncertain about the effect of casting versus botulinum toxin A plus casting versus physiotherapy on spasticity and were unable to draw any conclusions. </p> </section> <section id="CD008929-sec-0106"> <h5 class="title">Adverse events</h5> <p><a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a> withdrew two participants due to an adverse event (see <a href="#CD008929-tbl-0007">Table 4</a>). One was due to deep vein thrombosis (DVT) in the physiotherapy group and one was due to soft tissue contracture at the subtalar joint in the placebo plus casting group. For the adverse events related to botulinum toxin A, see the adverse events listed under the comparison above, botulinum toxin A with and without casting versus placebo with and without casting. </p> <p>The quality of the evidence for physiotherapy versus placebo plus casting or botulinum toxin A plus casting on adverse events was very low. This was due to concerns about risk of bias related to insufficient information provided about allocation concealment and blinding, and a further downgrade for there only being one study for this outcome and the likelihood of publication bias in this area. As such, we were very uncertain about the effect of casting versus botulinum toxin A plus casting versus physiotherapy on adverse events and were unable to draw any conclusions. </p> </section> <section id="CD008929-sec-0107"> <h5 class="title">Neuromusculoskeletal and movement‐related functions</h5> <p><a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a> reported between‐group differences in ankle dorsiflexion and found no differences between groups in a one‐way ANOVA (physiotherapy versus placebo plus casting: P value not significant, physiotherapy versus botulinum toxin A plus casting: P = 0.07). However, they did not report any summary statistics for this, or any baseline scores. </p> <p>The quality of the evidence for physiotherapy versus placebo plus casting or botulinum toxin A plus casting on neuromuscular and movement‐related outcomes was very low (downgraded three times). This was due to concerns about risk of bias (related to insufficient information provided about randomisation schedule generation and allocation concealment, a lack of blinding and selective outcome reporting), an inability to assess imprecision relating to an absence of data and a further downgrade for there only being one study for this outcome and the likelihood of publication bias in this area. As such, we were very uncertain about the effect of casting versus botulinum toxin A plus casting on neuromuscular and movement‐related functions and were unable to draw any conclusions. </p> </section> <section id="CD008929-sec-0108"> <h5 class="title">Major life areas (e.g. Functional Assessment Measure)</h5> <p><a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a> reported GOS and GCS scores at follow‐up in each of the three groups, but reported mean values and did not report between‐group differences. </p> </section> <section id="CD008929-sec-0109"> <h5 class="title">Outcomes not measured</h5> <p>The study did not report: sensory functions and pain; general tasks and demands; mobility; self‐care; domestic life; and community, social and civic life. </p> </section> </section> <section id="CD008929-sec-0110"> <h4 class="title">Pseudoelastic orthosis versus traditional (static) splint</h4> <p>One study compared pseudoelastic orthosis versus traditional (static) splint in children (<a href="./references#CD008929-bbs2-0008" title="PittaccioS , GaravagliaL , ViscusoS , BerettaE , StrazzerS . Implementation, testing and pilot clinical evaluation of superelastic splints that decrease joint stiffness. Annals of Biomedical Engineering2013;41:2003‐17. ">Pittaccio 2013</a>). A summary of the results of the main outcomes for this comparison is provided in <a href="./full#CD008929-tbl-0003">summary of findings Table 3</a>. </p> <section id="CD008929-sec-0111"> <h5 class="title">Spasticity</h5> <p><a href="./references#CD008929-bbs2-0008" title="PittaccioS , GaravagliaL , ViscusoS , BerettaE , StrazzerS . Implementation, testing and pilot clinical evaluation of superelastic splints that decrease joint stiffness. Annals of Biomedical Engineering2013;41:2003‐17. ">Pittaccio 2013</a> measured spasticity using the Ashworth Scale, but reporting for clinical outcomes in this paper was scant. The authors provided no outcome data for spasticity but stated that, "there were no significant differences on means by paired 2‐tailed Student's t test" between the two types of splint. </p> <p>The quality of the evidence was very low. The rating was downgraded four times due to risk of bias limitations (the study provided no information about sequence generation and allocation concealment; blinding was impossible for participants or personnel and not reported for outcome assessors; selective outcome reporting bias was high); our concerns about indirectness of the Ashworth score and indirectness due to 36% of participants not having TBI and one participant was of dubious eligibility; an inability to assess imprecision relating to an absence of meaningful outcome data (no numerical data were provided for spasticity; investigators reported only that there were no significant differences), there was only one study for this comparison/outcome and publication bias was possible in this area. As such, we were very uncertain about the effect of pseudoelastic orthoses versus a traditional (static) splint on spasticity and were unable to draw any conclusions. </p> </section> <section id="CD008929-sec-0112"> <h5 class="title">Adverse events</h5> <p><a href="./references#CD008929-bbs2-0008" title="PittaccioS , GaravagliaL , ViscusoS , BerettaE , StrazzerS . Implementation, testing and pilot clinical evaluation of superelastic splints that decrease joint stiffness. Annals of Biomedical Engineering2013;41:2003‐17. ">Pittaccio 2013</a> reported that both participants and families 'reacted positively' to the pseudoelastic orthoses, which were described as well‐tolerated for several hours a day, and never caused problems familiar to those using more traditional devices including a skin rash, haematomas or pain (see <a href="#CD008929-tbl-0007">Table 4</a>). None of the pseudoelastic orthoses had to be modified to improve comfort, while some adjustments were required for approximately 30% of traditional splints, in order to reduce skin rash, haematomas and oedema. Tolerability was assessed by questionnaire. The investigators conceded that true knowledge of comfort/discomfort experienced by children in the trial was impossible to assess as most participants were unable to communicate; nevertheless, questionnaire data were reported to be encouraging and on average, the pseudoelastic devices were tolerated 40% longer than traditional splints. </p> <p>The quality of the evidence was very low (downgraded four times). The quality was downgraded due to risk of bias limitations (this study provided insufficient information about sequence generation and allocation concealment, blinding was impossible for participants and personnel and not reported for outcome assessors, and selective reporting bias was high). We had concerns about indirectness given that 36% of participants did not have TBI and one participant was of dubious eligibility. Furthermore, there was only one study for this comparison/outcome and publication bias was possible in this area. As such, we were very uncertain about the effect of pseudoelastic orthoses versus a traditional (static) splint on adverse events and were unable to draw any conclusions. </p> </section> <section id="CD008929-sec-0113"> <h5 class="title">Neuromusculoskeletal and movement‐related functions</h5> <p><a href="./references#CD008929-bbs2-0008" title="PittaccioS , GaravagliaL , ViscusoS , BerettaE , StrazzerS . Implementation, testing and pilot clinical evaluation of superelastic splints that decrease joint stiffness. Annals of Biomedical Engineering2013;41:2003‐17. ">Pittaccio 2013</a> reported results for range of motion as non‐significant ("no significant differences on means by paired 2‐tailed Student's t tests") and no further numerical data were given. </p> <p>The quality of the evidence was very low. The quality of the evidence was downgraded five times due to risk of bias limitations (this study provided insufficient information about sequence generation and allocation concealment, blinding was impossible for participants and personnel and not reported for outcome assessors, and selective reporting bias was high). We had concerns about indirectness due to 36% of participants not having TBI and one participant was of dubious eligibility; our inability to assess imprecision given that means and standard deviations were only presented within a small box and whiskers plot, and a further downgrade for there only being one study for this comparison/outcome and the likelihood of publication bias in this area. As such, we were very uncertain about the effect of pseudoelastic orthoses versus a traditional (static) splint on neuromusculoskeletal and movement‐related functions and were unable to draw any conclusions. </p> </section> <section id="CD008929-sec-0114"> <h5 class="title">Outcomes not measured</h5> <p>The study did not report: sensory functions and pain; general tasks and demands; mobility; self‐care; domestic life; major life areas; and community, social and civic life. </p> </section> </section> <section id="CD008929-sec-0115"> <h4 class="title">Tilt table standing, electrical stimulation and ankle splinting versus tilt table standing alone </h4> <p>One study compared tilt table standing, electrical stimulation and ankle splinting versus tilt table standing alone (<a href="./references#CD008929-bbs2-0002" title="LeungJ , HarveyLA , MoseleyAM , WhitesideB , SimpsonM , StroudK . Standing with electrical stimulation and splinting is no better than standing alone for management of ankle plantarflexion contractures in people with traumatic brain injury: a randomised trial. Journal of Physiotherapy2014;60:201‐8. ">Leung 2014</a>). </p> <section id="CD008929-sec-0116"> <h5 class="title">Spasticity</h5> <p><a href="./references#CD008929-bbs2-0002" title="LeungJ , HarveyLA , MoseleyAM , WhitesideB , SimpsonM , StroudK . Standing with electrical stimulation and splinting is no better than standing alone for management of ankle plantarflexion contractures in people with traumatic brain injury: a randomised trial. Journal of Physiotherapy2014;60:201‐8. ">Leung 2014</a> measured spasticity at six weeks (end of programme) and 10 weeks (end of trial) using the 5‐point 'reaction to passive stretch at high speed' component of the Tardieu Scale. <a href="./references#CD008929-bbs2-0002" title="LeungJ , HarveyLA , MoseleyAM , WhitesideB , SimpsonM , StroudK . Standing with electrical stimulation and splinting is no better than standing alone for management of ankle plantarflexion contractures in people with traumatic brain injury: a randomised trial. Journal of Physiotherapy2014;60:201‐8. ">Leung 2014</a> treated this as a continuous scale and reported the difference between groups using change scores, which we plotted using postintervention scores only (see <a href="./references#CD008929-fig-0007" title="">Analysis 4.1</a>). This resulted in an MD of ‐1.00 points (95% CI ‐1.66 to ‐0.34) at week six (in favour of tilt table standing, electrical stimulation and ankle splinting) and an MD of 1.00 (95% CI 0.31 to 1.69) at week 10 (in favour of tilt table standing alone). This is broadly consistent with the conclusions of the authors that "there was a small mean reduction of 1 point in spasticity at Week 6 (95% CI 0.1 to 1.8) in favour of the experimental group, but this effect disappeared at Week 10." </p> <p>The quality of the evidence for tilt table standing, electrical stimulation and ankle splinting versus tilt table standing alone on spasticity was very low (downgraded three times). This was due to concerns about indirectness (downgraded once for potentially inappropriate analysis of the Tardieu Scale as a continuous measure), imprecision (downgraded once as there was only one small study for this outcome) and the likelihood of publication bias in this area (downgraded once). As such, we were very uncertain about the effect of tilt table standing, electrical stimulation and ankle splinting versus tilt table standing alone on spasticity and were unable to draw any conclusions. </p> </section> <section id="CD008929-sec-0117"> <h5 class="title">Adverse events</h5> <p>While <a href="./references#CD008929-bbs2-0002" title="LeungJ , HarveyLA , MoseleyAM , WhitesideB , SimpsonM , StroudK . Standing with electrical stimulation and splinting is no better than standing alone for management of ankle plantarflexion contractures in people with traumatic brain injury: a randomised trial. Journal of Physiotherapy2014;60:201‐8. ">Leung 2014</a> did not explicitly measure adverse events, they provided a description of a number of factors that influenced several participants' adherence to tilt table standing, including fainting, fatigue and storming (when someone with a head injury responds to a sensation with a tonic posture or sympathetic response). Additionally, two participants' adherence to splinting was affected by "skin problems" and "poor tolerance." </p> </section> <section id="CD008929-sec-0118"> <h5 class="title">Neuromusculoskeletal and movement‐related functions</h5> <p><a href="./references#CD008929-bbs2-0002" title="LeungJ , HarveyLA , MoseleyAM , WhitesideB , SimpsonM , StroudK . Standing with electrical stimulation and splinting is no better than standing alone for management of ankle plantarflexion contractures in people with traumatic brain injury: a randomised trial. Journal of Physiotherapy2014;60:201‐8. ">Leung 2014</a> measured passive ankle dorsiflexion at 12 Nm at six weeks (end of programme) and 10 weeks (end of trial). Dorsiflexion was measured relative to a neutral ankle position (0 degrees), with a positive score indicating dorsiflexion (the desired direction of movement) and a negative score indicating plantarflexion. They explored the differential effects using change scores, but we recalculated this using postintervention scores (see <a href="./references#CD008929-fig-0008" title="">Analysis 4.2</a>). This yielded an MD of ‐2.00 degrees (95% CI ‐7.19 to 3.19) at six weeks and an MD of 1.00 degree (95% CI ‐3.31 to 5.31) at 10 weeks. </p> <p>The quality of the evidence for tilt table standing, electrical stimulation and ankle splinting versus tilt table standing alone on neuromuscular and movement‐related functions was very low (downgraded three times). This was due to imprecision (downgraded once) related to the CI including both a meaningful benefit and harm, using <a href="./references#CD008929-bbs2-0002" title="LeungJ , HarveyLA , MoseleyAM , WhitesideB , SimpsonM , StroudK . Standing with electrical stimulation and splinting is no better than standing alone for management of ankle plantarflexion contractures in people with traumatic brain injury: a randomised trial. Journal of Physiotherapy2014;60:201‐8. ">Leung 2014</a>'s prespecified 'minimum worthwhile treatment effect' of 5 degrees, there was only one study for this outcome (downgraded once) and the likelihood of publication bias in this area (downgraded once). As such, we were very uncertain about the effect of tilt table standing, electrical stimulation and ankle splinting versus tilt table standing alone on neuromusculoskeletal and movement‐related functions and were unable to draw any conclusions. </p> </section> <section id="CD008929-sec-0119"> <h5 class="title">Mobility</h5> <p><a href="./references#CD008929-bbs2-0002" title="LeungJ , HarveyLA , MoseleyAM , WhitesideB , SimpsonM , StroudK . Standing with electrical stimulation and splinting is no better than standing alone for management of ankle plantarflexion contractures in people with traumatic brain injury: a randomised trial. Journal of Physiotherapy2014;60:201‐8. ">Leung 2014</a> measured mobility using walking speed (in metres/second) at six weeks (end of programme) and 10 weeks (end of trial). They assessed between‐group differences using change scores, which we recalculated using postintervention scores (see <a href="./references#CD008929-fig-0009" title="">Analysis 4.3</a>). This yielded a MD of ‐0.10 m/second (95% CI ‐0.43 to 0.23) at six weeks and 0.00 (95% CI ‐0.38 to 0.38) at 10 weeks. </p> <p>The quality of the evidence for tilt table standing, electrical stimulation and ankle splinting versus tilt table standing alone on mobility was very low. The quality of the evidence was downgraded four times due to risk of bias concerns (participants and personnel could not be blinded and there were some imbalances between groups in the length of time since injury and the number of tilt table sessions received), for imprecision (single study and the CI included a potential benefit and harm) and the likelihood of publication bias in this area. As such, we were uncertain about the effect of tilt table standing, electrical stimulation and ankle splinting versus tilt table standing alone on mobility and were unable to draw any conclusions. </p> <p>The study did not report: sensory functions and pain; general tasks and demands; self‐care; domestic life; major life areas; and community, social and civic life. </p> </section> </section> <section id="CD008929-sec-0120"> <h4 class="title">Tizanidine versus placebo</h4> <p>One study compared tizanidine versus placebo (<a href="./references#CD008929-bbs2-0007" title="NCT00287157 . Pilot, proof‐of‐concept study of sublingual tizanidine in children with chronic traumatic brain injury (TBI). clinicaltrials.gov/ct2/show/NCT00287157 Date first received: 6 February 2006. ">NCT00287157</a>) in children. However, we have no information regarding participants and no information about the effect of tizanidine versus placebo on spasticity or any other outcomes as the results of this study are unavailable and unpublished. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008929-sec-0121" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008929-sec-0121"></div> <section id="CD008929-sec-0122"> <h3 class="title" id="CD008929-sec-0122">Summary of main results</h3> <p>We found nine RCTs, including 385 participants (of whom 134 had TBI), that assessed the effect of a wide range of pharmacological and non‐pharmacological treatments for spasticity as a result of TBI. Only five of these studies reported results in sufficient detail to allow synthesis in the review. As such, we included data from studies with 350 participants (105 of whom had TBI) in which baclofen, botulinum toxin A, casting, physiotherapy, splints, tilt table standing and electrical stimulation were tested, either alone or in combination. </p> <p>Given such heterogeneity of interventions, trials for any given intervention were few, and sample sizes were small. Added to this, reporting of methods and results for trials was patchy, we had concerns about indirectness given the number of studies in this review with mixed populations, and publication bias given the known (and potentially unknown) unpublished studies in this area. These factors combined to mean there was a paucity of evidence about the effect of interventions for the management of spasticity in people with TBI. The quality of the evidence for all outcomes was very low. </p> <p>In the interests of completeness, we provided a rudimentary summary of the results for the primary outcomes of spasticity and adverse events. Results were mixed for spasticity, but we cautioned against drawing conclusion given the very low quality evidence. For pharmacological interventions, baclofen had a greater effect than placebo after six hours of treatment in the lower limbs but not upper limbs (<a href="./references#CD008929-bbs2-0003" title="MeythalerJM , DeVivoMJ , HadleyM . Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Archives of Physical Medicine and Rehabilitation1996; Vol. 77, issue 5:461‐6. ">Meythaler 1996</a>), and botulinum toxin A had a greater effect than placebo at four weeks in the upper limbs (<a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a>), but when combined with casting it had no greater effect than casting alone in the lower limbs (<a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a>). For non‐pharmacological studies, physiotherapy compared with casting in the lower limbs (<a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a>), and novel pseudoelastic splints with traditional splints at the ankle or elbow (<a href="./references#CD008929-bbs2-0008" title="PittaccioS , GaravagliaL , ViscusoS , BerettaE , StrazzerS . Implementation, testing and pilot clinical evaluation of superelastic splints that decrease joint stiffness. Annals of Biomedical Engineering2013;41:2003‐17. ">Pittaccio 2013</a>), demonstrated no differences between treatments. </p> <p>For adverse events, the quality of the evidence was similarly very low, but the results were a little more consistent. For pharmacological treatments, there were no adverse events reported in the baclofen study (<a href="./references#CD008929-bbs2-0003" title="MeythalerJM , DeVivoMJ , HadleyM . Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Archives of Physical Medicine and Rehabilitation1996; Vol. 77, issue 5:461‐6. ">Meythaler 1996</a>), or the group which received botulinum toxin A in <a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a>, but 7/23 participants in the botulinum toxin A study by <a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a> experienced a "treatment emergent adverse event" (no further information provided). Many of the non‐pharmacological treatments were associated tolerability/adherence issues, including traditional splints (<a href="./references#CD008929-bbs2-0002" title="LeungJ , HarveyLA , MoseleyAM , WhitesideB , SimpsonM , StroudK . Standing with electrical stimulation and splinting is no better than standing alone for management of ankle plantarflexion contractures in people with traumatic brain injury: a randomised trial. Journal of Physiotherapy2014;60:201‐8. ">Leung 2014</a>; <a href="./references#CD008929-bbs2-0008" title="PittaccioS , GaravagliaL , ViscusoS , BerettaE , StrazzerS . Implementation, testing and pilot clinical evaluation of superelastic splints that decrease joint stiffness. Annals of Biomedical Engineering2013;41:2003‐17. ">Pittaccio 2013</a>) and tilt table standing (<a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a>). In <a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a>, between 41.7% and 50% of participants who received casting developed minor skin damage, of which, 90% resolved spontaneously. In <a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a>, two more serious adverse events developed in the physiotherapy group (DVT) and the casting plus placebo group (joint contracture). </p> <p>Due to the very low quality of evidence, we were uncertain about the effects of any of these interventions for managing spasticity. </p> </section> <section id="CD008929-sec-0123"> <h3 class="title" id="CD008929-sec-0123">Overall completeness and applicability of evidence</h3> <p>This review indicated that the evidence for existing interventions for managing spasticity in TBI is limited. Given the paucity of well‐designed and reported trials, the applicability of this review to the TBI population was limited as there were many factors that needed to be considered which none of the studies addressed. </p> <p>Clinicians can find the management of TBI challenging due to the varying extent of the UMN damage causing spasticity affecting many muscles and joints, trunk, limbs, head and neck leading to complex physical disabilities and often coexisting cognitive and behavioural impairments. These confounding factors can impact on spasticity management as people with TBI may have a lower tolerance for treatments, as well as an inability to monitor or participate in the learning and practice required for rehabilitation. Consideration for a greater research base to be developed in this area is extremely important. </p> <p>There are varying levels of evidence for the management of spasticity in other neurological populations (<a href="./references#CD008929-bbs2-0076" title="Ade‐HallR , MooreP . Botulinum toxin type A in the treatment of lower limb spasticity in cerebral palsy. Cochrane Database of Systematic Reviews2000, Issue 1. [DOI: 10.1002/14651858.CD001408] ">Ade‐Hall 2000</a>; <a href="./references#CD008929-bbs2-0078" title="AmatyaB , KhanF , LaML , DemetriosM , WadeDT . Non pharmacological interventions for spasticity in multiple sclerosis. Cochrane Database of Systematic Reviews2013, Issue 2. [DOI: 10.1002/14651858.CD009974.pub2] ">Amatya 2013</a>; <a href="./references#CD008929-bbs2-0090" title="DuarteGS , CastelãoM , RodriguesFB , MarquesRE , FerreiraJ , SampaioC , et al. Botulinum toxin type A versus botulinum toxin type B for cervical dystonia. Cochrane Database of Systematic Reviews2016, Issue 10. [DOI: 10.1002/14651858.CD004314.pub3] ">Duarte 2016</a>; <a href="./references#CD008929-bbs2-0088" title="DemetriosM , KhanF , Turner‐StokesL , BrandC , McSweeneyS . Multidisciplinary rehabilitation following botulinum toxin and other focal intramuscular treatment for post‐stroke spasticity. Cochrane Database of Systematic Reviews2013, Issue 6. [DOI: 10.1002/14651858.CD009689.pub2] ">Demetrios 2013</a>; <a href="./references#CD008929-bbs2-0108" title="LindsayC , PandyanAD . Pharmacological interventions other than botulinum toxin for spasticity after stroke. Cochrane Database of Systematic Reviews2013, Issue 2. [DOI: 10.1002/14651858.CD010362.pub2] ">Lindsay 2013</a>; <a href="./references#CD008929-bbs2-0126" title="Royal College of Physicians. Spasticity in Adults: Management using Botulinum Toxin: National Guidelines. London (UK): Royal College of Physicians, 2009. ">RCP 2009</a>; <a href="./references#CD008929-bbs2-0130" title="ShakespeareD , BoggildM , YoungCA . Anti‐spasticity agents for multiple sclerosis. Cochrane Database of Systematic Reviews2003, Issue 4. [DOI: 10.1002/14651858.CD001332; CD001332] ">Shakespeare 2003</a>; <a href="./references#CD008929-bbs2-0133" title="TariccoM , AdoneR , PagliacciC , TelaroE . Pharmacological interventions for spasticity following spinal cord injury. Cochrane Database of Systematic Reviews2000, Issue 2. [DOI: 10.1002/14651858.CD001131] ">Taricco 2000</a>). There is an assumption made that the effects of pharmacological and non‐pharmacological interventions in other conditions (e.g. multiple sclerosis, stroke) are the same for TBI. While at an impairment level the outcome may potentially be comparable, there can be a difference at a functional level. There is little evidence for the effect of these interventions at a functional level (<a href="./references#CD008929-bbs2-0093" title="FrancisHP , WadeDT , Turner‐StokesL , KingswellRS , DottCS , CoxonEA . Does reducing spasticity translate into functional benefit? An exploratory meta‐analysis. Journal of Neurology, Neurosurgery and Psychiatry2004; Vol. 75, issue 11:1547‐51. ">Francis 2004</a>). </p> </section> <section id="CD008929-sec-0124"> <h3 class="title" id="CD008929-sec-0124">Quality of the evidence</h3> <p>The quality of the evidence for all outcomes was very low due to risk of bias concerns (a combination of poor reporting and poor conduct), indirectness related to mixed populations or the outcome measures used (or both), imprecision and the likelihood of publication/reporting biases in this area. We did not formally downgrade the quality of the evidence for the analysis approach taken in studies that measured spasticity (where all the authors treated the ordinal scales as continuous) given the lack of consensus about how best to analyse these data, but this may introduce a further flaw in the interpretation. </p> </section> <section id="CD008929-sec-0125"> <h3 class="title" id="CD008929-sec-0125">Potential biases in the review process</h3> <p>The decision to limit inclusion of studies with a mixed clinical population to those with greater than 50% of participants with TBI had a major impact on the number of included studies in the review. Had we reduced or removed the threshold, we could have increased the number of included studies by a further 27. Had we increased the threshold to 100% (similar to the approach taken in one TBI trial overview (<a href="./references#CD008929-bbs2-0083" title="BraggeP , SynnotA , MaasAI , MenonDK , CooperDJ , RosenfeldJV , et al. A state of the science overview of randomised controlled trials evaluating acute management of moderate to severe traumatic brain injury. Journal of Neurotrauma2016;33(16):1461‐78.. [DOI: 10.1089/neu.2015.4233] ">Bragge 2016</a>)) we would have reduced the number of included studies to three. As such, the level of the threshold used in the review may have affected the results and conclusions. This threshold was set during the screening stages of the review (i.e. before extraction of results data) and was determined using clinical judgement. </p> </section> <section id="CD008929-sec-0126"> <h3 class="title" id="CD008929-sec-0126">Agreements and disagreements with other studies or reviews</h3> <p>As far as we are aware, this is the only systematic review evaluating any intervention for skeletal muscle spasticity, specifically in people with TBI. Three non‐Cochrane systematic reviews of RCTs have each investigated the efficacy of botulinum toxin A for spasticity (due to TBI and other causes) in the upper limbs (<a href="./references#CD008929-bbs2-0089" title="DongY , WuT , HuX , WangT . Efficacy and safety of botulinum toxin type A for upper limb spasticity after stroke or traumatic brain injury: a systematic review with meta‐analysis and trial sequential analysis. European Journal of Physical Rehabilitation Medicine2017;53:256‐67. ">Dong 2017</a>), lower limbs (<a href="./references#CD008929-bbs2-0087" title="DashtipourK , ChenJJ , WalkerHW , LeeMY . Systematic literature review of abobotulinumtoxinA in clinical trials for lower limb spasticity. Medicine2016;95:e2468. ">Dashtipour 2016</a>), and upper and lower limbs (<a href="./references#CD008929-bbs2-0081" title="BakerJA , PereiraG . The efficacy of botulinum toxin A on improving ease of care in the upper and lower limbs: a systematic review and meta‐analysis using the Grades of Recommendation, Assessment, Development and Evaluation approach. Clinical Rehabilitation2015;29:731‐40. ">Baker 2015</a>). Each review included a majority of studies in people with stroke, but all included some studies with mixed stroke and TBI populations. <a href="./references#CD008929-bbs2-0087" title="DashtipourK , ChenJJ , WalkerHW , LeeMY . Systematic literature review of abobotulinumtoxinA in clinical trials for lower limb spasticity. Medicine2016;95:e2468. ">Dashtipour 2016</a> was the only review to include any study (<a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a>) that was common to our review. These reviews concluded that there was favourable evidence to support the use of botulinum toxin A in the upper limb (both <a href="./references#CD008929-bbs2-0081" title="BakerJA , PereiraG . The efficacy of botulinum toxin A on improving ease of care in the upper and lower limbs: a systematic review and meta‐analysis using the Grades of Recommendation, Assessment, Development and Evaluation approach. Clinical Rehabilitation2015;29:731‐40. ">Baker 2015</a> and <a href="./references#CD008929-bbs2-0089" title="DongY , WuT , HuX , WangT . Efficacy and safety of botulinum toxin type A for upper limb spasticity after stroke or traumatic brain injury: a systematic review with meta‐analysis and trial sequential analysis. European Journal of Physical Rehabilitation Medicine2017;53:256‐67. ">Dong 2017</a> found improvements in global benefit or "ease of care" measures) and either an absence of evidence (<a href="./references#CD008929-bbs2-0081" title="BakerJA , PereiraG . The efficacy of botulinum toxin A on improving ease of care in the upper and lower limbs: a systematic review and meta‐analysis using the Grades of Recommendation, Assessment, Development and Evaluation approach. Clinical Rehabilitation2015;29:731‐40. ">Baker 2015</a>) or 'the beginnings of an evidence base' showing spasticity reductions (<a href="./references#CD008929-bbs2-0087" title="DashtipourK , ChenJJ , WalkerHW , LeeMY . Systematic literature review of abobotulinumtoxinA in clinical trials for lower limb spasticity. Medicine2016;95:e2468. ">Dashtipour 2016</a>) in the lower limb. Given the included studies in each of these reviews included predominantly people with stroke, we would question the applicability of these results to people with TBI. One other non‐Cochrane systematic review looked at the use of casting in people with brain injury, the majority of whom had TBI (<a href="./references#CD008929-bbs2-0117" title="MortensonPA , EngJJ . The use of casts in the management of joint mobility and hypertonia following brain injury in adults: a systematic review. Physical Therapy2003;83:648‐58. ">Mortenson 2003</a>). Only five out of the 13 included studies measured spasticity as an outcome and reported improvement to some extent following casting. However, it was noted by the author that the quality of this evidence was low and that none of these studies used a true randomised design. </p> <p>There are several Cochrane Reviews that investigated a broader range of treatments for spasticity in other conditions such as stroke (<a href="./references#CD008929-bbs2-0088" title="DemetriosM , KhanF , Turner‐StokesL , BrandC , McSweeneyS . Multidisciplinary rehabilitation following botulinum toxin and other focal intramuscular treatment for post‐stroke spasticity. Cochrane Database of Systematic Reviews2013, Issue 6. [DOI: 10.1002/14651858.CD009689.pub2] ">Demetrios 2013</a>), multiple sclerosis (<a href="./references#CD008929-bbs2-0078" title="AmatyaB , KhanF , LaML , DemetriosM , WadeDT . Non pharmacological interventions for spasticity in multiple sclerosis. Cochrane Database of Systematic Reviews2013, Issue 2. [DOI: 10.1002/14651858.CD009974.pub2] ">Amatya 2013</a>; <a href="./references#CD008929-bbs2-0130" title="ShakespeareD , BoggildM , YoungCA . Anti‐spasticity agents for multiple sclerosis. Cochrane Database of Systematic Reviews2003, Issue 4. [DOI: 10.1002/14651858.CD001332; CD001332] ">Shakespeare 2003</a>), amyotrophic lateral sclerosis/motor neuron disease (<a href="./references#CD008929-bbs2-0079" title="AshworthNL , SatkunamLE , DeforgeD . Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2012, Issue 2. [DOI: 10.1002/14651858.CD004156.pub4] ">Ashworth 2012</a>), cerebral palsy (<a href="./references#CD008929-bbs2-0076" title="Ade‐HallR , MooreP . Botulinum toxin type A in the treatment of lower limb spasticity in cerebral palsy. Cochrane Database of Systematic Reviews2000, Issue 1. [DOI: 10.1002/14651858.CD001408] ">Ade‐Hall 2000</a>; <a href="./references#CD008929-bbs2-0099" title="HoareBJ , WallenMA , ImmsC , VillanuevaE , RawickiHB , CareyL . Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy (update). Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD003469.pub4] ">Hoare 2010</a>), and spinal cord injury (<a href="./references#CD008929-bbs2-0133" title="TariccoM , AdoneR , PagliacciC , TelaroE . Pharmacological interventions for spasticity following spinal cord injury. Cochrane Database of Systematic Reviews2000, Issue 2. [DOI: 10.1002/14651858.CD001131] ">Taricco 2000</a>). Interventions ranged from multidisciplinary rehabilitation following botulinum toxin A (and other intramuscular treatment), pharmacological (e.g. botulinum toxin A, baclofen, tizanidine) and non‐pharmacological interventions (e.g. physical activity), or a combination of interventions. It is notable that with the exception of one review (<a href="./references#CD008929-bbs2-0099" title="HoareBJ , WallenMA , ImmsC , VillanuevaE , RawickiHB , CareyL . Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy (update). Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD003469.pub4] ">Hoare 2010</a>), all reviews reported low or insufficient evidence for any of these interventions as a result of heterogeneity, high risk of bias and lack of information. <a href="./references#CD008929-bbs2-0099" title="HoareBJ , WallenMA , ImmsC , VillanuevaE , RawickiHB , CareyL . Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy (update). Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD003469.pub4] ">Hoare 2010</a> found strong evidence to support botulinum toxin A as an adjunct to occupational therapy in managing upper limb spasticity in children with cerebral palsy. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008929-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/media/CDSR/CD008929/urn:x-wiley:14651858:media:CD008929:CD008929-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/media/CDSR/CD008929/image_t/tCD008929-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram for searches up until June 2017. TBA: traumatic brain injury." data-id="CD008929-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008929.pub2/media/CDSR/CD008929/image_n/nCD008929-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram for searches up until June 2017. TBA: traumatic brain injury.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/full#CD008929-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/media/CDSR/CD008929/image_n/nCD008929-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008929-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/media/CDSR/CD008929/urn:x-wiley:14651858:media:CD008929:CD008929-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/media/CDSR/CD008929/image_t/tCD008929-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. Nine studies are included in this review." data-id="CD008929-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008929.pub2/media/CDSR/CD008929/image_n/nCD008929-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. Nine studies are included in this review. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/full#CD008929-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/media/CDSR/CD008929/image_n/nCD008929-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008929-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/media/CDSR/CD008929/urn:x-wiley:14651858:media:CD008929:CD008929-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/media/CDSR/CD008929/image_t/tCD008929-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study (note: only Meythaler 1996 and Verplancke 2005 contributed outcome data to the review)." data-id="CD008929-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008929.pub2/media/CDSR/CD008929/image_n/nCD008929-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study (note: only <a href="./references#CD008929-bbs2-0003" title="MeythalerJM , DeVivoMJ , HadleyM . Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Archives of Physical Medicine and Rehabilitation1996; Vol. 77, issue 5:461‐6. ">Meythaler 1996</a> and <a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a> contributed outcome data to the review). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/full#CD008929-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/media/CDSR/CD008929/image_n/nCD008929-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008929-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/media/CDSR/CD008929/urn:x-wiley:14651858:media:CD008929:CD008929-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/media/CDSR/CD008929/image_t/tCD008929-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Casting plus botulinum toxin A versus casting plus placebo, Outcome 1 Spasticity at 12 weeks." data-id="CD008929-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008929.pub2/media/CDSR/CD008929/image_n/nCD008929-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Casting plus botulinum toxin A versus casting plus placebo, Outcome 1 Spasticity at 12 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/references#CD008929-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/media/CDSR/CD008929/image_n/nCD008929-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008929-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/media/CDSR/CD008929/urn:x-wiley:14651858:media:CD008929:CD008929-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/media/CDSR/CD008929/image_t/tCD008929-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Casting plus botulinum toxin A versus physiotherapy, Outcome 1 Spasticity at 12 weeks." data-id="CD008929-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008929.pub2/media/CDSR/CD008929/image_n/nCD008929-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Casting plus botulinum toxin A versus physiotherapy, Outcome 1 Spasticity at 12 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/references#CD008929-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/media/CDSR/CD008929/image_n/nCD008929-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008929-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/media/CDSR/CD008929/urn:x-wiley:14651858:media:CD008929:CD008929-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/media/CDSR/CD008929/image_t/tCD008929-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Casting plus placebo versus physiotherapy, Outcome 1 Spasticity at 12 weeks." data-id="CD008929-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008929.pub2/media/CDSR/CD008929/image_n/nCD008929-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Casting plus placebo versus physiotherapy, Outcome 1 Spasticity at 12 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/references#CD008929-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/media/CDSR/CD008929/image_n/nCD008929-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008929-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/media/CDSR/CD008929/urn:x-wiley:14651858:media:CD008929:CD008929-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/media/CDSR/CD008929/image_t/tCD008929-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Tilt table plus electrical stimulation plus splint versus tilt table, Outcome 1 Spasticity." data-id="CD008929-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008929.pub2/media/CDSR/CD008929/image_n/nCD008929-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Tilt table plus electrical stimulation plus splint versus tilt table, Outcome 1 Spasticity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/references#CD008929-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/media/CDSR/CD008929/image_n/nCD008929-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008929-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/media/CDSR/CD008929/urn:x-wiley:14651858:media:CD008929:CD008929-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/media/CDSR/CD008929/image_t/tCD008929-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Tilt table plus electrical stimulation plus splint versus tilt table, Outcome 2 Passive ankle dorsiflexion." data-id="CD008929-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008929.pub2/media/CDSR/CD008929/image_n/nCD008929-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Tilt table plus electrical stimulation plus splint versus tilt table, Outcome 2 Passive ankle dorsiflexion. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/references#CD008929-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/media/CDSR/CD008929/image_n/nCD008929-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008929-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/media/CDSR/CD008929/urn:x-wiley:14651858:media:CD008929:CD008929-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/media/CDSR/CD008929/image_t/tCD008929-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Tilt table plus electrical stimulation plus splint versus tilt table, Outcome 3 Walking speed." data-id="CD008929-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008929.pub2/media/CDSR/CD008929/image_n/nCD008929-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Tilt table plus electrical stimulation plus splint versus tilt table, Outcome 3 Walking speed. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/references#CD008929-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/media/CDSR/CD008929/image_n/nCD008929-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008929-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Baclofen compared with placebo for spasticity in people with traumatic brain injury</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Baclofen compared with placebo for spasticity in people with traumatic brain injury</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with traumatic brain injury with spasticity in their arms and legs </p> <p><b>Settings:</b> outpatient rehabilitation clinic (US) </p> <p><b>Intervention:</b> intrathecal baclofen 50 μg (injected into the lumbar spine) </p> <p><b>Comparison:</b> saline placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Results and conclusions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Spasticity at up to 6 hours after treatment</b> </p> <p>(measured by the Ashworth Scale, 0‐, with a higher score indicating greater spasticity)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>We are uncertain about the effect of baclofen on spasticity compared with placebo.<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11<br/> (1)<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>V ery low</b><sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>We are uncertain about the effect of baclofen on adverse events compared with placebo.<sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>11<br/> (1)<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>V ery low</b><sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sensory functions and pain</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>No study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Neuromusculoskeletal and movement‐related functions up to 6 hours after treatment</b> </p> <p>(Measured by spasm and deep tendon reflex scores, 0‐5, with 0 being no reflexes and 5 being clonus, or repeated involuntary muscle contractions) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>We are uncertain about the effect of baclofen on neuromusculoskeletal and movement‐related functions compared with placebo.<sup>6</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>11</p> <p>(1)<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>V ery low</b><sup>7</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>General tasks and demands</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>No study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mobility</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>No study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Self‐care</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>No study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>1</sup>One study of baclofen reported an improvement in spasticity in the upper and lower limbs, compared to placebo, several hours after the injections but it was unclear how meaningful this improvement was due to reporting of P values only (<a href="./references#CD008929-bbs2-0003" title="MeythalerJM , DeVivoMJ , HadleyM . Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Archives of Physical Medicine and Rehabilitation1996; Vol. 77, issue 5:461‐6. ">Meythaler 1996</a>). </p> <p><sup>2</sup>Three additional studies, with 35 participants, measured this outcome but had no useable results (<a href="./references#CD008929-bbs2-0004" title="MeythalerJM , McCaryA , HadleyMN . Prospective assessment of continuous intrathecal infusion of baclofen for spasticity caused by acquired brain injury: a preliminary report. Journal of Neurosurgery1997; Vol. 87, issue 3:415‐9. ">Meythaler 1997</a>; <a href="./references#CD008929-bbs2-0005" title="MeythalerJM , Guin‐RenfroeS , HadleyMN . Continuously infused intrathecal baclofen for spastic/dystonic hemiplegia: a preliminary report. American Journal of Physical Medicine &amp; Rehabilitation1999; Vol. 78, issue 3:247‐54. ">Meythaler 1999a</a>; <a href="./references#CD008929-bbs2-0006" title="MeythalerJM , Guin‐RenfroeS , GrabbP , HadleyMN . Long‐term continuously infused intrathecal baclofen for spastic‐dystonic hypertonia in traumatic brain injury: 1‐year experience. Archives of Physical Medicine and Rehabilitation1999; Vol. 80, issue 1:13‐9. ">Meythaler 1999b</a>). </p> <p><sup>3</sup>Downgraded four times due to risk of bias limitations (this study provided insufficient information about random sequence generation or allocation concealment), our concerns about indirectness of the Ashworth Score, an inability to assess imprecision relating to an absence of confidence intervals and a further downgrade for there only being one study for this outcome and the likelihood of publication bias in this area. </p> <p><sup>4</sup>No adverse events or changes in alertness level were observed in the baclofen or placebo group. </p> <p><sup>5</sup>Downgraded three times due to risk of bias limitations (no study provided sufficient information about random sequence generation or allocation concealment), the fact that there was only one study for this outcome and the likelihood of publication bias in this area. </p> <p><sup>6</sup>One study reported improvement in upper and lower limb spasm and reflexes compared to placebo several hours after treatment but it was unclear how meaningful this improvement was due to reporting of P values only (<a href="./references#CD008929-bbs2-0003" title="MeythalerJM , DeVivoMJ , HadleyM . Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Archives of Physical Medicine and Rehabilitation1996; Vol. 77, issue 5:461‐6. ">Meythaler 1996</a>). </p> <p><sup>7</sup>Downgraded four times due to risk of bias limitations (no study provided sufficient information about random sequence generation or allocation concealment), an inability to assess imprecision relating to an absence of confidence intervals, the fact that there was only one study for this outcome and the likelihood of publication bias in this area. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Baclofen compared with placebo for spasticity in people with traumatic brain injury</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/full#CD008929-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008929-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Botulinum toxin A (with and without casting) compared with placebo (with and without casting) for spasticity in people with traumatic brain injury</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Botulinum toxin A (with and without casting) compared with placebo (with and without casting) for spasticity in people with traumatic brain injury</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with traumatic brain injury with spasticity in their arms (1 study) or calves (1 study) </p> <p><b>Settings:</b> rehabilitation/neurology clinics or acute general hospital, in Europe or the UK </p> <p><b>Intervention:</b> botulinum toxin A × 1 dose (500/1000 U) or botulinum toxin A × 1 dose of 200 U + serial casting </p> <p><b>Comparison:</b> placebo (± casting) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Results and conclusions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Spasticity at 4‐12 weeks</b> (measured by both Modified Ashworth Scale, 0‐5, at 12 weeks and Tardieu Scale, 0‐5, at 4 weeks) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>We are uncertain about the effect of botulinum toxin A (± casting) vs placebo (± casting) on spasticity.<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>47</p> <p>(2)<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>We are uncertain about the effect of botulinum toxin A (± casting) vs placebo (± casting) on adverse events.<sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>47</p> <p>(2)<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sensory functions and pain</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>No study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Neuromusculoskeletal and movement‐related functions at 12 weeks</b> (measured by ankle dorsiflexion) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>We are uncertain about the effect of botulinum toxin A (± casting) vs placebo (± casting) on adverse events.<sup>6</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>47</p> <p>(2)<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>7</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>General tasks and demands</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>No study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mobility</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>No study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Self‐care</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>No study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a> reported that "with abobotulinumtoxinA, the angle of catch (XV3 of the Tardieu Scale) improved in finger (+35 degree), elbow (+22 degree) and wrist (+12 degree) flexors" but no further outcome data were provided. For <a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a>, we calculated the between‐group difference in spasticity (as measured by the Modified Ashworth Scale) as mean difference 0.30 (95% confidence interval ‐0.87 to 1.47). </p> <p><sup>2</sup>Included studies: <a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a>; <a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a>. </p> <p><sup>3</sup>Downgraded four times due to: risk of bias concerns for both studies (downgraded twice, because either insufficient information about random sequence generation and allocation concealment, in one study, and potential selective outcome reporting in both studies), indirectness (one study included mixed traumatic brain injury and stroke populations, and measured spasticity using the Modified Ashworth Scale) and a high likelihood of publication bias in this area. </p> <p><sup>4</sup>In the main trial of <a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a> (in which the traumatic brain injury population was a part (9.5%)) the most common botulinum toxin A‐related adverse event was 'mild muscle weakness' and investigators reported that all adverse events were mild or moderate only. In <a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a>, botulinum toxin A was reported to be well tolerated, with only one participant with 'flu‐like' symptoms (i.e. shivering, sweating and fever). In groups who received casting (either alone, or in addition to botulinum toxin A), 41% to 50% developed 'minor' skin damage. Overall, 90.9% of those resolved spontaneously or with therapeutic dressing. </p> <p><sup>5</sup>Downgraded three times due to: risk of bias concerns for both studies (downgraded twice, because in one study there was insufficient information about random sequence generation and allocation concealment, and in both studies the adverse events data was reporting in percentages only) and a high likelihood of publication bias in this area. </p> <p><sup>6</sup><a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a> reported between‐group differences in ankle dorsiflexion, finding no differences between groups in a one‐way ANOVA (casting + placebo versus casting + botulinum toxin A: P = 0.11). However, they did not report any summary statistics for this, or any baseline scores. </p> <p><sup>7</sup>Downgraded four times due to: risk of bias concerns for both studies (downgraded twice, because either insufficient information about random sequence generation and allocation concealment, in one study, and potential selective outcome reporting in both studies), indirectness (one study included mixed traumatic brain injury and stroke populations) and a high likelihood of publication bias in this area. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Botulinum toxin A (with and without casting) compared with placebo (with and without casting) for spasticity in people with traumatic brain injury</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/full#CD008929-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008929-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Pseudoelastic orthosis versus traditional (static) splint for spasticity in people with traumatic brain injury</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Pseudoelastic orthosis versus traditional (static) splint for spasticity in people with traumatic brain injury</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Patient or population:</b> children/young people aged 4‐18 years with traumatic brain injury and with 'mild to severe spastic tetraparesis' (weakness) in all limbs </p> <p><b>Settings:</b> Istituro Eugenio Media (Italy) </p> <p><b>Intervention:</b> repositioning splints equipped with participant‐specific pseudoelastic hinges </p> <p><b>Comparison:</b> traditional splints with fixed angle braces </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Results and conclusions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Spasticity at up to 6 hours after treatment</b> </p> <p>(measured by the Modified Ashworth Scale, 0‐4, with a higher score indicating greater spasticity) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>We are uncertain about the effect of pseudoelastic splints compared with traditional splints on spasticity.<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>2</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>We are uncertain about the effect of pseudoelastic splints compared with traditional splints on adverse events.<sup>3</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>25<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>4</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sensory functions and pain</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>The included study did not report this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Neuromusculoskeletal and movement‐related functions post treatment</b> </p> <p>(measured by range of movement)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>We are uncertain about the effect of pseudoelastic splints compared with traditional splints on range of movement.<sup>5</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>25</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>6</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>General tasks and demands</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>The included study did not report this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mobility</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>The included study did not report this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Self‐care</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p>The included study did not report this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>1</sup>One study comparing novel pseudoelastic orthoses to traditional fixed angle splints reported no improvement in spasticity in the upper and lower limbs, over a period of one month of intervention. and that results of the two steps were not significantly different (<a href="./references#CD008929-bbs2-0008" title="PittaccioS , GaravagliaL , ViscusoS , BerettaE , StrazzerS . Implementation, testing and pilot clinical evaluation of superelastic splints that decrease joint stiffness. Annals of Biomedical Engineering2013;41:2003‐17. ">Pittaccio 2013</a>). </p> <p><sup>2</sup>Downgraded four times due to risk of bias limitations (study provided no information about sequence generation and allocation concealment; blinding was impossible for participants or personnel and not reported for outcome assessors; selective outcome reporting bias was high); our concerns about indirectness of the Ashworth Score and indirectness due to 36% of participants not having traumatic brain injury and one participant was of dubious eligibility; an inability to assess imprecision relating to an absence of meaningful outcome data (no numerical data were provided for spasticity; investigators reported only that there were no significant differences), and there was only one study for this comparison/outcome and that publication bias was possible in this area. </p> <p><sup>3</sup>No adverse events were reported for pseudoelastic orthoses neither did any require adjustments after fitting. Adjustments were required for 30% of traditional splints to reduce skin rash, haematomas and oedema. </p> <p><sup>4</sup>Downgraded four times due to risk of bias limitations (study provided insufficient information about sequence generation and allocation concealment, blinding was impossible for participants and personnel and not reported for outcome assessors, and selective reporting bias was high). We had concerns about indirectness given that 36% of participants did not have traumatic brain injury and one participant was of dubious eligibility. Furthermore, there was only one study for this comparison/outcome and publication bias was possible in this area. </p> <p><sup>5</sup>One study reported no improvement in range of movement in the upper and lower limbs, over a period of one month of intervention (<a href="./references#CD008929-bbs2-0008" title="PittaccioS , GaravagliaL , ViscusoS , BerettaE , StrazzerS . Implementation, testing and pilot clinical evaluation of superelastic splints that decrease joint stiffness. Annals of Biomedical Engineering2013;41:2003‐17. ">Pittaccio 2013</a>). </p> <p><sup>6</sup>Downgraded five times due to risk of bias limitations (this study provided insufficient information about sequence generation and allocation concealment, blinding was impossible for participants and personnel and not reported for outcome assessors, and selective reporting bias was high). We had concerns about indirectness due to 36% of participants not having traumatic brain injury and one participant was of dubious eligibility; our inability to assess imprecision given that means and standard deviations were only presented within a small box and whiskers plot, and a further downgrade for there only being one study for this comparison/outcome and the likelihood of publication bias in this area. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Pseudoelastic orthosis versus traditional (static) splint for spasticity in people with traumatic brain injury</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/full#CD008929-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008929-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Excluded studies with less than 50% of participants with traumatic brain injury</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Author (year)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n TBI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>% TBI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>%TBI Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>%TBI comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Botulinum toxin A vs placebo</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0053" title="NCT00900666 . Efficacy of botulinum toxin Injections in the rectus femoris to treat stiff knee gait following acquired brain injury. clinicaltrials.gov/ct2/show/NCT00900666 Date first received: 13 May 2009. ">NCT00900666</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Botulinum toxin A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0020" title="BurbaudP , WiartL , DubosJL , GaujardE , DebelleixX , JosephPA , et al. A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. Journal of Neurology, Neurosurgery, and Psychiatry. 1996/09/01 1996; Vol. 61, issue 3:265‐9. ">Burbaud 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Botulinum toxin A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0029" title="FietzekUM , KossmehlP , ScheloskyL , EbersbachG , WisselJ . Early botulinum toxin treatment for spastic pes equinovarus ‐ a randomized double‐blind placebo‐controlled study. European Journal of Neurology2014;21:1089‐95. ">Fietzek 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Botulinum toxin A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0032" title="GrazkoMA , PoloKB , JabbariB . Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology. 1995/04/01 1995; Vol. 45, issue 4:712‐7. [0028‐3878: (Print)] ">Grazko 1995</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Botulinum toxin A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cross‐over trial</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0060" title="SimpsonDM , GraciesJM , YablonSA , BarbanoR , BrashearA , BoNT/TZD Study Team. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo‐controlled study. Journal of Neurology, Neurosurgery, and Psychiatry2009; Vol. 80, issue 4:380‐5. ">Simpson 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Botulinum toxin A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tizanidine or placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 and 26 placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008929-bbs2-0061" title="SmithSJ , EllisE , WhiteS , MooreAP . A double‐blind placebo‐controlled study of botulinum toxin in upper limb spasticity after stroke or head injury. Clinical Rehabilitation2000; Vol. 14, issue 1:5‐13. ">Smith 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Botulinum toxin A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Botulinum toxin A vs therapy</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0033" title="GuoF , YueW , RenL , ZhangYM , YangJ . Botulinum toxin type A plus rehabilitative training for improving the motor function of the upper limbs and activities of daily life in patients with stroke and brain injury. Neural Regeneration Research2006; Vol. 1, issue 9:859‐61. ">Guo 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Botulinum toxin A with rehab</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rehab only</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Botulinum toxin A vs botulinum toxin A (dosage)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0031" title="GraciesJM , LugassyM , WeiszDJ , VecchioM , FlanaganS , SimpsonDM . Botulinum toxin dilution and endplate targeting in spasticity: a double‐blind controlled study. Archives of Physical Medicine and Rehabilitation2009; Vol. 90, issue 1:9‐16. GraciesJM , WeiszDJ , YangBY , FlanaganS , SimpsonDM . Impact of botulinum toxin type A (BTX‐A) dilution and endplate targeting technique in upper limb spasticity (abstract). Annals of Neurology2002;52(Suppl 3):S87. ">Gracies 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High dilution botulinum toxin A with endplate target</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low dilution botulinum toxin A with end plate target</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Botulinum toxin A vs botulinum toxin A (volume)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0030" title="FranciscoGE , BoakeC , VaughnA . Botulinum toxin in upper limb spasticity after acquired brain injury: a randomized trial comparing dilution techniques. American Journal of Physical Medicine &amp; Rehabilitation2002; Vol. 81, issue 5:355‐63. ">Francisco 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High volume botulinum toxin A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low volume botulinum toxin A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008929-bbs2-0013" title="BarnesM , SchnitzlerA , MedeirosL , AguilarM , Lehnert‐BatarA , MinnaschP . Efficacy and safety of NT 201 for upper limb spasticity of various etiologies ‐ a randomized parallel‐group study. Acta Neurologica Scandinavica2010; Vol. 122, issue 4:295‐302. ">Barnes 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High volume botulinum toxin A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low volume botulinum toxin A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Botulinum toxin A vs botulinum toxin A (location)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0023" title="ChildersMK , StacyM , CookeDL , StonningtonHH . Comparison of two injection techniques using botulinum toxin in spastic hemiplegia. American Journal of Physical Medicine &amp; Rehabilitation1996; Vol. 75, issue 6:462‐9. ">Childers 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Botulinum toxin A injections towards mid belly</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Botulinum toxin A injections away from mid belly</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0031" title="GraciesJM , LugassyM , WeiszDJ , VecchioM , FlanaganS , SimpsonDM . Botulinum toxin dilution and endplate targeting in spasticity: a double‐blind controlled study. Archives of Physical Medicine and Rehabilitation2009; Vol. 90, issue 1:9‐16. GraciesJM , WeiszDJ , YangBY , FlanaganS , SimpsonDM . Impact of botulinum toxin type A (BTX‐A) dilution and endplate targeting technique in upper limb spasticity (abstract). Annals of Neurology2002;52(Suppl 3):S87. ">Gracies 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High dilution botulinum toxin A with endplate target</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low dilution botulinum toxin A with end plate target</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Baclofen vs placebo</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0010" title="ArmstrongRW , SteinbokP , CochraneDD , KubeSD , FifeSE , FarrellK . Intrathecally administered baclofen for treatment of children with spasticity of cerebral origin. Journal of Neurosurgery1997;87(3):409‐14. ">Armstrong 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intrathecal dose of baclofen</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Saline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0065" title="VanSchaeybroeckP , NuttinB , LagaeL , SchrijversE , BorghgraefC , FeysP . Intrathecal baclofen for intractable cerebral spasticity: a prospective placebo‐controlled, double‐blind study. Neurosurgery2000; Vol. 46, issue 3:603‐9. ">Van Schaeybroeck 2000</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intrathecal baclofen</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Cyclobenzaprine vs placebo</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0011" title="AshbyP , BurkeD , RaoS , JonesRF . Assessment of cyclobenzaprine in the treatment of spasticity. Journal of Neurology, Neurosurgery, and Psychiatry1972; Vol. 35, issue 5:599‐605. ">Ashby 1972</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cyclobenzaprine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cross‐over trial</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Phenothiazine vs placebo</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0021" title="BurkeD , HammondC , SkuseN , JonesRF . A phenothiazine derivative in the treatment of spasticity. Journal of Neurology, Neurosurgery, and Psychiatry1975; Vol. 38, issue 5:469‐74. ">Burke 1975</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phenothiazine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cross‐over trial</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Tizanidine vs placebo</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0047" title="MeythalerJM , Guin‐RenfroeS , JohnsonA , BrunnerRM . Prospective assessment of tizanidine for spasticity due to acquired brain injury. Archives of Physical Medicine and Rehabilitation2001; Vol. 82, issue 9:1155‐63. ">Meythaler 2001b</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tizanidine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cross‐over trial</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Tizanidine vs botulinum toxin A</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0060" title="SimpsonDM , GraciesJM , YablonSA , BarbanoR , BrashearA , BoNT/TZD Study Team. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo‐controlled study. Journal of Neurology, Neurosurgery, and Psychiatry2009; Vol. 80, issue 4:380‐5. ">Simpson 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Botulinum toxin A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tizanidine or placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 and 26 placebo</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Tizanidine vs diazepam</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0017" title="BesA , EyssetteM , Pierrot‐DeseillignyE , RohmerF , WarterJM . A multi‐centre, double‐blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia. Current Medical Research and Opinion1988; Vol. 10, issue 10:709‐18. ">Bes 1988</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tizanidine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diazepam</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Casting vs control</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0035" title="HarveyL , deJongI , GoehlG , MardwedelS . Twelve weeks of nightly stretch does not reduce thumb web‐space contractures in people with a neurological condition: a randomised controlled trial. Australian Journal of Physiotherapy2006;52(4):251‐8. ">Harvey 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Splint</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No splint</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Casting vs therapy</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0035" title="HarveyL , deJongI , GoehlG , MardwedelS . Twelve weeks of nightly stretch does not reduce thumb web‐space contractures in people with a neurological condition: a randomised controlled trial. Australian Journal of Physiotherapy2006;52(4):251‐8. ">Harvey 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Splint</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No splint</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Splinting vs control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0026" title="CopleyJ , KuipersK , FlemingJ , RassafianiM . Individualised resting hand splints for adults with acquired brain injury: a randomized, single blinded, single case design. Neurorehabilitation2013;32:885‐98. ">Copley 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Individualised hand splint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No splint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0039" title="LanninNA , HorsleySA , HerbertR , McCuskeyA , CusiekA . Splinting the hand in the functional position after brain impairment: a randomized, controlled trial. Archives of Physical Medicine and Rehabilitation2003; Vol. 84, issue 2:297‐302. ">Lannin 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stretching and hand splint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stretching only</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0064" title="ThibautA , DeltombeT , WannezS , GosseriesO , ZieglerE , DieniC , et al. Impact of soft splints on upper limb spasticity in chronic patients with disorders of consciousness: a randomized, single‐blind, controlled trial. Brain Injury2015;29:830‐6. ">Thibaut 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Soft splints</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Splinting vs therapy</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0039" title="LanninNA , HorsleySA , HerbertR , McCuskeyA , CusiekA . Splinting the hand in the functional position after brain impairment: a randomized, controlled trial. Archives of Physical Medicine and Rehabilitation2003; Vol. 84, issue 2:297‐302. ">Lannin 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stretching and hand splint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stretching only</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0064" title="ThibautA , DeltombeT , WannezS , GosseriesO , ZieglerE , DieniC , et al. Impact of soft splints on upper limb spasticity in chronic patients with disorders of consciousness: a randomized, single‐blind, controlled trial. Brain Injury2015;29:830‐6. ">Thibaut 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Soft splints</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stretching</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Functional electrical stimulation vs control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0022" title="ChangCL , MuninMC , SkidmoreER , NiyonkuruC , HuberLM , WeberDJ . Effect of baseline spastic hemiparesis on recover of upper‐limb function following botulinum toxin type A injections and postinjection therapy. Archives of Physical Medicine and Rehabilitation2009;90:1462‐7. ">Chang 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Upper limb botulinum toxin A injections for higher hand function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Upper limb botulinum toxin A injections for lower hand function</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Electrical stimulation + splinting vs splinting</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0040" title="LeungJ , HarveyLA , MoseleyAM , TseC , BryantJ , WyndhamS , et al. Electrical stimulation and splinting were not clearly more effective than splinting alone for contracture management after acquired brain injury: a randomised trial. Journal of Physiotherapy2012;58:231‐40. ">Leung 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Electrical stimulation to the wrist and finger extensor muscles for 1 hour a day + wrist splint for 12 hours a day, over 4 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wrist splint for 12 hours a day, over 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Repetitive peripheral magnetic stimulation vs sham</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0038" title="KrewerC , HartlS , MüllerF , KoenigE . Effects of repetitive peripheral magnetic stimulation on upper‐limb spasticity and impairment in patients with spastic hemiparesis: a randomized, double‐blind, sham‐controlled study. Archives of Physical and Medical Rehabilitation2014;95:1039‐47. ">Krewer 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Repetitive peripheral magnetic stimulation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham stimulation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Transcutaneous electrical acupoint stimulation vs another dose</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0067" title="ZhaoW , WangC , LiZ , ChenL , LiJ , CuiW , et al. Efficacy and safety of transcutaneous electrical acupoint stimulation to treat muscle spasticity following brain injury: a double‐blinded, multicenter, randomized controlled trial. PLoS One2015;2:e0116976. ">Zhao 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transcutaneous electrical acupoint stimulation (100 Hz)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transcutaneous electrical acupoint stimulation (2 Hz)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Transcutaneous electrical acupoint stimulation vs sham</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0067" title="ZhaoW , WangC , LiZ , ChenL , LiJ , CuiW , et al. Efficacy and safety of transcutaneous electrical acupoint stimulation to treat muscle spasticity following brain injury: a double‐blinded, multicenter, randomized controlled trial. PLoS One2015;2:e0116976. ">Zhao 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transcutaneous electrical acupoint stimulation (100 Hz)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham stimulation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Ultrasound vs infrared</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0051" title="Nakhostin AnsariN , NaghdiS , HassonS , RastgooM . Efficacy of therapeutic ultrasound and infrared in the management of muscle spasticity. Brain Injury2009; Vol. 23, issue 7‐8:632‐8. ">Nakhostin 2009</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Infrared</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Therapeutic ultrasound</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Robot vs bobath</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0028" title="FazekasG , HorvathM , TroznaiT , TothA . Robot‐mediated upper limb physiotherapy for patients with spastic hemiparesis: a preliminary study. Journal of Rehabilitation Medicine2007; Vol. 39, issue 7:580‐2. [1650‐1977] ">Fazekas 2007</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Robot‐mediated therapy with bobath therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bobath therapy</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>n: number of participants; NR: not reported; TBI: traumatic brain injury.</p> <p>Some studies are listed in the table twice, given their multiple comparisons.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Excluded studies with less than 50% of participants with traumatic brain injury</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/full#CD008929-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008929-tbl-0005"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Primary outcome measures</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Outcome measure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Domains with score</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Studies referring to this outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Time point analysis</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Ashworth Scale (0‐4, lower score = better; <a href="./references#CD008929-bbs2-0121" title="PandyanAD , JohnsonGR , PriceCI , CurlessRH , BarnesMP , RodgersH . A review of the properties and limitations of the Ashworth and modified Ashworth Scales as measures of spasticity. Clinical Rehabilitation1999; Vol. 13, issue 5:373‐83. ">Pandyan 1999</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0: no increase in muscle tone.</p> <p>1: slight increase in muscle tone, manifested by a catch and release or by minimum resistance through remainder of range of motion </p> <p>2: more marked increase in muscle tone through most of the range of motion; limb easily moved. </p> <p>3: considerable increase in muscle tone; passive movement is difficult.</p> <p>4: rigid limb.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0003" title="MeythalerJM , DeVivoMJ , HadleyM . Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Archives of Physical Medicine and Rehabilitation1996; Vol. 77, issue 5:461‐6. ">Meythaler 1996</a>; </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline, and 1, 2, 4, 6 hours</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0008" title="PittaccioS , GaravagliaL , ViscusoS , BerettaE , StrazzerS . Implementation, testing and pilot clinical evaluation of superelastic splints that decrease joint stiffness. Annals of Biomedical Engineering2013;41:2003‐17. ">Pittaccio 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline, and 4, 8 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Modified Ashworth Scale (0‐5, lower score = better; <a href="./references#CD008929-bbs2-0121" title="PandyanAD , JohnsonGR , PriceCI , CurlessRH , BarnesMP , RodgersH . A review of the properties and limitations of the Ashworth and modified Ashworth Scales as measures of spasticity. Clinical Rehabilitation1999; Vol. 13, issue 5:373‐83. ">Pandyan 1999</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0: no increase in muscle tone.</p> <p>1: slight increase in muscle tone, manifested by a catch and release or is moved in flexion, extension/abduction, adduction, etc. </p> <p>1+: slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the range of motion. </p> <p>2: More marked increase in muscle tone through most of the range of motion, but the affected part is easily moved. </p> <p>3: considerable increase in muscle tone, passive movement is difficult.</p> <p>4: affected part is rigid flexion or extension/abduction or adduction.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline, 12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline, 4 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tardieu Scale (TS; 2 measurements: Quality of Muscle Reaction 0‐4, lower score better, and Angle of muscle reaction, R2 ‐ R1; <a href="./references#CD008929-bbs2-0097" title="HaughAB , PandyanAD , JohnsonGR . A systematic review of the Tardieu Scale for the measurement of spasticity. Disability and Rehabilitation2006; Vol. 28, issue 15:899‐907. ">Haugh 2006</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Quality of muscle reaction </p> <p>0: no resistance throughout the course of the passive movement.</p> <p>1: slight resistance throughout the course of the passive movement, with no clear catch at precise angle. </p> <p>2: clear catch at precise angle, interrupting the passive movement, followed by release.</p> <p>3: fatigable clonus (&lt; 10 seconds when maintaining pressure) occurring at precise angle. </p> <p>4: infatigable clonus (&gt; 10 seconds when maintaining pressure) occurring at precise angle. </p> <p>Angle of muscle reaction (also referred to as R2 ‐ R1)</p> <p>Measured relative to the position of minimal stretch of the muscle (corresponding to angle) where it is relative to the resting anatomic position. </p> <p>R2: first measure (the maximum passive range of movement of the muscle group).</p> <p>R1: second measure (the angle at which the initial 'catch' or muscle resistance is felt when the muscle is moved from its shortest to longest position using a 'rapid velocity stretch'). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline, 4 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0002" title="LeungJ , HarveyLA , MoseleyAM , WhitesideB , SimpsonM , StroudK . Standing with electrical stimulation and splinting is no better than standing alone for management of ankle plantarflexion contractures in people with traumatic brain injury: a randomised trial. Journal of Physiotherapy2014;60:201‐8. ">Leung 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline, and 6 and 10 weeks</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Primary outcome measures</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/full#CD008929-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008929-tbl-0006"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Secondary outcome measures</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Outcome measure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Domains with score</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Studies referring to this outcome</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> ICF classification</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Glasgow Coma Scale (<a href="./references#CD008929-bbs2-0134" title="TeasdaleG , JennettB . Assessment of coma and impaired consciousness. Lancet1974;304:814. ">Teasdale 1974</a>) </p> <p>(3‐15, higher score = better)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eye opening (E)</p> <p>4: spontaneous</p> <p>3: to voice</p> <p>2: to pain</p> <p>1: none</p> <p>Verbal response (V)</p> <p>5: normal conversation</p> <p>4: disoriented conversation</p> <p>3: words, but not coherent</p> <p>2: no words, only sounds</p> <p>1: none</p> <p>Motor response (M)</p> <p>6: normal</p> <p>5: localised to pain</p> <p>4: withdraws to pain</p> <p>3: decorticate posture (an abnormal posture that can include rigidity, clenched fists, legs held straight out, and arms bent inward towards the body with the wrists and fingers bend and held on the chest) </p> <p>2: decerebrate (an abnormal posture that can include rigidity, arms and legs held straight out, toes pointed downward, head and neck arched backwards) </p> <p>1: none</p> <p>The final GCS score or grade is the sum of these numbers.</p> <p>Severe: GCS 3‐8 (minimum possible score is 3)</p> <p>Moderate: GCS 9‐12</p> <p>Mild: GCS 13‐15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>b. Body functions</p> <p>b1‐b8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Glasgow Outcome Scale (<a href="./references#CD008929-bbs2-0101" title="JennettB , BondM . Assessment of outcome after severe brain damage. Lancet1975;1:480‐4. ">Jennett 1975</a>) </p> <p>(1‐5, higher score = better)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To generalise and categorise the outcomes of people with TBI.</p> <p>1: dead</p> <p>2: vegetative state (meaning the person is unresponsive, but alive; a "vegetable" in lay language) </p> <p>3: severely disabled (conscious but the person requires others for daily support due to disability) </p> <p>4: moderately disabled (the person is independent but disabled)</p> <p>5: good recovery (the person has resumed most normal activities but may have minor residual problems) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Body function</p> <p>b1‐b8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range of movement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The joint is taken through the total arc of movement from flexion to extension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a> (ankle) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Body function</p> <p>b7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Deep tendon reflexes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0: reflexes absent</p> <p>1: hyporeflexia</p> <p>2: normal</p> <p>3: mild hyperreflexia</p> <p>4: 3 or 4 beats clonus only</p> <p>5: clonus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0003" title="MeythalerJM , DeVivoMJ , HadleyM . Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Archives of Physical Medicine and Rehabilitation1996; Vol. 77, issue 5:461‐6. ">Meythaler 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Body function</p> <p>b750</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disability Assessment Scale (DAS; <a href="./references#CD008929-bbs2-0084" title="BrashearA , ZafonteR , CorcoranM , Galvez‐JimenezN , GraciesJM , GordonMF , et al. Inter‐ and intrarater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper‐limb poststroke spasticity. Archives of Physical and Medical Rehabilitation2002;83:1349‐54. ">Brashear 2002</a>; 0‐3, lower score better) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>People are interviewed to determine the extent of functional impairment in: hygiene, dressing, limb position and pain, according to the following scale: </p> <p>0: no disability</p> <p>1: mild disability (noticeable but does not interfere significantly with normal activities)</p> <p>2: moderate disability (normal activities require increased effort or assistance, or both) </p> <p>3: severe disability (normal activities limited)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Activities and participation</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>ICF: International Classification of Functioning.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Secondary outcome measures</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/full#CD008929-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008929-tbl-0007"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Adverse effects</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Adverse effect</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Number of participants affected</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Studies</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Deep vein thrombosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 participants withdrawn from physiotherapy group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Contracture at subtalar joint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 participants withdrawn from the casting + placebo group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No adverse events or changes in alertness level were observed in the baclofen group or placebo arm </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0003" title="MeythalerJM , DeVivoMJ , HadleyM . Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Archives of Physical Medicine and Rehabilitation1996; Vol. 77, issue 5:461‐6. ">Meythaler 1996</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unspecified "treatment emergent AE [adverse effects]": "none were unexpected"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/23 participants, no other information given.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0001" title="GraciesJM , BrashearA , JechR , McAllisterP , BanachM , ValkovicP , et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double‐blind randomised controlled trial. Lancet Neurology2015;14:992‐1001. O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">Gracies 2015</a> (<a href="./references#CD008929-bbs2-0119" title="O'DellMW , WalkerHW , EdgleySR , GraciesJM , GulF , WimmerM , et al. AbobotulinumtoxinA (Dysport®) in the treatment of adult patients with upper limb spasticity due to traumatic brain injury. PM &amp; R : the Journal of Injury, Function, and Rehabilitation2015;7:S103. ">O'Dell 2015</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skin rashes/oedema/tolerability issues</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No pseudoelastic device required adjustment for comfort; 30% of traditional devices did. Families reported novel treatment tolerated for 40% longer than traditional (<a href="./references#CD008929-bbs2-0008" title="PittaccioS , GaravagliaL , ViscusoS , BerettaE , StrazzerS . Implementation, testing and pilot clinical evaluation of superelastic splints that decrease joint stiffness. Annals of Biomedical Engineering2013;41:2003‐17. ">Pittaccio 2013</a>). </p> <p>2 participants adherence to splinting was affected by 'skin problems' and 'poor tolerance' (<a href="./references#CD008929-bbs2-0002" title="LeungJ , HarveyLA , MoseleyAM , WhitesideB , SimpsonM , StroudK . Standing with electrical stimulation and splinting is no better than standing alone for management of ankle plantarflexion contractures in people with traumatic brain injury: a randomised trial. Journal of Physiotherapy2014;60:201‐8. ">Leung 2014</a>). </p> <p>50% of participants in casting group and 41.7% of participants in casting + botulinum toxin A group developed 'minor skin damage'. Overall, 90% of those resolved spontaneously or with therapeutic dressing (<a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0002" title="LeungJ , HarveyLA , MoseleyAM , WhitesideB , SimpsonM , StroudK . Standing with electrical stimulation and splinting is no better than standing alone for management of ankle plantarflexion contractures in people with traumatic brain injury: a randomised trial. Journal of Physiotherapy2014;60:201‐8. ">Leung 2014</a>; <a href="./references#CD008929-bbs2-0008" title="PittaccioS , GaravagliaL , ViscusoS , BerettaE , StrazzerS . Implementation, testing and pilot clinical evaluation of superelastic splints that decrease joint stiffness. Annals of Biomedical Engineering2013;41:2003‐17. ">Pittaccio 2013</a>; <a href="./references#CD008929-bbs2-0009" title="VerplanckeD , SnapeS , SalisburyCF , JonesPW , WardAB . A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clinical Rehabilitation2005; Vol. 19, issue 2:117‐25. ">Verplancke 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fainting, fatigue, storming<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Several participants' adherence to the tilt table was affected due to fainting, fatigue and storming. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008929-bbs2-0002" title="LeungJ , HarveyLA , MoseleyAM , WhitesideB , SimpsonM , StroudK . Standing with electrical stimulation and splinting is no better than standing alone for management of ankle plantarflexion contractures in people with traumatic brain injury: a randomised trial. Journal of Physiotherapy2014;60:201‐8. ">Leung 2014</a> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p><sup>1</sup>When someone with a head injury responds to a sensation with a tonic posture or sympathetic response. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Adverse effects</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/full#CD008929-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008929-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Casting plus botulinum toxin A versus casting plus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Spasticity at 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Casting plus botulinum toxin A versus casting plus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/references#CD008929-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008929-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Casting plus botulinum toxin A versus physiotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Spasticity at 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Casting plus botulinum toxin A versus physiotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/references#CD008929-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008929-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Casting plus placebo versus physiotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Spasticity at 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Casting plus placebo versus physiotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/references#CD008929-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008929-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Tilt table plus electrical stimulation plus splint versus tilt table</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Spasticity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Passive ankle dorsiflexion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Walking speed <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Tilt table plus electrical stimulation plus splint versus tilt table</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008929.pub2/references#CD008929-tbl-0011">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008929.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD008929-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD008929-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008929-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD008929-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD008929-note-0016">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD008929-note-0004">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008929\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008929\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008929\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008929\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008929\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008929\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008929\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008929\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008929\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008929\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008929\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008929\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008929\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008929\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008929\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008929\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008929\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008929\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tIsQXAzh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008929.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008929.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008929.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008929.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008929.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724511888"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008929.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724511891"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008929.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e64a08ea8f44a',t:'MTc0MDcyNDUxMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 